Schizophrenia

🏷

Classifications

Harrison's Part

◈

Mechanistic Hypotheses

3

Canonical Dopamine / Glutamate / Neurodevelopmental Model

canonical_dopamine_glutamate_neurodevelopmental_model CANONICAL

Evidence balance 2 support 2 refute

Schizophrenia is a polygenic neurodevelopmental disorder in which rare large-effect (e.g., 22q11.2 deletion, NRXN1, SETD1A) and common variants (>250 GWAS loci) converge on synaptic, dopaminergic, and glutamatergic pathways. Striatal dopamine D2-receptor hyperactivity drives positive symptoms (psychosis, hallucinations); cortical NMDA-receptor hypofunction and parvalbumin-interneuron dysfunction produce negative and cognitive symptoms. Aberrant synaptic pruning during adolescence (C4-complement-driven) and altered early-life neurodevelopment provide the substrate for later-onset psychotic phenotypes. Antipsychotic efficacy (all first-line drugs are D2 antagonists) and NMDA-channel-blocker models (ketamine, PCP) corroborate the dopamine-glutamate axis as the canonical pharmacologic substrate.

Retained as CANONICAL with major qualifications. The 2026 openscientist hypothesis-search report (kb/hypotheses/Schizophrenia/canonical_dopamine_glutamate_neurodevelopmental_model) finds PARTIALLY SUPPORTED — pathophysiology validated, pharmacological predictions fractured. Core architecture is well-supported: meta-analytic PET shows elevated presynaptic dopamine synthesis (Hedges' g = 0.68; effect size 1.18 in prospective pre-psychosis), C4A overexpression replicated, perineuronal-net density reduced in 6/7 postmortem studies (a proxy for PV-associated circuitry, not a direct measure of PV-cell number or function), SV2A PET confirms synaptic density loss, 2022 GWAS (>287 loci) confirms synaptic-biology convergence, and 22q11.2/SETD1A/ NRXN1 validate the polygenic-to-synaptic axis. Five critical qualifications: (1) dopamine synthesis capacity is heterogeneous rather than uniformly elevated: in PET comparison, treatment resistant patients were indistinguishable from controls while responders were elevated. The report's figure of ~30% dopamine normal patients is not established, and appears to transfer the approximate prevalence of treatment resistance onto the prevalence of normal dopamine physiology; (2) dopamine pathology localizes to the ASSOCIATIVE striatum, not the canonical mesolimbic pathway; (3) glutamate pharmacology has failed its primary endpoints in large placebo-controlled trials (pomaglumetad, the iclepertin CONNEX programme, bitopertin), which falsifies the model's therapeutic prediction for those agents and targets but does not refute glutamate pathophysiology as a class, since target engagement and biological enrichment were not uniform across them; (4) KarXT (xanomeline-trospium, muscarinic agonist, FDA approved 2024) demonstrates that direct D2 antagonism is not required for antipsychotic efficacy, though M4 agonism can itself depress striatal dopamine release, so this is not yet a demonstration of a dopamine independent mechanism; (5) the largest snRNA-seq study (536,618 nuclei) prioritizes excitatory cortical neurons rather than PV interneurons for genetic risk, with prominent mitochondrial gene dysregulation. Read that as a strong lead rather than proof of causal primacy: postmortem differential expression cannot order excitatory against inhibitory changes in time, and a separate orbitofrontal multi-omic analysis instead prioritized glial and endothelial cells, so cell-type primacy currently varies with region, assay, and method.

Deep research

OpenScientist citations 47 citations 2026-05-24T15:46:10.106159

Show evidence (4 references)

PMID:11532718 SUPPORT Other

"Research has implicated dysfunction of glutamatergic neurotransmission in the pathophysiology of schizophrenia."

Existing canonical mechanism citation in the dismech knowledge base, used as the seed for the hypothesis-search deep-research run.

PMID:35396580 SUPPORT Human Clinical

"Associations were concentrated in genes that are expressed in excitatory and inhibitory neurons of the central nervous system, but not in other tissues or cell types."

The 287-locus GWAS (76,755 cases, 243,649 controls) is the primary source behind this hypothesis's polygenic-to-synaptic claim, which the entry previously asserted in prose without citing it. Note the enrichment falls on excitatory and inhibitory neurons together, so it does not by itself privilege either compartment.

PMID:40162239 REFUTE Human Clinical

"Gene expression in excitatory layer 2-3 intra-telencephalic neurons had the greatest number of differentially expressed transcripts and, together with excitatory deep layer intra-telencephalic neurons, conferred most of the genetic risk for schizophrenia."

Cuts against this hypothesis's assignment of genetic risk to parvalbumin interneurons: in dorsal prefrontal cortex the risk enrichment falls on excitatory intratelencephalic neurons. It qualifies one component of the framework rather than the framework itself, and cannot establish temporal primacy, since postmortem differential expression is also sensitive to illness state, treatment, and tissue effects.

+ 1 more reference

Complement-Mediated Synaptic Pruning Hypothesis

complement_synaptic_pruning_hypothesis EMERGING

Evidence balance 5 support

Schizophrenia risk alleles that increase complement C4A activity may increase complement tagging of vulnerable synapses during adolescent and young-adult cortical maturation. Microglia then remove more synaptic material than is developmentally appropriate, especially in prefrontal and hippocampal circuits, creating synaptic-density loss and circuit dysconnectivity that can feed into downstream dopamine dysregulation and clinical symptom domains.

Modeled separately from the canonical dopamine/glutamate framework because the complement-C4A link has strong genetic, patient-derived cellular, and mouse-model support, but the full human causal chain from C4A dosage to synapse loss, dopamine changes, developmental timing, and symptom-domain specificity remains partially inferred. The 2026 openscientist hypothesis-search report (kb/hypotheses/Schizophrenia/complement_synaptic_pruning_hypothesis) grades this PARTIALLY SUPPORTED at its genetic and cellular core but flags substantial revision of the effector mechanism, developmental timing, and downstream chain. Well-established: the C4A expression-dosage dose-response for schizophrenia risk (Sekar 2016), C4A overexpression driving cortical synapse loss and increased microglial engulfment in mice (Yilmaz 2021), increased synapse elimination in patient-derived iPSC microglia-neuron models (Sellgren 2019), and the inverse sex-biased C4A relationship between schizophrenia and SLE/Sjögren's (Kamitaki 2020). Key qualifications: (1) the microglial-phagocytosis effector step is now contested by contradictory 2025-2026 mouse studies proposing CR3-dependent reduced-surveillance vs CR3-independent SNX27/AMPAR-trafficking mechanisms; (2) the adolescent-timing claim is challenged by human postmortem data showing complement activators peak in toddlers and decline in teenagers (Sager 2021); (3) the link to downstream dopamine dysregulation remains unsupported by direct evidence; and (4) after a decade there are still no complement-targeted schizophrenia trials and peripheral complement biomarkers are inconsistent across cohorts. C4 sits within a highly polygenic (287+ locus) architecture and contributes a modest effect for a common locus. The frequently repeated "OR ~1.27" should not be read as an odds ratio per unit of C4A expression: Sekar et al. reported relative risks running from 1.00 to 1.27 across four common C4 structural alleles, and did not estimate C4A's share of schizophrenia heritability.

Pathograph links

Complement-Mediated Excessive Synaptic Pruning -> Dysregulation of Dopamine Neurotransmission INDIRECT KNOWN INTERMEDIATES Excessive complement- and microglia-mediated synapse elimination can disrupt cortical pyramidal-neuron circuits and disinhibit mesostriatal projections, providing an indirect route from adolescent synaptic loss to dopamine overactivity and psychosis. Intermediates: cortical pyramidal-neuron dysfunction; disinhibited projections to mesostriatal regions

Complement-Mediated Excessive Synaptic Pruning -> Abnormality of Glutamergic Signaling DIRECT The synapses removed are overwhelmingly cortical excitatory ones, so over-pruning is a route into the glutamatergic node as well as the dopaminergic one. The same sentence of the synaptic-hypothesis review carries both arms: pyramidal-neuron dysfunction here, mesostriatal disinhibition on the dopamine edge above.

Deep research

OpenScientist citations 27 citations 2026-07-06T04:13:56.531418

Show evidence (5 references)

PMID:26814963 SUPPORT Human Clinical

"each common C4 allele associating with schizophrenia in proportion to its tendency to generate greater expression of C4A"

Foundational genetic evidence that C4 structural alleles associate with schizophrenia risk in proportion to how much C4A expression they generate, anchoring the upstream (C4A dosage) step of the hypothesis.

PMID:33353966 SUPPORT Model Organism

"overexpressing C4A in mice reduced cortical synapse density, increased microglial engulfment of synapses and altered mouse behavior"

Mouse model showing C4A overexpression is sufficient to drive cortical synapse loss with increased microglial engulfment, supporting the core complement-driven over-pruning effector step (in a model organism).

PMID:30718903 SUPPORT In Vitro

"schizophrenia risk-associated variants within the human complement component 4 locus are associated with increased neuronal complement deposition and synapse uptake"

Patient-derived iPSC microglia-neuron model links C4-locus risk variants to increased complement deposition and synapse uptake, supporting the cellular effector mechanism in human-derived cells; the same study notes the variants do not fully explain the excess, consistent with C4A being one contributor among several.

+ 2 more references

Muscarinic Cholinergic (M1/M4) Hypothesis

muscarinic_cholinergic_hypothesis EMERGING

Evidence balance 3 support 1 refute

Deficient signalling through the M1 and M4 muscarinic acetylcholine receptors is a primary driver of psychosis rather than a downstream consequence of dopaminergic pathology. Cortical M1 receptor loss — marked in a postmortem-defined subgroup termed muscarinic receptor-deficit schizophrenia (MRDS) — is proposed to degrade prefrontal circuit function underlying cognitive and negative symptoms, while loss of M4-mediated cholinergic restraint on striatal dopamine release permits the dopamine dysregulation that produces positive symptoms. The model predicts that a muscarinic agonist should be antipsychotic without D2 blockade, and that prediction has now been met in three placebo-controlled phase 3 trials of xanomeline-trospium (KarXT), approved in 2024.

Held as EMERGING rather than CANONICAL because the therapeutic arm is far stronger than the aetiological one, and the two do not entail each other: a drug that raises muscarinic tone can relieve psychosis whether or not deficient muscarinic tone caused it, exactly as D2 antagonism was antipsychotic long before striatal dopamine excess was demonstrated. Well-supported: selective cortical M1 loss in dorsolateral prefrontal cortex (PMID:12476323); a bimodal distribution separating an MRDS subgroup at roughly a quarter of cases with ~74% lower cortical pirenzepine binding (PMID:18317461); reduced in-vivo muscarinic availability in unmedicated patients, with striatal and frontal binding correlating inversely with positive symptoms (PMID:12505810); and the M4-dependent suppression of striatal dopamine release that supplies the mechanistic bridge to the canonical dopamine node (PMID:27618677, PMID:29268098). Four qualifications. (1) The receptor deficit is a subgroup finding, not a property of the syndrome — MRDS was defined postmortem and no prospective in-life biomarker stratifies patients today, so KarXT is prescribed without regard to muscarinic status. (2) The deficit has no established genetic origin: MRDS could not be separated from non-MRDS schizophrenia by CHRM1 sequence, so it is not explained by coding variation in the receptor gene, and nothing here anchors it to the polygenic architecture the way C4A anchors the complement hypothesis. (3) The M4/dopamine-release mechanism rests on rodent pharmacology, and the CB2-receptor dependence reported for it (PMID:27618677) has not been shown in humans. (4) Antipsychotic exposure is itself a confound: clozapine lowers in-vivo muscarinic receptor availability by 45-79% across regions in a dose-dependent way (PMID:12799613), so postmortem and unmedicated-patient designs are load-bearing for the aetiological claim and treated cohorts cannot settle it.

Show evidence (4 references)

PMID:12505810 SUPPORT Human Clinical

"These results indicate a reduction in muscarinic acetylcholine receptor availability in vivo in unmedicated patients with schizophrenia, confirming results from postmortem studies and adding further evidence that the muscarinic system is involved in the pathophysiology of schizophrenia."

In-vivo SPECT in medication-free patients, so the reduction cannot be attributed to antipsychotic exposure — the central aetiological claim of the hypothesis.

PMID:27801890 SUPPORT Human Clinical

"Overall, our data argue a prominent role for glial function in MRDS and neurodevelopment in non-MRDS."

Independent molecular support for the subgroup division underlying qualification 1: MRDS and non-MRDS cortex differ in which pathways are disrupted, so the receptor deficit marks a biologically distinct population rather than one tail of a continuum.

PMID:38104575 SUPPORT BACKGROUND Human Clinical

"Xanomeline is a dual M1 and M4-preferring muscarinic receptor agonist that does not block D2 dopamine receptors, unlike all currently approved treatments for schizophrenia."

Establishes that the tested agent has no D2 activity, which is what makes the trial result a test of the muscarinic prediction rather than of dopamine blockade.

+ 1 more reference

?

Discussions and Knowledge Gaps

6

How do schizophrenia-associated complement C4A activity, microglial synapse engulfment, adolescent cortical synapse loss, dopamine dysregulation, and positive, negative, or cognitive symptom domains connect causally in living human patients?

KNOWLEDGE GAP OPEN gap_schizophrenia_complement_pruning_human_causal_chain

Attached to

pathophysiology#Complement-Mediated Excessive Synaptic Pruning pathophysiology#Dysregulation of Dopamine Neurotransmission

The complement-pruning mechanism is supported by convergent review evidence, patient-derived in vitro models, and mouse C4A-overexpression experiments. The remaining gap is the human-specific causal ordering: whether C4A dosage or activity is sufficient to drive excessive synapse elimination during the relevant developmental window, whether this produces measurable synaptic density loss in the same cortical circuits in patients, and how that loss maps onto dopamine overactivity and specific symptom domains. Resolving this gap would require longitudinal human data that align complement genotype or expression, microglial activation or complement tagging, synaptic-density imaging, dopamine-system readouts, and symptom trajectories in the same individuals.

Proposed experiments

Longitudinal C4A-pruning-dopamine cohort

longitudinal multimodal cohort study

exp_schizophrenia_c4a_pruning_longitudinal_cohort

Follow adolescents and young adults stratified by complement C4 structural alleles or C4A expression with serial synaptic-density PET, microglial or complement-activation biomarkers, dopamine-system imaging, cognitive and negative-symptom measures, and positive-symptom conversion outcomes.

Decision criterion

The complement-pruning model would be strengthened if higher C4A risk or activity preceded increased microglial/complement activation, accelerated cortical synaptic-density loss, subsequent dopamine dysregulation, and worsening symptom trajectories in the same participants.

Which H3K4 demethylase is the correct therapeutic target for restoring the SETD1A-H3K4 methylation imbalance in human neurons - KDM5, which rescues SETD1A-deficiency phenotypes in human iPSC-derived neural models, or LSD1 (KDM1A), which rescues them in mouse Setd1a models where KDM5 inhibition does not?

HUMAN MODEL MISMATCH OPEN mismatch_schizophrenia_setd1a_h3k4_demethylase_target

Attached to

pathophysiology#Reduced SETD1A H3K4 Methyltransferase Activity at Psychiatric Risk Gene Promoters genetic#SETD1A

The therapeutic logic of SETD1A haploinsufficiency is unusually direct: SETD1A writes H3K4 methylation, so inhibiting the demethylase that erases it should restore the balance. Which demethylase to inhibit, however, comes out differently in mouse and in human cells, and the two results are not reconcilable by dose or timing alone. In mouse Setd1a models the neuronal-morphology and synaptic phenotypes are rescued by LSD1 (KDM1A) inhibition and explicitly NOT by KDM5 inhibition. In human iPSC-derived isogenic SETD1A loss-of-function neurons, KDM5 inhibition rescues the DNA damage accumulation, and in independent patient-derived cells carrying the Old Order Amish p.Pro596Leu hypomorph, KDM5 inhibition partially rescues replication stress and neurite deficits. So the human evidence converges on KDM5 across two different SETD1A perturbations and two laboratories, while the mouse evidence specifically excludes it. This matters beyond the rare LoF carriers: postmortem cortex from schizophrenia cases WITHOUT SETD1A mutations shows reduced SETD1A expression and downregulation of SETD1A-regulated genes, so the target population for H3K4-restoring therapy would be far broader than the mutation carriers, and picking the wrong demethylase on the strength of the mouse data would misdirect it. Note also that the human rescue is explicitly partial - 10-20% of neural progenitors still became senescent under KDM5 inhibition - so even the human-supported target does not fully normalise the cellular phenotype.

Proposed experiments

Head-to-head KDM5 versus LSD1 inhibition in matched human and mouse SETD1A models

comparative pharmacologic rescue study

exp_schizophrenia_setd1a_kdm5_vs_lsd1_head_to_head

Apply KDM5 and LSD1 (KDM1A) inhibitors side by side, at matched target engagement, to isogenic human iPSC-derived SETD1A loss-of-function neurons and to primary neurons from Setd1a haploinsufficient mice, reading out the same endpoints in both (H3K4me3 at SETD1A-bound promoters, DNA damage markers, neurite complexity, progenitor senescence, network activity).

Decision criterion

A genuine species difference would be supported if the KDM5-versus-LSD1 ordering reverses between human and mouse cells under identical endpoints and matched target engagement; a shared mechanism obscured by assay differences would instead show both inhibitors rescuing in both species once the endpoints are harmonised, in which case the original discrepancy is methodological rather than biological.

Show evidence (4 references)

PMID:41422157 SUPPORT In Vitro

"SETD1A haploinsufficiency causes accelerated neurogenesis, reduced neuronal complexity, and DNA damage accumulation in postmitotic neurons that is rescued by inhibiting the H3K4me2/3 demethylase KDM5."

The human-model arm of the mismatch - KDM5 inhibition rescues SETD1A loss-of-function phenotypes in isogenic human iPSC-derived neurons.

PMID:41422157 SUPPORT Model Organism

"These phenotypes are rescued by LSD1 (KDM1A) inhibition but not by KDM5 inhibition"

The animal-model arm of the mismatch. Note the provenance: this sentence is PMID:41422157's introduction summarizing prior mouse work by a different group (Mukai et al., their reference 16), not a result of the citing study. The same paper elsewhere contrasts "our CUT&Tag findings and ChIP-seq findings in Mukai et al." as mouse-versus-human differences. In those mouse Setd1a models the rescuing demethylase is LSD1 and KDM5 inhibition specifically fails, which is the claim the mismatch turns on.

PMID:41422157 SUPPORT Human Clinical

"In postmortem SCZ cortical tissue, individuals who lack SETD1A mutations exhibit reduced SETD1A expression, associated with downregulation of SETD1A-regulated genes, implicating SETD1A-H3K4me dysfunction in sporadic SCZ cases."

Establishes why resolving the target question matters beyond rare mutation carriers - SETD1A-H3K4 dysfunction is also present in sporadic schizophrenia cortex.

+ 1 more reference

Does the cortical muscarinic M1 receptor deficit that defines MRDS predict who responds to a muscarinic agonist, and can that deficit be measured in a living patient before treatment?

KNOWLEDGE GAP OPEN gap_schizophrenia_mrds_stratification_of_muscarinic_response

Attached to

pathophysiology#Cortical Muscarinic M1 Receptor Deficit treatments#Xanomeline-Trospium (KarXT)

The muscarinic hypothesis and the drug built on it have never been joined at the level of the individual patient. MRDS was defined on postmortem tissue by pirenzepine binding in Brodmann area 9, and separates roughly a quarter of cases with a ~74% reduction from a majority overlapping controls — so the receptor deficit the mechanism turns on is present in a minority. Every KarXT trial, from the 20-patient pilot through the EMERGENT phase 3 programme, enrolled without regard to muscarinic status, and the drug is prescribed the same way. Two readings of the phase 3 results are therefore still open and have different consequences. If response tracks the deficit, the unstratified trials understate the effect in MRDS patients and a pre-treatment assay would be worth having. If response is independent of it, then M1/M4 agonism is a general pharmacological lever on the dopamine and prefrontal circuitry rather than replacement of a specific missing signal — which would weaken the aetiological hypothesis while leaving the treatment untouched. Closing this needs an in-life measure: the postmortem assay does not transfer, and existing muscarinic PET/SPECT ligands such as IQNB bind muscarinic receptors non-selectively rather than reporting M1 specifically. Current antipsychotic treatment lowers muscarinic availability on its own — dose-dependently and substantially for clozapine (PMID:12799613) — so any such measure has to handle medication status as a confound rather than a covariate.

Proposed experiments

M1-stratified trial of muscarinic agonism

biomarker-stratified randomized controlled trial

exp_schizophrenia_m1_biomarker_stratified_muscarinic_trial

Develop or qualify an M1-selective in-life measure of cortical muscarinic status (subtype-selective PET ligand, or a validated peripheral or transcriptomic proxy benchmarked against postmortem pirenzepine binding), then stratify patients by that measure at entry to a placebo-controlled trial of xanomeline-trospium and compare symptom and cognitive response between the deficit and non-deficit strata, with washout or medication status handled as a prespecified confounder.

Decision criterion

The aetiological arm of the muscarinic hypothesis would be strengthened if receptor-deficit patients respond better than non-deficit patients under identical dosing, and weakened if the strata respond equivalently.

Would support

pathophysiology#Cortical Muscarinic M1 Receptor Deficit

Supporting outcome

A larger reduction in PANSS total score, or a larger cognitive gain, in the receptor-deficit stratum than in the non-deficit stratum, under identical dosing.

Refuting outcome

Equivalent response across strata, showing that M1/M4 agonism works independently of baseline receptor status — the treatment effect intact, its support for the cortical deficit as a driving lesion removed.

Show evidence (1 reference)

PMID:18317461 SUPPORT Human Clinical

"Being able to define a subgroup within schizophrenia using a central biological parameter is a pivotal step towards understanding the biochemistry underlying at least one form of the disorder and may represent a biomarker that can be used in neuroimaging."

The authors themselves propose the deficit as a candidate neuroimaging biomarker, which is the step this gap records as still not taken almost two decades later.

Which pathophysiological node in this entry produces catatonia, and is catatonic schizophrenia mechanistically continuous with the rest of the disorder or a distinct process that co-occurs with it?

KNOWLEDGE GAP OPEN gap_schizophrenia_catatonia_has_no_mechanism_node

Attached to

phenotypes#Catatonia pathophysiology#Abnormality of GABAergic Signaling

Catatonia is the one phenotype in this entry with no incoming causal edge, and that is a recorded finding rather than an unfinished section. The candidate parent is the GABAergic node — catatonia responds to lorazepam, which argues for a GABA-A mechanism — but the argument does not survive inspection. The benzodiazepine response is a treatment observation, not a localisation; the reviews that discuss mechanism list aberrant motor-pathway activity, neurotransmitter dysregulation and oligodendrocyte dysfunction side by side as proposals without deciding between them; and catatonia is transdiagnostic, occurring in mania, depression, anti-NMDA-receptor encephalitis, and several general medical conditions, which cuts against its arising from the cortical circuit lesion this entry models. Drawing an edge from the GABAergic node on the strength of lorazepam would assert a localisation nobody has established, in the graph position where readers expect a mechanism. What would close it is a study relating a measured GABAergic parameter — motor-cortex GABA-A binding, or prefrontal GABA concentration — to catatonic sign severity within schizophrenia, rather than to diagnosis or to treatment response.

Show evidence (1 reference)

PMID:34842777 SUPPORT Other

"Aberrant neuronal activity in different motor pathways, defective neurotransmitter regulation, and impaired oligodendrocyte function have all been proposed as the pathophysiology behind catatonia."

Three unreconciled proposals listed together in a clinical review is the state of the field, and is the reason this phenotype is left unattached rather than wired to the GABAergic node.

Do the failed phase 3 trials of glutamate-modulating drugs mean that the glutamatergic target is wrong in schizophrenia, or that the trials enrolled patients unselected for a glutamatergic abnormality?

KNOWLEDGE GAP OPEN gap_schizophrenia_glutamate_pharmacology_translation

Attached to

pathophysiology#Abnormality of Glutamergic Signaling mechanistic_hypotheses#canonical_dopamine_glutamate_neurodevelopmental_model

This entry curates glutamatergic dysfunction as an established pathophysiological component while the therapeutic prediction that follows from it has repeatedly failed: an mGluR2/3 agonist and a GlyT1 inhibitor both missed their primary endpoints in large placebo-controlled trials. The gap is that neither programme tested the mechanistic prediction directly. Enrolment was by clinical diagnosis, not by a glutamatergic biomarker, and target engagement was not uniformly demonstrated, so a null result in an unselected population cannot separate a wrong target from the wrong patients. Nothing here licenses the stronger reading that trial failure refutes glutamate pathophysiology as a class; it bounds the therapeutic prediction for the specific agents, doses, endpoints, and populations that were studied.

Proposed experiments

Biomarker-stratified glutamate-modulator trial

biomarker-stratified randomized controlled trial

exp_schizophrenia_biomarker_stratified_glutamate_trial

Randomize first-episode psychosis patients to a glutamate-modulating agent or placebo after stratifying on baseline hippocampal glutamate and glutamine by magnetic resonance spectroscopy, with SV2A PET as a secondary synaptic-density measure, and test the treatment-by-stratum interaction rather than the unstratified main effect.

Decision criterion

A significant treatment-by-stratum interaction on the primary symptom or cognition endpoint, with target engagement independently confirmed.

Would support

pathophysiology#Abnormality of Glutamergic Signaling

Supporting outcome

Patients in the elevated-glutamate stratum improve relative to placebo while patients with normal baseline glutamate do not, indicating that the earlier null results reflect an unselected population rather than an invalid target.

Refuting outcome

No benefit in either stratum despite demonstrated target engagement, indicating that the glutamatergic abnormality is not a tractable therapeutic target in established illness.

Show evidence (2 references)

PMID:25539791 SUPPORT Human Clinical

"Neither LY2140023 dose showed significant improvement compared to placebo on PANSS total in either population"

Documents one half of the gap. Pomaglumetad, a selective mGluR2/3 agonist, failed on PANSS total in 1013 patients while risperidone separated from placebo in the same trial, so the null result is not attributable to an insensitive study. Patients were enrolled on clinical criteria, not on a glutamatergic biomarker.

PMID:41233083 SUPPORT Human Clinical

"Iclepertin was not associated with significant improvements in cognition in adults with schizophrenia, but it was well tolerated by patients."

Documents the other half. Three phase 3 trials of the GlyT1 inhibitor iclepertin in 1835 patients found no cognitive benefit, extending the failure to a second glutamatergic target and to the cognitive endpoint the NMDA-hypofunction account most directly predicts. Enrolment was again unselected for glutamatergic abnormality.

By what effector mechanism does elevated C4 reduce cortical synapse density: CR3-dependent alteration of microglia-synapse interaction, or a neuron-intrinsic endosomal trafficking defect that does not require CR3?

CONTROVERSY OPEN controversy_schizophrenia_c4_synaptic_loss_effector_mechanism

Attached to

pathophysiology#Complement-Mediated Excessive Synaptic Pruning mechanistic_hypotheses#complement_synaptic_pruning_hypothesis

Two mouse C4-overexpression studies reach opposite conclusions about whether microglial complement receptor 3 is required. One finds the synaptic phenotype rescued in CR3-deficient mice and attributes it to decreased microglial surveillance and contact, which is itself the opposite of the excess-engulfment model this node was built on. The other finds the hypoconnectivity CR3-independent and locates it in impaired GluR1 trafficking via the endosomal protein SNX27. The disagreement is real but should not be read as two mutually exclusive universal mechanisms: the studies differ in construct, expression pattern, circuit, age, and readout, so parallel or context-dependent extracellular and intracellular routes remain possible. Neither identifies the operative pathway in human disease, which is why the effector step in this entry is now recorded as contested rather than as CR3-mediated engulfment.

Raised by the 2026 openscientist assessment of the complement synaptic pruning hypothesis, which retained the disagreement as real while qualifying the report's stronger claim of universal contradiction. The supporting citations sit on the pathophysiology node itself.

⚙

Pathophysiology

11

Reduced SETD1A H3K4 Methyltransferase Activity at Psychiatric Risk Gene Promoters

SETD1A deposits H3K4 methylation at active promoters, and it binds those promoters selectively at schizophrenia risk loci controlling chromatin remodeling, DNA repair, and synaptic function. Loss-of-function variants reduce that activity directly. The same deficit is reached without a rare variant in sporadic disease, where cortical SETD1A expression is low and SETD1A-regulated genes are correspondingly downregulated, which is why this node is curated as a mechanism of schizophrenia rather than as an annotation on the mutation carriers.

SETD1A histone H3K4 methyltransferase activity GO:0042800 ↓ DECREASED

Downstream

DNA Damage Accumulation in Postmitotic Neurons

Abnormality of Glutamergic Signaling

Show evidence (2 references)

PMID:41422157 SUPPORT In Vitro

"SETD1A preferentially binds the promoters of polygenic risk loci for psychiatric disorders that regulate chromatin remodeling, DNA repair, and synaptic function"

Establishes that SETD1A's targets are themselves psychiatric risk loci, which is what makes reduced SETD1A activity a disease mechanism rather than a generic chromatin defect.

PMID:41422157 SUPPORT Human Clinical

"In postmortem SCZ cortical tissue, individuals who lack SETD1A mutations exhibit reduced SETD1A expression, associated with downregulation of SETD1A-regulated genes, implicating SETD1A-H3K4me dysfunction in sporadic SCZ cases."

Extends the node beyond rare mutation carriers: postmortem cortex from sporadic cases shows the same reduced SETD1A expression and target-gene downregulation.

DNA Damage Accumulation in Postmitotic Neurons

Neurons carrying SETD1A loss-of-function alleles accumulate DNA double-strand breaks, preferentially at long neural genes. SETD1A occupies DNA damage-prone sites in both neural progenitors and postmitotic neurons, so the instability tracks where the methyltransferase normally acts rather than being a nonspecific consequence of illness.

cortical neuron CL:0000540

DNA damage response GO:0006974 ↑ INCREASED

Show evidence (1 reference)

PMID:41422157 SUPPORT In Vitro

"Additionally, SETD1A binds to DNA damage-prone sites in neural progenitor cells and postmitotic neurons."

Locates the damage where SETD1A binds, in the cell types this node names.

Dysregulation of Dopamine Neurotransmission

Imbalance in dopamine transmission in the brain. Meta-analytic PET localizes the elevation of presynaptic dopamine function to the associative and sensorimotor (dorsal) striatal subdivisions rather than the limbic subdivision, which is inconsistent with a strictly mesolimbic formulation. Elevation is a group-level finding rather than a universal feature: patients whose illness is treatment resistant do not show it.

DRD2 hgnc:3023 COMT hgnc:2228

dopamine secretion GO:0014046

striatum

Downstream

Hallucinations Aberrant salience attributed to internal representations is experienced directly as hallucination. The intermediate step is psychological rather than neurochemical, which is why this is not a direct link.

Delusions Delusions arise as the patient's explanatory response to aberrantly salient experience, so the dopaminergic state reaches this phenotype through an interposed cognitive step.

Show evidence (7 references)

PMID:27206569 SUPPORT

"Findings have converged to suggest early dysregulation in the striatum, especially in the rostral caudate, manifesting as excess synthesis and release. Recent data showed deficit extending to most cortical regions and even to other extrastriatal subcortical regions not previously considered to..."

While the literature supports dopamine dysregulation in various brain regions, it does not specifically emphasize the mesolimbic and mesocortical pathways alone.

PMID:24986384 NO_EVIDENCE

"A neurobiological hypothesis for the classification of schizophrenia: type A (hyperdopaminergic) and type B (normodopaminergic)."

The abstract does not provide specific information supporting the imbalance of dopamine transmission specifically in the mesolimbic and mesocortical pathways as described in the statement.

PMID:1981107 NO_EVIDENCE

"This article discusses the possibility that a deficient activity within the cortico-striatal glutamatergic pathway is an important pathophysiological component in some cases of schizophrenia and that glutamatergic agonists may prove beneficial in this disorder."

The study focuses on glutamate dysregulation rather than dopamine transmission dysregulation in mesolimbic and mesocortical pathways.

+ 4 more references

Abnormality of Glutamergic Signaling

Dysfunction in glutamate neurotransmission, impacting synaptic plasticity and brain circuit function.

parvalbumin-positive interneuron CL:0000099

GRIN1 hgnc:4584 GRIN2A hgnc:4585

synaptic transmission, glutamatergic GO:0035249

prefrontal cortex UBERON:0000451 hippocampus UBERON:0001954

Downstream

Abnormality of GABAergic Signaling NMDA receptors on fast-spiking parvalbumin interneurons are the first casualty of receptor hypofunction; losing their excitatory drive disinhibits the pyramidal cells they normally restrain. This is the step that makes the glutamatergic and GABAergic nodes one circuit rather than two parallel abnormalities.

Disorganized Thinking NMDA antagonists reproduce formal thought disorder in humans, which dopaminergic psychotomimetics do not — the observation that first separated the glutamatergic model from the dopamine model on symptom coverage.

Social Withdrawal NMDA receptor blockade produces the negative-symptom domain, including emotional withdrawal, in people with no psychiatric illness.

Flat Affect Blunted affect is part of the negative-symptom picture NMDA antagonism reproduces in healthy volunteers.

Show evidence (4 references)

PMID:11532718 SUPPORT

"Research has implicated dysfunction of glutamatergic neurotransmission in the pathophysiology of schizophrenia."

The literature specifically states that glutamatergic neurotransmission dysfunction is associated with the pathophysiology of schizophrenia, supporting the provided statement.

PMID:28754595 SUPPORT

"Accumulating evidence suggests that synaptic plasticity is impaired in schizophrenia. Given the role of synaptic plasticity in learning, memory, and neural circuit maturation, impaired plasticity may underlie many features of the schizophrenia syndrome."

The literature discusses the impairment of synaptic plasticity in schizophrenia and its interaction with brain maturation, aligning with the statement.

PMID:29954475 SUPPORT

"Psychosis is now widely hypothesized to involve neural networks beyond the classical dopaminergic mesolimbic pathway, including serotonin and glutamate systems as well."

This reference supports the involvement of glutamatergic systems in schizophrenia, reinforcing the statement.

+ 1 more reference

Abnormality of GABAergic Signaling

Dysfunction in GABAergic inhibitory neurotransmission, contributing to excitatory/inhibitory (E/I) imbalance in cortical circuits.

parvalbumin-positive interneuron CL:0000099

GAD1 hgnc:4092 RELN hgnc:9957

synaptic transmission, GABAergic GO:0051932

prefrontal cortex UBERON:0000451

Downstream

Dysregulation of Dopamine Neurotransmission Loss of interneuron restraint leaves pyramidal cells overactive, and that overactivity — hippocampal in particular — drives the subcortical hyperdopaminergic state. This is the edge that makes the cortical and dopaminergic halves of the entry one graph: it is how a cortical lesion produces a striatal symptom.

Working Memory Deficits Parvalbumin basket-cell inhibition of pyramidal cells is what generates prefrontal gamma oscillations, and those oscillations are required for working memory. The deficit is a direct functional consequence of the inhibitory abnormality, not a downstream dopaminergic effect — which is why antipsychotics do not treat it.

Show evidence (5 references)

PMID:10372507 SUPPORT

"At the cellular level, gamma-aminobutyric acid (GABA)-ergic interneurons are a common feature in psychotic states... and are themselves synchronised by the ascending dopamine and serotonin innervations."

The literature highlights that GABAergic interneurons play a significant role in the cellular characteristics found in psychotic states, including schizophrenia.

PMID:22308256 SUPPORT

"Disturbances in glutamate and GABAergic neurotransmission may underlie the pathophysiology of schizophrenia."

This reference directly states that disturbances in GABAergic neurotransmission may underlie the pathophysiology of schizophrenia.

PMID:34584230 SUPPORT

"Reduced GABA levels indicate that the disruption of excitatory/inhibitory balance may be related to the pathophysiology of schizophrenia-spectrum disorders."

This meta-analysis supports the idea that reduced GABA levels and thus GABAergic dysfunction are related to the pathophysiology of schizophrenia.

+ 2 more references

Cortical Muscarinic M1 Receptor Deficit

Mechanism confidence: Provisional

Selective loss of M1 muscarinic acetylcholine receptor protein, mRNA and pirenzepine binding in dorsolateral prefrontal cortex (Brodmann area 9). The deficit is bimodally rather than uniformly distributed: kernel density estimation separates a distinct postmortem subgroup — muscarinic receptor-deficit schizophrenia (MRDS) — at roughly a quarter of cases, with a ~74% reduction in cortical binding, from a non-MRDS majority whose binding overlaps controls.

CHRM1 hgnc:1950

muscarinic acetylcholine receptor signalling in prefrontal cortex GO:0007213 ↓ DECREASED

M1 muscarinic acetylcholine receptor activity GO:0016907 ↓ DECREASED

dorsolateral prefrontal cortex (Brodmann area 9) UBERON:0009834

Downstream

Working Memory Deficits Prefrontal M1 signalling supports working memory and verbal learning, and a muscarinic agonist improved exactly those measures in patients — an inference from therapeutic response rather than a direct demonstration that the receptor deficit causes the impairment.

Show evidence (3 references)

PMID:12476323 SUPPORT DIRECT Human Clinical

"The level of M1R protein (0.11 +/- 0.007 vs 0.15 +/- 0.008 OD; P < 0.01), but not M4R protein, was decreased in BA9 from schizophrenic subjects with neither receptor protein being altered in BA 40."

The measured protein-level deficit, in 20 patients against 20 age/sex-matched controls, and the source of this node's two selectivity claims — M1 over M4, and BA9 over BA40.

PMID:18317461 SUPPORT DIRECT Human Clinical

"We suggest that these individuals make up 'muscarinic receptor-deficit schizophrenia' (MRDS)."

Names the subgroup that the study's kernel density estimation separated from the rest of the schizophrenia cohort — 26% of subjects, with a 74% reduction in cortical pirenzepine binding — which is what licenses stating this node as a subgroup finding rather than a syndrome-wide one.

PMID:12505810 SUPPORT DIRECT Human Clinical

"Muscarinic receptor availability was significantly less in patients with schizophrenia than in normal subjects in all regions of interest except the pons."

Replicates the cortical deficit in living, medication-free patients by SPECT, ruling out both postmortem artefact and antipsychotic-induced receptor change.

Loss of M4 Receptor Restraint of Striatal Dopamine Release

Mechanism confidence: Hypothetical

Cholinergic input to the striatum and substantia nigra normally holds dopaminergic transmission in check through the M4 muscarinic receptor: M4 activation on spiny projection neurons produces a sustained depression of striatal dopamine release, and nigral M4 opposes D1 signalling in direct-pathway presynaptic terminals. Weakened M4 restraint is proposed to permit the striatal dopamine dysregulation that generates positive symptoms, and supplies the mechanistic route by which a non-D2 muscarinic agonist reaches the canonical dopamine node.

striatal spiny projection neuron CL:1001474 cholinergic neuron CL:0000108

CHRM4 hgnc:1953

muscarinic restraint of striatal dopamine release GO:0033602 ↓ DECREASED

striatum UBERON:0002435 substantia nigra pars reticulata UBERON:0002038

Downstream

Dysregulation of Dopamine Neurotransmission Reduced M4-mediated cholinergic braking releases striatal dopamine release from restraint, feeding the dopaminergic dysregulation that drives positive symptoms.

Show evidence (2 references)

PMID:29268098 SUPPORT DIRECT Model Organism

"extra-striatal cholinergic projections from the pedunculopontine nucleus to the substantia nigra pars reticulata (SNr) act on muscarinic acetylcholine receptor subtype 4 (M4) to oppose cAMP-dependent dopamine receptor subtype 1 (D1) signaling in presynaptic terminals of direct pathway striatal..."

Locates a second, extra-striatal arm of M4 opposition to dopamine signalling, and is why this node's locations include the substantia nigra as well as the striatum.

PMID:12505810 SUPPORT INDIRECT Human Clinical

"Positive symptoms of schizophrenia correlated negatively with muscarinic receptor availability in the striatum and the frontal cortex."

The only human data tying striatal muscarinic tone to the symptom domain this node is proposed to explain. INDIRECT because it is a cross-sectional correlation with total muscarinic binding, not a measurement of M4-specific control of dopamine release.

Complement-Mediated Excessive Synaptic Pruning

Excessive loss of cortical and hippocampal synapses associated with complement component C4A. The effector step is contested rather than settled: mouse C4 overexpression paradigms disagree on whether the synaptic loss requires microglial complement receptor 3, and one of them reports decreased rather than increased microglia-synapse interaction, so CR3-dependent microglial engulfment should be read as one candidate mechanism among several. The developmental window is likewise unsettled, since human postmortem complement activator expression peaks well before adolescence.

Complement-Mediated Synaptic Pruning Hypothesis

microglial cell CL:0000129

C4A hgnc:1323 C3 hgnc:1318

complement activation GO:0006956 synapse pruning GO:0098883

prefrontal cortex UBERON:0000451 hippocampus UBERON:0001954

Downstream

Dysregulation of Dopamine Neurotransmission Excessive complement- and microglia-mediated synapse elimination can disrupt cortical pyramidal-neuron circuits and disinhibit mesostriatal projections, providing an indirect route from adolescent synaptic loss to dopamine overactivity and psychosis.

Abnormality of Glutamergic Signaling The synapses removed are overwhelmingly cortical excitatory ones, so over-pruning is a route into the glutamatergic node as well as the dopaminergic one. The same sentence of the synaptic-hypothesis review carries both arms: pyramidal-neuron dysfunction here, mesostriatal disinhibition on the dopamine edge above.

Show evidence (7 references)

PMID:26814963 SUPPORT Human Clinical

"We found that these alleles generated widely varying levels of C4A and C4B expression in the brain, with each common C4 allele associating with schizophrenia in proportion to its tendency to generate greater expression of C4A."

Human genetic and brain-expression evidence anchors the upstream C4A-risk component of the complement-pruning hypothesis without relying on the paper's separate model-organism synapse-elimination result.

PMID:37041418 SUPPORT Other

"Genome-wide association studies have identified a number of schizophrenia risk variants converging on pathways regulating synaptic elimination, formation and plasticity, including complement factors and microglial-mediated synaptic pruning."

This review integrates genetic, imaging, postmortem, iPSC, and preclinical data and directly places complement factors and microglial synaptic pruning in the synaptic hypothesis of schizophrenia.

PMID:30718903 SUPPORT In Vitro

"Using a reprogrammed in vitro model of microglia-mediated synapse engulfment, we demonstrate increased synapse elimination in patient-derived neural cultures and isolated synaptosomes."

Patient-derived neural cultures and synaptosomes provide disease-relevant in vitro evidence that microglia-mediated synapse elimination is increased in schizophrenia models.

+ 4 more references

Oligodendrocyte and Myelin Dysfunction

Abnormalities in oligodendrocytes and myelin sheaths leading to white matter changes and network dysconnectivity across brain regions.

oligodendrocyte CL:0000128

myelination GO:0042552

prefrontal cortex UBERON:0000451 hippocampus UBERON:0001954

Show evidence (2 references)

PMID:31653579 SUPPORT DIRECT Human Clinical

"A significant reduction in the Nv of oligodendrocytes was found in schizophrenia and BPD as compared to the control group"

Postmortem stereological cell counts establishing the cellular deficit this node asserts. Not specific to schizophrenia — the same reduction appears in bipolar disorder, which the node's description should not be read as denying.

PMID:29861197 REFUTE DIRECT Human Clinical

"No difference in FA was found between patients with severe and patients with mild FTD."

Cited against the tempting downstream link rather than for it: if white matter integrity does not separate severe from mild formal thought disorder, it does not support an edge from this node to Disorganized Thinking. Recorded so the absent edge reads as a finding rather than an omission.

Mitochondrial Dysfunction and Oxidative Stress

Bioenergetic deficits including complex I inhibition, decreased glutathione, increased lactate, and oxidative/nitrosative stress creating a feed-forward cycle with neuroinflammation.

oxidative phosphorylation GO:0006119 cellular response to oxidative stress GO:0034599

prefrontal cortex UBERON:0000451

Downstream

Abnormality of GABAergic Signaling Parvalbumin interneurons are the cortical cell type most exposed to redox stress — their high firing rate and metabolic load make them the first to fail when glutathione synthesis is impaired. This is the node's route into the cortical circuit, and it is why an antioxidant is a candidate treatment for a GABAergic lesion.

Show evidence (2 references)

PMID:33221354 SUPPORT DIRECT Human Clinical

"Decreased activity of complexes I and IV are prominent as well as abnormal levels of individual subunits that comprise the complexes of the electron transport chain."

Postmortem review supporting the complex I deficit this node's description asserts, which until now carried no citation at all.

PMID:40162239 SUPPORT Human Clinical

"A gene program largely shared between neuronal subtypes, astrocytes, and oligodendrocytes was significantly enriched for schizophrenia risk, supporting an aetiological role for perturbed protein modification, ion transport, and mitochondrial function."

Single-nucleus RNA-seq of 536,618 nuclei from dorsal prefrontal cortex of 43 cases and 42 controls ties a mitochondrial gene program to schizophrenia genetic risk. This is a different claim from the postmortem enzyme-activity citation above: it connects the bioenergetic lesion to inherited risk rather than measuring respiratory-chain function. Two limits on how far it reaches: the finding is postmortem differential expression and co-expression enrichment, so it cannot order bioenergetic failure relative to synaptic or interneuron changes, and the deposited record is a medRxiv preprint.

Blood-Brain Barrier Dysfunction

Increased BBB permeability with elevated CSF albumin and immunoglobulins, involving dysfunction of endothelial cells, pericytes, and astrocytes in the neurovascular unit.

endothelial cell CL:0000115 astrocyte CL:0000127

blood-brain barrier

Show evidence (1 reference)

PMID:35939296 SUPPORT DIRECT Human Clinical

"CSF/serum albumin ratio (Relative Mean Difference (MD): 1.11; 95%CI: 1.00-1.23; P = .044) and CSF/serum IgG ratio (MD: 1.17; 95%CI: 1.01-1.36; P = .036) was increased in patients compared to controls."

104 recent-onset psychosis patients against 104 individually matched controls — the largest matched CSF series for this claim, and the source for the raised albumin and IgG ratios in this node's description, which previously carried no citation.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

7

Nervous System 3

Hallucinations FREQUENT HP:0000738

Often auditory in nature, such as hearing voices. Can also be visual, tactile, or olfactory.

Show evidence (4 references)

PMID:28437056 SUPPORT

"Schizophrenia symptoms fall into six common symptom clusters: delusions and hallucinations, disorganization of speech, cognitive dysfunction, negative symptoms, affective symptoms, and motor system abnormalities."

Delusions and hallucinations are recognized as common symptom clusters in schizophrenia, supporting the statement that hallucinations are frequent and a part of the psychiatric diagnostic category.

PMID:25773224 SUPPORT

"Schizophrenia is a complex mental disorder associated with not only cognitive dysfunctions, such as memory and attention deficits, but also changes in basic sensory processing."

This supports the note that hallucinations in schizophrenia can be auditory, visual, tactile, or olfactory in nature, indicating changes in sensory processing.

PMID:21545448 SUPPORT

"Prevalence of OHs and hallucinations in other modalities differed according to the WHO-10 international centre. Across centres, OHs were present in 13% of the WHO-10 dataset, similar to the 17% prevalence rate in the SAPS/SANS dataset."

This supports the claim that olfactory hallucinations are among the types of hallucinations experienced by schizophrenic patients, although less frequent than auditory hallucinations.

+ 1 more reference

Delusions FREQUENT HP:0000746

False beliefs, often paranoid or grandiose in nature. Resistant to contradictory evidence.

Show evidence (4 references)

PMID:33485408 SUPPORT

"Delusions are commonly conceived as false beliefs that are held with certainty and which cannot be corrected. This conception of delusion has been influential throughout the history of psychiatry and continues to inform how delusions are approached in clinical practice and in contemporary..."

The literature describes delusions as false beliefs that are resistant to contradictory evidence, which aligns with the statement's note that delusions in schizophrenia are often paranoid or grandiose in nature.

PMID:949230 SUPPORT

"The underlying diagnosis of Capgras delusion is not found to be exclusively paranoid schizophrenia, nor is the sex exclusively female, as once was believed."

While Capgras delusion may involve delusions, the reference suggests that these delusions are not exclusively found in paranoid schizophrenia. This partially supports the statement but adds another layer of complexity.

PMID:29151090 NO_EVIDENCE

"Non-bizarre delusion, defined as a false belief possible although highly unlikely, is the main manifestation of delusional disorders, previously known as paranoia."

The description of non-bizarre delusions aligns with the statement that delusions, which are false beliefs, are a frequent psychiatric diagnostic category in schizophrenia.

+ 1 more reference

Flat Affect FREQUENT Emotional dearth HP:0030213

Reduced expression of emotions. May appear unresponsive or lacking emotional depth.

Show evidence (6 references)

PMID:16452608 SUPPORT

"Impaired emotional functioning in schizophrenia is a prominent clinical feature that manifests primarily as flat affect... Flat affect was more common in men and was associated with poorer premorbid adjustment, worse current quality of life, and worse outcome at 1-year follow-up."

The study provides evidence that flat affect is a frequent and prominent clinical feature of schizophrenia, which aligns with the statement.

PMID:23846857 SUPPORT

"Schizophrenia probands showed more symptoms and lower psychosocial functioning than probands with psychotic bipolar disorder, but there was considerable overlap in clinical manifestations."

The reference suggests that flat affect, which is an emotional deficit, is part of the clinical phenotype of schizophrenia.

PMID:31839552 SUPPORT

"Voice atypicalities have been a characteristic feature of schizophrenia ... They are often associated with core negative symptoms such as flat affect and alogia ... This suggests that voice atypicalities may represent a marker of clinical features and social functioning in schizophrenia."

The study mentions flat affect as one of the core negative symptoms of schizophrenia, supporting its frequent occurrence within the schizophrenia phenotype.

+ 3 more references

Other 4

Disorganized Thinking FREQUENT

Impaired logical thought process and communication. May manifest as loose associations or incoherent speech.

Show evidence (5 references)

PMID:30488088 SUPPORT

"Disorganized speech is one of the key symptoms of schizophrenia. This article provides an overview of those areas of speech and communication impaired in patients with schizophrenia."

Disorganized thinking is closely related to disorganized speech, which is highlighted as a frequent impairment in schizophrenia.

PMID:2084786 SUPPORT

"The course of psychoses of schizophrenic type follows rules which are still not adequately understood. It is, however, clear that certain symptoms appear mostly early, others only late... we studied 44 final phase patients whose main symptom was disordered thinking of the schizophasic type."

The study highlights disordered thinking (a form of cognitive impairment) as a main symptom in later stages of schizophrenia.

PMID:37040138 SUPPORT

"Patients with schizophrenia were impaired in both analytic and common-sense thinking."

Impaired logical thought processes and communication, which might manifest as loose associations or incoherent speech, align with the cognitive phenotype of disorganized thinking.

+ 2 more references

Working Memory Deficits FREQUENT

Difficulties in short-term information storage and manipulation.

Show evidence (4 references)

PMID:36252418 SUPPORT

"Our data gives preliminary support to the hypotheses that there is a working memory deficit phenotype within the syndrome of schizophrenia with has a biological underpinning."

Evidence suggests there is a working memory deficit phenotype within schizophrenia.

PMID:30104335 SUPPORT

"PFC dysfunction is widely believed to underlie working memory (WM) deficits in people with schizophrenia (PSZ)...These results indicate that PPC dysfunction is central to WM storage deficits in PSZ and may play a key role in the broad cognitive deficits associated with schizophrenia."

The literature highlights WM deficits as a central part of cognitive impairment in schizophrenia.

PMID:20053864 SUPPORT

"Working memory impairment is considered a core deficit in schizophrenia."

The study directly supports the existence of working memory deficits as a core phenotype in schizophrenia.

+ 1 more reference

Catatonia OCCASIONAL

Abnormal motor behavior, ranging from excessive movement to immobility.

Show evidence (6 references)

PMID:11478416 SUPPORT

"Catatonia is a parallel behavior phenomenon to delusions (in thought) and delirium (in cognition)."

The reference suggests catatonia is associated with schizophrenia but does not specify the frequency of this phenotype.

PMID:34785041 SUPPORT

"Lower activity levels correlated with increased age and severity of catatonia and parkinsonism. The 22 patients with catatonia had lower activity as well as higher scores on parkinsonism, involuntary movements, and negative symptoms compared to the 30 patients without catatonia."

The study indicates catatonia is present in some patients with schizophrenia but does not specify its frequency.

PMID:22814247 SUPPORT

"Classical schizophrenia literature reports motor symptoms as characteristic of the disorder... This review of the literature supports the idea that motor symptoms are closely related to the neurodevelopmental disturbances of schizophrenia and a distinct syndromal dimension with its own pathophysiology."

The literature suggests catatonia, as a motor symptom, is a recognized aspect of schizophrenia.

+ 3 more references

🧬

Genetic Associations

14

SETD1A (Risk Factor)

Gene: SETD1A hgnc:29010 gene page relationship_type: RISK_FACTOR

Show evidence (4 references)

PMID:26974950 SUPPORT Human Clinical

"we identified a genome-wide significant association between rare loss-of-function (LoF) variants in SETD1A and risk for schizophrenia (P = 3.3 × 10(-9))"

The primary genome-wide-significant association establishing SETD1A rare loss-of-function variants as a large-effect schizophrenia risk factor.

PMID:26974950 SUPPORT Human Clinical

"We found only two heterozygous LoF variants in 45,376 exomes from individuals without a neuropsychiatric diagnosis, indicating that SETD1A is substantially depleted of LoF variants in the general population."

Quantifies the constraint that underlies the large effect size - SETD1A LoF is close to absent in unaffected individuals.

PMID:26974950 SUPPORT Human Clinical

"Combining these data with previous common variant evidence, we suggest that epigenetic dysregulation, specifically in the histone H3K4 methylation pathway, is an important mechanism in the pathogenesis of schizophrenia."

Sources the mechanistic claim in the notes - that the relevant lesion is H3K4-methylation-pathway epigenetic dysregulation, not a synaptic protein defect.

+ 1 more reference

NRXN1 (Risk Factor)

Gene: NRXN1 hgnc:8008

22q11.2 deletion (DiGeorge / Velocardiofacial Syndrome locus) (Risk Factor)

DRD2 (Risk Factor)

Gene: DRD2 hgnc:3023 gene page

GRIN1 (Risk Factor)

Gene: GRIN1 hgnc:4584 gene page

GRIN2A (Risk Factor)

Gene: GRIN2A hgnc:4585 gene page

GAD1 (Risk Factor)

Gene: GAD1 hgnc:4092 gene page

RELN (Risk Factor)

Gene: RELN hgnc:9957 gene page

C4A (Risk Factor)

Gene: C4A hgnc:1323 gene page

C3 (Risk Factor)

Gene: C3 hgnc:1318 gene page

DISC1 (Risk Factor)

Gene: DISC1 hgnc:2888

Show evidence (4 references)

PMID:30286368 SUPPORT

"DISC1 gene has been shown as a risk factor for schizophrenia in some reports."

The meta-analysis confirms associations between specific SNPs in the DISC1 gene and schizophrenia risk.

PMID:24056909 NO_EVIDENCE

"Questions about DISC1 as a genetic risk factor for schizophrenia."

This reference raises questions about the role of DISC1 as a risk factor, implying a lack of consensus.

PMID:30285728 SUPPORT

"The human DISC1 gene is located on chromosome 1 and is highly associated with schizophrenia and other mental disorders."

This study associates the DISC1 gene with schizophrenia among other mental disorders, supporting its role as a risk factor.

+ 1 more reference

COMT (Risk Factor)

Gene: COMT hgnc:2228 gene page

Show evidence (1 reference)

PMID:23573605 SUPPORT

"COMT is an enzyme that is distributed widely throughout the brain, but seems to be uniquely relevant to how dopamine affects information-processing in the prefrontal cortex. There is a common variation in the genetic sequence of the COMT gene, which causes a dramatic change in its enzyme..."

The COMT gene is identified as a weak genetic risk factor for schizophrenia, increasing the risk by 50-80% in family studies.

NRG1 (Risk Factor)

Gene: NRG1 hgnc:7997 gene page

Show evidence (4 references)

PMID:16520822 SUPPORT

"Our meta-analysis provides support for the association of NRG1 with schizophrenia, but indicates that firmly establishing the role of NRG1 gene in schizophrenia by genetic association requires much larger sample sizes than have hitherto been reported."

The meta-analysis found some evidence supporting the association of NRG1 with schizophrenia, but also highlighted the need for larger sample sizes to firmly establish this role.

PMID:15162166 SUPPORT

"Recently, the gene that encodes neuregulin-1 (NRG1) has been identified as a potential susceptibility gene for schizophrenia, and defects in the expression of erbB3, one of the NRG1 receptors, have been shown to occur in the prefrontal cortex of schizophrenic patients..."

This reference identifies NRG1 as a potential susceptibility gene for schizophrenia, indicating a genetic association.

PMID:20600464 SUPPORT

"We mainly focus on genes including:...NRG1 (Neuregulin 1)... Taken together there is converging evidence for the contribution of genes potentially related to alterations in intracellular Ca-homeostasis to the risk of schizophrenia."

This review points to NRG1 as a gene potentially related to the risk of schizophrenia.

+ 1 more reference

DTNBP1 (Risk Factor)

Gene: DTNBP1 hgnc:17328 gene page

Show evidence (3 references)

PMID:19862852 SUPPORT

"This study shows that DTNBP1 is a risk gene for schizophrenia in EAs. Variation at DTNBP1 may modify risk for schizophrenia in this population."

This reference provides evidence that DTNBP1 is associated with an increased risk of schizophrenia, particularly in European-Americans.

PMID:18474210 SUPPORT

"To date, DTNBP1 has provided the greatest evidence of illness modification, as associations with negative and cognitive symptoms and worse outcome have been published in independent samples."

This reference elaborates on the association of DTNBP1 with specific clinical features of schizophrenia, further supporting its role as a risk factor.

PMID:24968777 SUPPORT

"It considers models for understanding the role(s) of risk genes, with a particular focus on DTNBP1 and NRG1, their interactions with environmental factors, and with each other (epistasis)."

This reference discusses the role of DTNBP1 as a risk gene for schizophrenia within the context of genetic and environmental interactions.

💊

Medical Actions

7

Xanomeline-Trospium (KarXT)

Action: Pharmacotherapy NCIT:C15986

Agent: xanomeline CHEBI:10056 trospium CHEBI:145791

Platform: Small molecule

Dosing: twice per day every 0.5 days

First-in-class M1/M4 muscarinic receptor agonist (xanomeline) combined with the peripherally-restricted pan-muscarinic antagonist trospium chloride to mitigate peripheral cholinergic side effects. FDA-approved September 2024 for schizophrenia in adults, marketed as Cobenfy. Acts without direct D2 dopamine-receptor blockade, which shows that direct D2 antagonism is not required for antipsychotic efficacy. That is a weaker statement than a dopamine independent mechanism: M4 receptor activation produces a sustained depression of striatal dopamine release, so muscarinic agonism may still converge on the dopamine system downstream.

Mechanism Target:

RESTORES Loss of M4 Receptor Restraint of Striatal Dopamine Release — Xanomeline agonism at M4 restores cholinergic restraint on striatal dopamine release, which is the proposed route by which the drug reaches the dopamine node without binding D2 receptors.

Show evidence (1 reference)

PMID:38104575 SUPPORT INDIRECT BACKGROUND Human Clinical

"Xanomeline is a dual M1 and M4-preferring muscarinic receptor agonist that does not block D2 dopamine receptors, unlike all currently approved treatments for schizophrenia."

Establishes the pharmacology of the link — M4 agonism with no D2 activity. INDIRECT because the trial measures symptom change, not the striatal dopamine release this edge asserts is restored; that step rests on the rodent work cited at the target node.

MODULATES Cortical Muscarinic M1 Receptor Deficit — Agonist occupancy raises signalling through the M1 receptors that remain rather than replacing lost receptor protein, so the drug compensates for the deficit without correcting it. `MODULATES` rather than `BYPASSES`: the drug acts on the very receptor the node describes, so it is not routing around the lesion by another pathway. Not `RESTORES` either — receptor protein stays low. Whether patients with the marked cortical deficit (MRDS) respond better than others has never been tested, because trial entry has never been stratified by muscarinic status.

Show evidence (1 reference)

PMID:18593778 SUPPORT INDIRECT Human Clinical

"In the cognitive test battery, subjects in the xanomeline group showed improvements most robustly in measures of verbal learning and short-term memory function."

The cognitive domain attributed to prefrontal M1 signalling improved under M1/M4 agonism in an unstratified cohort. INDIRECT — it shows the pathway is drug-tractable, not that the cortical receptor deficit itself was engaged.

Show evidence (3 references)

PMID:41506001 SUPPORT Human Clinical

"The M1/M4 muscarinic receptor agonist xanomeline combined with the peripherally restricted pan-muscarinic receptor antagonist trospium chloride is the first approved treatment for adults with schizophrenia with no direct D2 dopamine receptor blockade."

EMERGENT-5 confirms KarXT's first-in-class non-D2 antipsychotic mechanism, supporting the model's qualification that D2 antagonism is not exclusively required for antipsychotic efficacy.

PMID:38104575 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"The trial met the primary endpoint with a mean change from baseline to week 5 in PANSS total score that favoured KarXT (-21·2 points, SE 1·7) versus placebo (-11·6 points, 1·6; least squares mean difference -9·6; 95% CI -13·9 to -5·2; p<0·0001, Cohen's d effect size=0·61)."

EMERGENT-2, the pivotal placebo-controlled phase 3 trial (n=252, 5 weeks), quantifying the efficacy of the treatment on total symptom burden.

PMID:38691387 SUPPORT DIRECT Human Clinical

"These findings, together with the previously reported and consistent results from the EMERGENT-1 and EMERGENT-2 trials, support the potential of xanomeline-trospium to be the first in a putative new class of antipsychotic medications without D2 dopamine receptor blocking activity."

EMERGENT-3 independently replicates the result in a second phase 3 cohort, which is what raises the finding above a single-trial effect.

Antipsychotic Medications

Action: Pharmacotherapy NCIT:C15986

Agent: risperidone CHEBI:8871 olanzapine CHEBI:7735 clozapine CHEBI:3766

Platform: Small molecule

Medications such as risperidone, olanzapine, and clozapine to manage symptoms.

Mechanism Target:

INHIBITS Dysregulation of Dopamine Neurotransmission — Antipsychotics block striatal dopamine D2 receptors, dampening the mesolimbic dopaminergic hyperactivity that drives positive psychotic symptoms.

Show evidence (6 references)

PMID:12769630 SUPPORT

"With the use of chlorpromazine and other traditional antipsychotics for psychosis, it was soon discovered that the antipsychotic efficacy of this class of medications was closely associated with their ability to block dopamine D(2) receptors in the brain."

This reference supports the statement that antipsychotic medications act through dopamine D2 receptor antagonism. It also mentions medications like clozapine, risperidone, and others, but does not specifically mention olanzapine in this context.

PMID:8626371 SUPPORT

"The introduction of novel antipsychotic agents, such as clozapine and risperidone, has enhanced the clinicians' ability to manage schizophrenic patients."

This supports the usage of clozapine and risperidone but does not detail the mechanism focused on dopamine D2 receptor antagonism.

PMID:8823348 SUPPORT

"Clozapine has shown to be effective in some poor or partially responsive patients in three prospective, random assignment, double-blind trials."

Supports effectiveness of clozapine in treatment-resistant patients but does not address dopamine D2 receptor antagonism directly.

+ 3 more references

Cognitive Behavioral Therapy (CBT)

Action: behavioral counseling Ontology label: Behavioral Counseling NCIT:C181743

Platform: Behavioral / lifestyle

Therapy aimed at changing maladaptive thought patterns and behaviors.

Show evidence (4 references)

PMID:20880828 SUPPORT

"There is good evidence from a considerable number of clinical trials that CBTp has a consistent clinical benefit when used in addition to standard care."

This indicates that Cognitive Behavioral Therapy (CBT) is a recognized treatment for schizophrenia that aims at changing maladaptive thought patterns and behaviors.

PMID:27335156 SUPPORT

"Cognitive behavioural therapy for psychosis and cognitive remediation are 2 psychosocial interventions that have demonstrated positive outcomes for violence in SCZ."

This highlights that CBT, which focuses on changing maladaptive thought patterns and behaviors, is effective in treating certain symptoms of schizophrenia.

PMID:17716100 SUPPORT

"A theoretical analysis of schizophrenia based on a cognitive model integrates the complex interaction of predisposing neurobiological, environmental, cognitive, and behavioral factors with the diverse symptomatology."

The statement aligns with the cognitive approach to schizophrenia, which underpins CBT.

+ 1 more reference

Social Skills Training

Action: behavioral counseling Ontology label: Behavioral Counseling NCIT:C181743

Platform: Behavioral / lifestyle

Programs to enhance social interactions and functioning.

Show evidence (6 references)

PMID:16885207 SUPPORT

"Social skills training consists of learning activities utilizing behavioral techniques that enable persons with schizophrenia and other disabling mental disorders to acquire interpersonal disease management and independent living skills for improved functioning in their communities."

The study states that social skills training helps individuals with schizophrenia to improve functioning in their communities by acquiring interpersonal and independent living skills.

PMID:31708048 SUPPORT

"Common elements to these interventions include building a therapeutic alliance, recovery orientation, education, and skills training, which can be directed to a range of targets, including problem-solving, communication, social skills, and social cognition."

Clinical therapies for first-episode psychosis as part of coordinated specialty care (CSC) include skills training directed at social skills.

PMID:23773889 SUPPORT

"METHODOLOGY: Social skills training, cognitive behavioral therapy, cognitive remediation, and social cognitive training therapy paradigms were searched and the extant literature is summarized for each, with particular focus on: 1) the rationale for treatment methodology; 2) particular methods of..."

This reference indicates that social skills training is a recognized psychosocial method used to treat schizophrenia and discusses its efficacy.

+ 3 more references

Supportive Therapy

Action: supportive care Ontology label: Supportive Care NCIT:C15747

Ongoing support to help manage daily life and stress.

Show evidence (3 references)

PMID:15176765 SUPPORT

"This article posits that the positive findings for supportive therapy (ST) in recent trials may indicate an important but undervalued aspect of psychosocial interventions for schizophrenia."

The article discusses the benefits of supportive therapy in schizophrenia treatment and emphasizes mechanisms such as the therapeutic alliance and social support, indicating that ongoing support helps manage daily life and stress.

PMID:23244011 SUPPORT

"The intervention group improved significantly on measures of both PANSS and GAF scores, with large effect sizes at two years follow-up after inclusion. Further, improvement on GAF(function) (p = 0.000) and GAF(symptom) (p = 0.010) significantly favored SPP in combination with TaU over TaU alone."

Supportive psychodynamic psychotherapy, a variant of supportive therapy, was found to significantly improve symptoms and functional outcomes, underscoring its role in ongoing support for managing stress and daily life in schizophrenia.

PMID:31708048 SUPPORT

"Group, individual, and family therapies in CSC aim to help the client and family understand and cope with the experience of psychosis, promote symptomatic and functional recovery and improve quality of life, and support the pursuit of personally meaningful goals of the client."

Coordinated specialty care, including supportive interventions, focuses on coping, recovery, and quality of life, indicating the importance of ongoing support.

Vocational Rehabilitation

Action: occupational therapy Ontology label: Occupational Therapy NCIT:C121351

Platform: Behavioral / lifestyle

Help with gaining and maintaining employment.

Show evidence (5 references)

PMID:8749891 SUPPORT

"Most vocational rehabilitation programs have a positive influence on work-related activities, but most have failed to show substantial and enduring impacts on independent, competitive employment."

While vocational rehabilitation programs have positive influences on work-related activities, they have not generally shown substantial and enduring impacts on competitive employment.

PMID:31327504 SUPPORT

"At the end of two years in the service, 829 (70.4%) patients were meaningfully employed and 348 (29.6%) patients were unemployed."

Vocational programs have shown promise with a significant portion of patients being gainfully employed, but it does not necessarily indicate maintaining stable employment over long periods.

PMID:18715755 SUPPORT

"NET training improved vocational outcomes, suggesting the value of combining cognitive remediation with other rehabilitation methods to enhance functional outcomes."

Neurocognitive enhancement therapy combined with vocational services showed improved employment outcomes, supporting the positive impact on gaining and maintaining employment.

+ 2 more references

Virtual Reality-Assisted Therapy (VRT)

Action: behavioral counseling Ontology label: Behavioral Counseling NCIT:C181743

Platform: Behavioral / lifestyle

Immersive virtual reality-based intervention that uses simulated environments to help patients with auditory verbal hallucinations (AVH) confront, understand, and manage their voices. VRT creates a presence-based experience where patients can practice coping strategies in a safe, controlled setting with voice avatars representing hallucinations.

Mechanism Target:

INHIBITS Hallucinations — Nine sessions of virtual reality-assisted therapy reduced auditory verbal hallucination severity relative to a 9-session targeted short course of cognitive behavioral therapy in a randomized, assessor-blind trial of adults with treatment-resistant schizophrenia. VRT achieved moderate effect sizes at 3 months (d=0.614) and showed sustained benefits compared to that CBT comparator.

Show evidence (1 reference)

PMID:42671824 SUPPORT Human Clinical

"VRT outperformed a targeted short course of CBT in reducing persistent AVH for up to three months after the intervention"

Randomized, assessor-blind, parallel-group trial comparing 9-session VRT to 9-session CBT in 136 participants with treatment-resistant schizophrenia. Intention-to-treat analyses showed significant time-by-treatment interaction favoring VRT (p=0.013) with moderate effect size at 3 months (d=0.614).

Show evidence (1 reference)

PMID:42671824 SUPPORT Human Clinical

"VRT outperformed a targeted short course of CBT in reducing persistent AVH for up to three months after the intervention in a North American population with treatment-resistant schizophrenia."

Randomized, assessor-blind, parallel-group trial (NCT04054778) comparing 9-session VRT to 9-session CBT in 136 adults with treatment-resistant schizophrenia or schizoaffective disorder and persistent AVH. Intention-to-treat analyses showed significant time-by-treatment interaction favoring VRT (p=0.013) with moderate effect size at 3 months (d=0.614). Both therapies demonstrated within-group improvements, with VRT showing large effect sizes (d=0.81 post-therapy, d=1.17 at 3-month follow-up) versus CBT's moderate effects (d=0.58 post-therapy, d=0.39 at 3 months). There were no between-group differences for secondary outcomes; within-group improvements in general psychotic symptoms, emotional regulation, and voice acceptance were observed for both therapies.

🌍

Environmental Factors

2

Prenatal Stress

Exposure to stress during fetal development may increase risk.

Show evidence (5 references)

PMID:33544627 SUPPORT

"we appraise the evidence linking schizophrenia spectrum disorder to prenatal maternal stress."

The review provides evidence linking prenatal stress to the risk of schizophrenia spectrum disorder.

PMID:26968981 SUPPORT

"prenatal stress induces neurodevelopmental alterations in the prefrontal cortex that are expressed as cognitive impairment observed in schizophrenia."

The article discusses the association between prenatal stress and neurodevelopmental changes leading to schizophrenia.

PMID:26753951 SUPPORT

"Findings suggest sex-specific fetal sensitivity to maternal reported daily life stress during pregnancy on risk for SSD, with males appearing to be more vulnerable to the influences of maternal stress during pregnancy."

The study found that maternal stress during pregnancy is associated with increased risk of schizophrenia spectrum disorders in offspring, particularly males.

+ 2 more references

Cannabis Use

Associated with increased risk and earlier onset in genetically predisposed individuals.

Show evidence (5 references)

PMID:24957864 SUPPORT

"Although considerable evidence implicates cannabis use as a component cause of schizophrenia, it remains unclear whether this is entirely due to cannabis directly raising risk of psychosis, or whether the same genes that increases psychosis risk may also increase risk of cannabis use."

The study suggests that there is an association between cannabis use and schizophrenia, but it indicates that the genetic components might play a significant role, making it partially supportive.

PMID:26232243 SUPPORT

"Individuals with a history of cannabis abuse had an earlier age at onset by nearly six years."

The study provides direct evidence that cannabis use is associated with an earlier age at onset of psychosis.

PMID:21068828 SUPPORT

"onset is associated with environmental factors such as early life adversity, growing up in an urban environment, minority group position and cannabis use."

The association of environmental factors, including cannabis use, supports the idea of increased risk of schizophrenia.

+ 2 more references

🔬

Biochemical Markers

2

Dopamine Metabolites (Elevated)

Context: Observed in cerebrospinal fluid and postmortem brain analysis.

Show evidence (3 references)

PMID:37271040 SUPPORT

"CSF dopamine was reliably detected in 50% of healthy controls and in 65% of first-episode psychosis subjects and significantly higher in first-episode psychosis subjects compared to age-matched healthy controls."

This study shows increased cerebrospinal fluid dopamine levels, which are related to dopamine metabolism, in first-episode psychosis subjects, supporting elevated dopamine metabolites in CSF in schizophrenia.

PMID:9278185 NO_EVIDENCE

"The application of this strategy, and its value in overcoming some of the potential pitfalls of postmortem studies, is demonstrated in a series of investigations designed to test the hypothesis that dopamine neurotransmission is impaired in the entorhinal cortex in schizophrenia."

While it discusses postmortem brain analysis and dopamine dysfunction in schizophrenia, it does not specifically state elevated dopamine metabolites.

PMID:18366307 NO_EVIDENCE

"Although numerous studies have aimed to identify potential diagnostic markers in the CSF of schizophrenia patients, as yet not one has found its way to clinical application."

The study discusses the difficulty in identifying reliable diagnostic markers in the cerebrospinal fluid of schizophrenia patients without specifically mentioning elevated dopamine metabolites.

Glutamate Levels (Elevated)

Context: Observed in cerebrospinal fluid and postmortem brain analysis.

Show evidence (5 references)

PMID:18366307 NO_EVIDENCE

"Although numerous studies have aimed to identify potential diagnostic markers in the CSF of schizophrenia patients, as yet not one has found its way to clinical application."

The study discusses the search for diagnostic markers in CSF but does not provide specific evidence for elevated glutamate levels.

PMID:11684348 NO_EVIDENCE

"Kynurenic acid is an endogenous glutamate antagonist with a preferential action at the glycine-site of the N-methyl D-aspartate-receptor."

This study focuses on the elevated levels of kynurenic acid, not directly on glutamate levels.

PMID:20846490 SUPPORT

"Accordingly, it is possible that abnormalities in the biochemical cascades regulated by BH(4) may alter DA, 5-HT and Glu neurotransmission, and consequently contribute to the pathophysiology of different neuropsychiatric diseases including schizophrenia."

The study mentions alterations in glutamate (Glu) neurotransmission in schizophrenia, aligning with the statement.

+ 2 more references

🔬

Diagnosis

1

Positive and Negative Syndrome Scale (PANSS) (Clinician-rated scale for the typological and dimensional assessment of schizophrenia symptoms, used to grade symptom severity; a systematic review of its measurement properties calls it the most widely used tool for assessing the symptoms of schizophrenia. It is a severity measure, not a diagnostic test.)

PANSS NCIT:C124712

No LOINC code is bound because LOINC carries no PANSS code. The Monarch KG LOINC search returned nothing for "PANSS", "positive and negative syndrome scale", "BPRS" or "Brief psychiatric rating scale"; "schizophrenia" returned only a PhenX schizophrenia protocol panel, Minimum Data Set items and family-history items. No LOINC 2.83 Long Common Name (the Tuva Project release pinned in data/loinc/MANIFEST.yaml) contains PANSS, Positive and Negative Syndrome, BPRS or Brief Psychiatric Rating. With no LOINC score code there is nothing to key a severity band on, so no reference range is recorded. The diagnosis_term is the NCIT term for the PANSS, which is reachable from Clinical Intervention or Procedure. The instrument's items are not reproduced in this entry.

Show evidence (2 references)

PMID:3616518 SUPPORT PRIMARY RESULT Human Clinical

"We report on the development and initial standardization of the Positive and Negative Syndrome Scale (PANSS) for typological and dimensional assessment."

The development paper establishes the PANSS as a standardized instrument for assessing schizophrenia symptoms.

PMID:40255437 SUPPORT REVIEW SYNTHESIS Human Clinical

"Although the PANSS is the standard scale for schizophrenia symptom severity, its shortcomings regarding fundamental psychometric domains and practical applicability warrant the development of new scales for which appropriate methods should be applied from the start."

A systematic review identifies the PANSS as the standard severity scale while recording its psychometric limitations.

📈

Progression

3

Prodromal

Age: 15-25

Subtle changes in thoughts, feelings, and behavior

Show evidence (2 references)

PMID:10225329 SUPPORT

"In adolescence, preschizophrenics exhibit subtle changes in cognition and affect as well as a variety of anomalous subjective experiences (so-called 'basic symptoms'), suggesting 'trait' status of these features."

This reference indicates that during adolescence, which overlaps with the 15-25 age range, individuals who are preschizophrenic show subtle changes in their thoughts and feelings, aligning with the prodromal phase as described.

PMID:37027026 SUPPORT

"EOP patients had significantly more prodromal symptoms with a higher frequency of trouble with thinking, avolition and hallucinations than AOP patients."

This study supports the presence of subtle changes in thinking and behavior during the prodromal phase in early-onset psychosis, which includes patients younger than 18, blending into the 15-25 age range.

Onset

Age: 16-30

First episode of psychosis

Show evidence (4 references)

PMID:7654792 SUPPORT

"Early-onset schizophrenias (< or = 20 years) were compared with a medium-onset group (21 - < 35 years) and a late-onset group (35 - < 60 years) with regard to age and type of onset, early symptom-related course, social development and social course."

The study provides information about the age of onset and early course of schizophrenia that falls within the 16-30 age range but does not specifically address the entire age range spectrum for the onset of the first episode of psychosis.

PMID:20021319 SUPPORT

"There are progressive frontal changes in males with adolescent-onset psychosis... Ultra high-risk patients who subsequently develop psychosis and first-episode psychosis patients develop significant grey matter reduction in the planum polare, planum temporale and caudal region; a progressive..."

This literature provides evidence about the progression of schizophrenia, particularly related to brain changes, within the stated age range of 16-30 years during the onset phase of the first episode of psychosis.

PMID:10225329 SUPPORT

"Prodromal symptoms occur in a substantial proportion of preschizophrenics, followed by a short prepsychotic phase with the crystallization of a psychotic syndrome."

This reference supports the progression of schizophrenia during the onset phase and includes the age group that aligns with the 16-30 age range.

+ 1 more reference

Chronic

Long-term management of symptoms and functioning

Show evidence (4 references)

PMID:9789265 SUPPORT

"Long-term treatment of patients with chronic schizophrenias requires integration of many therapeutic approaches, co-operation of several professions, and regard for the views of patients and relatives."

The excerpt supports the idea that managing symptoms and functioning in chronic schizophrenia requires long-term management.

PMID:23172002 SUPPORT

"The evidence shows that although approximately 25% of people with schizophrenia have a poor long-term outcome, few of these show the incremental loss of function that is characteristic of neurodegenerative illnesses."

This statement supports the idea that while a subset of patients experience poor long-term outcomes, most do not have progressive deterioration like in neurodegenerative diseases.

PMID:10082190 SUPPORT

"The criteria proposed necessitate (i) diagnosis of schizophrenia by standard operational criteria, (ii) continuous hospitalization for at least the past 2 years, (iii) a level of psychosocial functioning of < or = 40 as measured by the Global Assessment Scale, and (iv) an intensity score of..."

The criteria for refractory schizophrenia include long-term management indicating that managing symptoms and functioning over time is essential.

+ 1 more reference

📊

Prevalence

1

global

Point Prevalence 300.0–700.0 per 100,000 >1 in 1,000

male_to_female_ratio: 1.4:1

Show evidence (1 reference)

PMID:18480098 SUPPORT

"The rate ratio for males:females was 1.4:1. Prevalence estimates also show prominent variation."

While the male to female ratio of incidence is reported as 1.4:1, the abstract does not provide exact figures on the percentage of the population affected except that there is prominent variation. Therefore, the part of the statement with the percentage is not directly supported by this source.

📊

Related Datasets

8

Mutations of schizophrenia risk gene SETD1A dysregulate synaptic function in human neurons geo:GSE278808

Schizophrenia (SCZ) is a complex neuropsychiatric disorder associated with both common risk variants of small effect sizes and rare risk variants of high penetrance. Rare protein truncating variants (PTVs) in SETD1A (SET Domain Containing 1A) show a strong association with SCZ; however, it remains largely unclear how rare PTVs in SETD1A contribute to the pathophysiology of SCZ. To understand the impact of SETD1A rare PTVs in human neurons, we CRISPR/Cas9-engineered five isogenic pairs of human induced pluripotent stem cells (iPSCs), with a recurrent heterozygous patient-specific PTV mutation c.4582-2delAG in two donor lines and a heterozygous frameshift mutation c.4596_4597insG (p.

human BULK RNA SEQ n=26

PMID:40962831

Identified by GEO DataSets index search for Schizophrenia (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.

SETD1A Regulates Psychiatric Gene Networks Involved in Genomic Stability and Synaptic Function in Rare and Sporadic Schizophrenia [CUT&Tag] geo:GSE293154

Rare loss-of-function (LoF) mutations in SETD1A are associated with schizophrenia (SCZ). However, how SETD1A haploinsufficiency leads to SCZ-associated phenotypes and its relevance to patients without these rare mutations is unknown. Here, we identify SETD1A bound loci and regulated genes in human prenatal cortex and isogenic pluripotent stem cell-derived neuronal models engineered with SETD1A LoF variants, including the most common patient mutation. SETD1A preferentially binds the promoters of SCZ and Bipolar risk loci that regulate chromatin remodeling, DNA repair, and synaptic function.

human ATAC SEQ n=48

PMID:41422157

Identified by GEO DataSets index search for Schizophrenia (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.

WTCCC2 Schizophrenia study ega:EGAS00000000118

A WTCCC2 project genome-wide case-control association study for schizophrenia (SP) in individuals from Ireland.

human

European Genome-phenome Archive study, matched because the disease is named in the study's own title ("Schizophrenia"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.

Full genome sequencing of a monozygotic twin discordant for schizophrenia ega:EGAS00001000152

We sequenced the genomes from a monozygotic twin discordant for schizophrenia and a tumor-normal pair of an ovarian cancer patient. Using whole-genome twin data to discriminate between correctly identified single nucleotide variants (SNVs) and errors a strategy for the accurate detection of SNVs was developed. By applying stringent sequencing quality measures, excluding error-prone regions and selecting SNVs identified by different mapping and variation calling algorithms, error rates were ~37-fold reduced. This enabled us to identify the first discordant SNVs in monozygotic twins using whole-genome sequencing.

human WGS

European Genome-phenome Archive study, matched because the disease is named in the study's own title ("Schizophrenia"); description-level mentions were not accepted. EGA study_type: Whole Genome Sequencing. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.

Novel CNV contribution to schizophrenia from a genome wide study of 41,321 subjects ega:EGAS00001001960

Genomic copy number variants (CNVs) have been strongly implicated in the etiology schizophrenia (SCZ). However, apart from a small number of risk variants, elucidation of the CNV contribution to risk has been difficult due to the very low frequencies of risk alleles, all occurring in less than 1% of patients. We sought to address this obstacle through a collaborative effort unprecedented in psychiatry in which we applied a centralized analysis pipeline to a large SCZ cohort of 21,094 cases and 20,227 controls. A global enrichment of CNV burden is observed in SCZ patients (OR=1.11, P=5.7e-15), and persists after excluding loci implicated in previous studies (OR=1.07, P=1.7e-6).

human

PMID:9820031

European Genome-phenome Archive study, matched because the disease is named in the study's own title ("Schizophrenia"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.

Schizophrenia Proteome Data High Resolution Method massive:MSV000086977

PTM-tolerant quantitative proteome analysis of plasma collected from schizophrenia patients and nonspychiatric healthy controls.

Located via OmicsDI, which aggregates across omics repositories; this record comes from massive. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Schizophrenia"). Retrieved 2026-08-02.

Schizophrenia Plasma Metabolome Analysis massive:MSV000086975

Metabolomics analysis of plasma collected from patients with schizophrenia and non-psychiatric control subjects.

Located via OmicsDI, which aggregates across omics repositories; this record comes from massive. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Schizophrenia"). Retrieved 2026-08-02.

Metabolomic study on a schizophrenia and type 2 diabetes susceptibility gene metabolomics_workbench:ST000568

Located via OmicsDI, which aggregates across omics repositories; this record comes from metabolomics_workbench. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Schizophrenia"). Retrieved 2026-08-02.

🔬

Clinical Trials

1

NCT04054778 NOT_APPLICABLE COMPLETED

Assessor-blind randomized controlled trial comparing 9-session virtual reality-assisted therapy with 9-session cognitive behavioral therapy for persistent auditory verbal hallucinations in adults with treatment-resistant schizophrenia. The trial enrolled 136 participants with treatment-resistant schizophrenia or schizoaffective disorder with chronic auditory verbal hallucinations.

Target Phenotypes: Auditory hallucination HP:0008765

Show evidence (1 reference)

clinicaltrials:NCT04054778 SUPPORT Other

"The main goal of the currently proposed RCT study will be to examine if AT is superior to CBT for the treatment of chronic auditory hallucinations in schizophrenia."

ClinicalTrials.gov registration record documenting the trial objective to compare avatar therapy versus cognitive behavioral therapy for treatment of auditory hallucinations in schizophrenia.

{ }

Source YAML

click to show

name: Schizophrenia
creation_date: '2025-12-04T16:57:31Z'
description: >-
  Schizophrenia is a severe chronic psychotic disorder characterized by positive
  symptoms (delusions, hallucinations, disorganized thought), negative symptoms
  (avolition, flat affect, social withdrawal), and cognitive impairment.
  Pathophysiology centers on dysregulated dopaminergic neurotransmission together
  with glutamatergic (NMDA receptor) and GABAergic abnormalities,
  complement-mediated excessive synaptic pruning, and oligodendrocyte/myelin dysfunction.
  Deficient M1/M4 muscarinic cholinergic signalling is a further axis, established as a
  drug target by the 2024 approval of xanomeline-trospium and supported as a lesion by
  reduced muscarinic receptor availability in vivo and by cortical M1 receptor loss that is
  most marked in a postmortem-defined subgroup.
category: Psychiatric
parents:
- Psychotic Disorder
- Mental Health Disorder
progression:
- phase: Prodromal
  age_range: 15-25
  notes: Subtle changes in thoughts, feelings, and behavior
  evidence:
  - reference: PMID:10225329
    reference_title: "From predisposition to psychosis: progression of symptoms in schizophrenia."
    supports: SUPPORT
    snippet: In adolescence, preschizophrenics exhibit subtle changes in cognition and affect as well as a variety of anomalous subjective experiences (so-called 'basic symptoms'), suggesting 'trait' status of these features.
    explanation: This reference indicates that during adolescence, which overlaps with the 15-25 age range, individuals who are preschizophrenic show subtle changes in their thoughts and feelings, aligning with the prodromal phase as described.
  - reference: PMID:37027026
    reference_title: "Prodromal symptoms and the duration of untreated psychosis in first episode of psychosis patients: what differences are there between early vs. adult onset and between schizophrenia vs. bipolar disorder?"
    supports: SUPPORT
    snippet: EOP patients had significantly more prodromal symptoms with a higher frequency of trouble with thinking, avolition and hallucinations than AOP patients.
    explanation: This study supports the presence of subtle changes in thinking and behavior during the prodromal phase in early-onset psychosis, which includes patients younger than 18, blending into the 15-25 age range.
- phase: Onset
  age_range: 16-30
  notes: First episode of psychosis
  evidence:
  - reference: PMID:7654792
    reference_title: "Epidemiology of early-onset schizophrenia."
    supports: SUPPORT
    snippet: Early-onset schizophrenias (< or = 20 years) were compared with a medium-onset group (21 - < 35 years) and a late-onset group (35 - < 60 years) with regard to age and type of onset, early symptom-related course, social development and social course.
    explanation: The study provides information about the age of onset and early course of schizophrenia that falls within the 16-30 age range but does not specifically address the entire age range spectrum for the onset of the first episode of psychosis.
  - reference: PMID:20021319
    reference_title: "Progressive structural brain changes in schizophrenia."
    supports: SUPPORT
    snippet: There are progressive frontal changes in males with adolescent-onset psychosis... Ultra high-risk patients who subsequently develop psychosis and first-episode psychosis patients develop significant grey matter reduction in the planum polare, planum temporale and caudal region; a progressive process in the superior temporal gyrus may precede the first expression of florid psychosis.
    explanation: This literature provides evidence about the progression of schizophrenia, particularly related to brain changes, within the stated age range of 16-30 years during the onset phase of the first episode of psychosis.
  - reference: PMID:10225329
    reference_title: "From predisposition to psychosis: progression of symptoms in schizophrenia."
    supports: SUPPORT
    snippet: Prodromal symptoms occur in a substantial proportion of preschizophrenics, followed by a short prepsychotic phase with the crystallization of a psychotic syndrome.
    explanation: This reference supports the progression of schizophrenia during the onset phase and includes the age group that aligns with the 16-30 age range.
  - reference: PMID:26467909
    reference_title: "Predictors of Relapse and Functioning in First-Episode Psychosis: A Two-Year Follow-Up Study."
    supports: SUPPORT
    snippet: Patients with first-episode psychosis were found to have high relapse rates during the first years after illness onset.
    explanation: While discussing the progression of symptoms and outcomes following the first episode of psychosis, this study does not focus specifically on the age range of 16-30 years.
- phase: Chronic
  notes: Long-term management of symptoms and functioning
  evidence:
  - reference: PMID:9789265
    reference_title: "[Long-term treatment of chronic schizophrenia]."
    supports: SUPPORT
    snippet: Long-term treatment of patients with chronic schizophrenias requires integration of many therapeutic approaches, co-operation of several professions, and regard for the views of patients and relatives.
    explanation: The excerpt supports the idea that managing symptoms and functioning in chronic schizophrenia requires long-term management.
  - reference: PMID:23172002
    reference_title: "The myth of schizophrenia as a progressive brain disease."
    supports: SUPPORT
    snippet: The evidence shows that although approximately 25% of people with schizophrenia have a poor long-term outcome, few of these show the incremental loss of function that is characteristic of neurodegenerative illnesses.
    explanation: This statement supports the idea that while a subset of patients experience poor long-term outcomes, most do not have progressive deterioration like in neurodegenerative diseases.
  - reference: PMID:10082190
    reference_title: "Criteria defining refractory schizophrenia."
    supports: SUPPORT
    snippet: The criteria proposed necessitate (i) diagnosis of schizophrenia by standard operational criteria, (ii) continuous hospitalization for at least the past 2 years, (iii) a level of psychosocial functioning of < or = 40 as measured by the Global Assessment Scale, and (iv) an intensity score of 'marked' or 'severe' on at least three of the six Manchester Scale items.
    explanation: The criteria for refractory schizophrenia include long-term management indicating that managing symptoms and functioning over time is essential.
  - reference: PMID:26168930
    reference_title: "Investigating the long-term course of schizophrenia by sequence analysis."
    supports: SUPPORT
    snippet: A cluster analysis performed on the resulting similarity matrix yielded two main groups (a 'improving' and a 'chronic' group), which comprised a total of six different types of illness course.
    explanation: The study's finding of an 'improving' and 'chronic' group supports that managing symptoms and functioning is a significant aspect for those in the chronic phase.
prevalence:
- population: global
  measure_type: POINT_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_low: 300.0
  rate_high: 700.0
  percentage: 0.3-0.7
  notes: 'male_to_female_ratio: 1.4:1'
  evidence:
  - reference: PMID:18480098
    reference_title: "Schizophrenia: a concise overview of incidence, prevalence, and mortality."
    supports: SUPPORT
    snippet: The rate ratio for males:females was 1.4:1. Prevalence estimates also show prominent variation.
    explanation: While the male to female ratio of incidence is reported as 1.4:1, the abstract does not provide exact figures on the percentage of the population affected except that there is prominent variation. Therefore, the part of the statement with the percentage is not directly supported by this source.
mechanistic_hypotheses:
- hypothesis_group_id: canonical_dopamine_glutamate_neurodevelopmental_model
  hypothesis_label: Canonical Dopamine / Glutamate / Neurodevelopmental Model
  status: CANONICAL
  description: >-
    Schizophrenia is a polygenic neurodevelopmental disorder in which rare large-effect (e.g., 22q11.2
    deletion, NRXN1, SETD1A) and common variants (>250 GWAS loci) converge on synaptic, dopaminergic,
    and glutamatergic pathways. Striatal dopamine D2-receptor hyperactivity drives positive symptoms
    (psychosis, hallucinations); cortical NMDA-receptor hypofunction and parvalbumin-interneuron
    dysfunction produce negative and cognitive symptoms. Aberrant synaptic pruning during adolescence
    (C4-complement-driven) and altered early-life neurodevelopment provide the substrate for later-onset
    psychotic phenotypes. Antipsychotic efficacy (all first-line drugs are D2 antagonists) and NMDA-channel-blocker
    models (ketamine, PCP) corroborate the dopamine-glutamate axis as the canonical
    pharmacologic substrate.
  notes: >-
    Retained as CANONICAL with major qualifications.
    The 2026 openscientist hypothesis-search report
    (kb/hypotheses/Schizophrenia/canonical_dopamine_glutamate_neurodevelopmental_model)
    finds PARTIALLY SUPPORTED — pathophysiology validated,
    pharmacological predictions fractured. Core architecture is
    well-supported: meta-analytic PET shows elevated presynaptic
    dopamine synthesis (Hedges' g = 0.68; effect size 1.18 in
    prospective pre-psychosis), C4A overexpression replicated,
    perineuronal-net density reduced in 6/7 postmortem studies
    (a proxy for PV-associated circuitry, not a direct measure of
    PV-cell number or function),
    SV2A PET confirms synaptic density loss, 2022 GWAS (>287 loci)
    confirms synaptic-biology convergence, and 22q11.2/SETD1A/
    NRXN1 validate the polygenic-to-synaptic axis. Five critical
    qualifications: (1) dopamine synthesis capacity is heterogeneous
    rather than uniformly elevated: in PET comparison, treatment
    resistant patients were indistinguishable from controls while
    responders were elevated. The report's figure of ~30% dopamine
    normal patients is not established, and appears to transfer the
    approximate prevalence of treatment resistance onto the prevalence
    of normal dopamine physiology; (2) dopamine pathology localizes
    to the ASSOCIATIVE striatum, not the canonical mesolimbic
    pathway; (3) glutamate pharmacology has failed its primary
    endpoints in large placebo-controlled trials (pomaglumetad,
    the iclepertin CONNEX programme, bitopertin), which falsifies the
    model's therapeutic prediction for those agents and targets but
    does not refute glutamate pathophysiology as a class, since target
    engagement and biological enrichment were not uniform across them;
    (4) KarXT (xanomeline-trospium, muscarinic agonist, FDA approved
    2024) demonstrates that direct D2 antagonism is not required for
    antipsychotic efficacy, though M4 agonism can itself depress
    striatal dopamine release, so this is not yet a demonstration of a
    dopamine independent mechanism; (5) the largest snRNA-seq study
    (536,618 nuclei) prioritizes excitatory cortical neurons rather
    than PV interneurons for genetic risk, with prominent
    mitochondrial gene dysregulation. Read that as a strong lead
    rather than proof of causal primacy: postmortem differential
    expression cannot order excitatory against inhibitory changes in
    time, and a separate orbitofrontal multi-omic analysis instead
    prioritized glial and endothelial cells, so cell-type primacy
    currently varies with region, assay, and method.
  evidence:
  - reference: PMID:11532718
    reference_title: "The emerging role of glutamate in the pathophysiology and treatment of schizophrenia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Research has implicated dysfunction of glutamatergic neurotransmission in the pathophysiology of schizophrenia."
    explanation: >
      Existing canonical mechanism citation in the dismech
      knowledge base, used as the seed for the hypothesis-search
      deep-research run.
  - reference: PMID:35396580
    reference_title: Mapping genomic loci implicates genes and synaptic biology in schizophrenia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Associations were concentrated in genes that are expressed in excitatory and inhibitory neurons of the central nervous system, but not in other tissues or cell types."
    explanation: >-
      The 287-locus GWAS (76,755 cases, 243,649 controls) is the primary source
      behind this hypothesis's polygenic-to-synaptic claim, which the entry
      previously asserted in prose without citing it. Note the enrichment falls
      on excitatory and inhibitory neurons together, so it does not by itself
      privilege either compartment.
  - reference: PMID:40162239
    reference_title: Transcriptomic and genetic analysis suggests a role for mitochondrial dysregulation in schizophrenia.
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "Gene expression in excitatory layer 2-3 intra-telencephalic neurons had the greatest number of differentially expressed transcripts and, together with excitatory deep layer intra-telencephalic neurons, conferred most of the genetic risk for schizophrenia."
    explanation: >-
      Cuts against this hypothesis's assignment of genetic risk to
      parvalbumin interneurons: in dorsal prefrontal cortex the risk enrichment
      falls on excitatory intratelencephalic neurons. It qualifies one component
      of the framework rather than the framework itself, and cannot establish
      temporal primacy, since postmortem differential expression is also
      sensitive to illness state, treatment, and tissue effects.
  - reference: PMID:40053590
    reference_title: "Contrasting genetic predisposition and diagnosis in psychiatric disorders: A multi-omic single-nucleus analysis of the human OFC."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "Dysregulation in gene expression and chromatin accessibility associated with diagnosis was pronounced in excitatory neurons. Conversely, genetic risk predominantly affected glial and endothelial cells."
    explanation: >-
      A second challenge to the interneuron-centred reading of genetic risk,
      and one that also disagrees with PMID:40162239 above. In orbitofrontal
      cortex the genetic effects land on glia and endothelium rather than on
      any neuronal class. Two large single-nucleus datasets therefore nominate
      different compartments, which is why cell-type primacy is recorded here
      as region-, assay-, and method-dependent rather than settled.
- hypothesis_group_id: complement_synaptic_pruning_hypothesis
  hypothesis_label: Complement-Mediated Synaptic Pruning Hypothesis
  status: EMERGING
  description: >-
    Schizophrenia risk alleles that increase complement C4A activity may
    increase complement tagging of vulnerable synapses during adolescent and
    young-adult cortical maturation. Microglia then remove more synaptic
    material than is developmentally appropriate, especially in prefrontal and
    hippocampal circuits, creating synaptic-density loss and circuit
    dysconnectivity that can feed into downstream dopamine dysregulation and
    clinical symptom domains.
  notes: >-
    Modeled separately from the canonical dopamine/glutamate framework because
    the complement-C4A link has strong genetic, patient-derived cellular, and
    mouse-model support, but the full human causal chain from C4A dosage to
    synapse loss, dopamine changes, developmental timing, and symptom-domain
    specificity remains partially inferred.
    The 2026 openscientist hypothesis-search report
    (kb/hypotheses/Schizophrenia/complement_synaptic_pruning_hypothesis)
    grades this PARTIALLY SUPPORTED at its genetic and cellular core but
    flags substantial revision of the effector mechanism, developmental
    timing, and downstream chain. Well-established: the C4A expression-dosage
    dose-response for schizophrenia risk (Sekar 2016), C4A overexpression
    driving cortical synapse loss and increased microglial engulfment in mice
    (Yilmaz 2021), increased synapse elimination in patient-derived iPSC
    microglia-neuron models (Sellgren 2019), and the inverse sex-biased C4A
    relationship between schizophrenia and SLE/Sjögren's (Kamitaki 2020).
    Key qualifications: (1) the microglial-phagocytosis effector step is now
    contested by contradictory 2025-2026 mouse studies proposing CR3-dependent
    reduced-surveillance vs CR3-independent SNX27/AMPAR-trafficking mechanisms;
    (2) the adolescent-timing claim is challenged by human postmortem data
    showing complement activators peak in toddlers and decline in teenagers
    (Sager 2021); (3) the link to downstream dopamine dysregulation remains
    unsupported by direct evidence; and (4) after a decade there are still no
    complement-targeted schizophrenia trials and peripheral complement
    biomarkers are inconsistent across cohorts. C4 sits within a highly
    polygenic (287+ locus) architecture and contributes a modest effect for a
    common locus. The frequently repeated "OR ~1.27" should not be read as an
    odds ratio per unit of C4A expression: Sekar et al. reported relative risks
    running from 1.00 to 1.27 across four common C4 structural alleles, and did
    not estimate C4A's share of schizophrenia heritability.
  evidence:
  - reference: PMID:26814963
    reference_title: Schizophrenia risk from complex variation of complement component 4.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: each common C4 allele associating with schizophrenia in proportion to its
      tendency to generate greater expression of C4A
    explanation: >
      Foundational genetic evidence that C4 structural alleles associate with
      schizophrenia risk in proportion to how much C4A expression they generate,
      anchoring the upstream (C4A dosage) step of the hypothesis.
  - reference: PMID:33353966
    reference_title: Overexpression of schizophrenia susceptibility factor human complement
      C4A promotes excessive synaptic loss and behavioral changes in mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: overexpressing C4A in mice reduced cortical synapse density, increased
      microglial engulfment of synapses and altered mouse behavior
    explanation: >
      Mouse model showing C4A overexpression is sufficient to drive cortical
      synapse loss with increased microglial engulfment, supporting the core
      complement-driven over-pruning effector step (in a model organism).
  - reference: PMID:30718903
    reference_title: Increased synapse elimination by microglia in schizophrenia patient-derived
      models of synaptic pruning.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: schizophrenia risk-associated variants within the human complement component
      4 locus are associated with increased neuronal complement deposition and synapse
      uptake
    explanation: >
      Patient-derived iPSC microglia-neuron model links C4-locus risk variants
      to increased complement deposition and synapse uptake, supporting the
      cellular effector mechanism in human-derived cells; the same study notes
      the variants do not fully explain the excess, consistent with C4A being
      one contributor among several.
  - reference: PMID:32499649
    reference_title: Complement genes contribute sex-biased vulnerability in diverse disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: alleles that increase expression of C4A in the brain are more common among
      research participants with schizophrenia
    explanation: >
      Establishes the inverse, sex-biased C4A relationship (greater C4A raises
      schizophrenia risk while protecting against SLE/Sjögren's), one of the
      strongest biological validations of the C4A pathway's clinical relevance.
  - reference: PMID:33190236
    reference_title: Trajectory of change in brain complement factors from neonatal to
      young adult humans.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: complement activator (C1QB and C3) transcripts peaked in early neurodevelopment,
      and were highest in toddlers, declining in teenagers
    explanation: >
      Human postmortem developmental trajectory that partially challenges the
      hypothesis: brain complement activity peaks in toddlers and declines in
      teenagers, arguing against the proposed adolescent-specific pruning window
      and implying an earlier or biphasic vulnerability period.
- hypothesis_group_id: muscarinic_cholinergic_hypothesis
  hypothesis_label: Muscarinic Cholinergic (M1/M4) Hypothesis
  status: EMERGING
  description: >-
    Deficient signalling through the M1 and M4 muscarinic acetylcholine receptors is a
    primary driver of psychosis rather than a downstream consequence of dopaminergic
    pathology. Cortical M1 receptor loss — marked in a postmortem-defined subgroup termed
    muscarinic receptor-deficit schizophrenia (MRDS) — is proposed to degrade prefrontal
    circuit function underlying cognitive and negative symptoms, while loss of M4-mediated
    cholinergic restraint on striatal dopamine release permits the dopamine dysregulation
    that produces positive symptoms. The model predicts that a muscarinic agonist should be
    antipsychotic without D2 blockade, and that prediction has now been met in three
    placebo-controlled phase 3 trials of xanomeline-trospium (KarXT), approved in 2024.
  notes: >-
    Held as EMERGING rather than CANONICAL because the therapeutic arm is far stronger than
    the aetiological one, and the two do not entail each other: a drug that raises muscarinic
    tone can relieve psychosis whether or not deficient muscarinic tone caused it, exactly as
    D2 antagonism was antipsychotic long before striatal dopamine excess was demonstrated.
    Well-supported: selective cortical M1 loss in dorsolateral prefrontal cortex
    (PMID:12476323); a bimodal distribution separating an MRDS subgroup at roughly a quarter
    of cases with ~74% lower cortical pirenzepine binding (PMID:18317461); reduced in-vivo
    muscarinic availability in unmedicated patients, with striatal and frontal binding
    correlating inversely with positive symptoms (PMID:12505810); and the M4-dependent
    suppression of striatal dopamine release that supplies the mechanistic bridge to the
    canonical dopamine node (PMID:27618677, PMID:29268098).
    Four qualifications. (1) The receptor deficit is a subgroup finding, not a property of
    the syndrome — MRDS was defined postmortem and no prospective in-life biomarker
    stratifies patients today, so KarXT is prescribed without regard to muscarinic status.
    (2) The deficit has no established genetic origin: MRDS could not be separated from
    non-MRDS schizophrenia by CHRM1 sequence, so it is not explained by coding variation in
    the receptor gene, and nothing here anchors it to the polygenic architecture the way
    C4A anchors the complement hypothesis.
    (3) The M4/dopamine-release mechanism rests on rodent pharmacology, and the CB2-receptor
    dependence reported for it (PMID:27618677) has not been shown in humans.
    (4) Antipsychotic exposure is itself a confound: clozapine lowers in-vivo muscarinic
    receptor availability by 45-79% across regions in a dose-dependent way (PMID:12799613),
    so postmortem and unmedicated-patient designs are load-bearing for the aetiological
    claim and treated cohorts cannot settle it.
  evidence:
  - reference: PMID:12505810
    reference_title: In vivo determination of muscarinic acetylcholine receptor availability
      in schizophrenia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: These results indicate a reduction in muscarinic acetylcholine receptor availability
      in vivo in unmedicated patients with schizophrenia, confirming results from postmortem
      studies and adding further evidence that the muscarinic system is involved in the pathophysiology
      of schizophrenia.
    explanation: >
      In-vivo SPECT in medication-free patients, so the reduction cannot be attributed to
      antipsychotic exposure — the central aetiological claim of the hypothesis.
  - reference: PMID:27801890
    reference_title: Changed gene expression in subjects with schizophrenia and low cortical
      muscarinic M1 receptors predicts disrupted upstream pathways interacting with that
      receptor.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Overall, our data argue a prominent role for glial function in MRDS and neurodevelopment
      in non-MRDS.
    explanation: >
      Independent molecular support for the subgroup division underlying qualification 1:
      MRDS and non-MRDS cortex differ in which pathways are disrupted, so the receptor
      deficit marks a biologically distinct population rather than one tail of a continuum.
  - reference: PMID:38104575
    reference_title: "Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium)
      in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind,
      placebo-controlled, flexible-dose phase 3 trial."
    supports: SUPPORT
    quote_role: BACKGROUND
    evidence_source: HUMAN_CLINICAL
    snippet: Xanomeline is a dual M1 and M4-preferring muscarinic receptor agonist that does
      not block D2 dopamine receptors, unlike all currently approved treatments for schizophrenia.
    explanation: >
      Establishes that the tested agent has no D2 activity, which is what makes the trial
      result a test of the muscarinic prediction rather than of dopamine blockade.
  - reference: PMID:18317461
    reference_title: Decreased cortical muscarinic receptors define a subgroup of subjects
      with schizophrenia.
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: The MRDS could not be separated from other subjects with schizophrenia by CHRM1
      sequence, gender, age, suicide, duration of illness or any particular drug treatment.
    explanation: >
      Cited as REFUTE against the description's claim that the deficit is "a primary driver
      of psychosis rather than a downstream consequence": a receptor loss with no genetic
      anchor, found in the same study that defines the subgroup, is at least as consistent
      with being acquired or secondary as with being the initiating lesion. The hypothesis
      never claims heritability, so this does not refute that; it undercuts primacy, which
      the description does assert. Basis for qualification 2.
pathophysiology:
- name: Reduced SETD1A H3K4 Methyltransferase Activity at Psychiatric Risk Gene Promoters
  biological_scale: MOLECULAR
  description: >-
    SETD1A deposits H3K4 methylation at active promoters, and it binds those
    promoters selectively at schizophrenia risk loci controlling chromatin
    remodeling, DNA repair, and synaptic function. Loss-of-function variants
    reduce that activity directly. The same deficit is reached without a rare
    variant in sporadic disease, where cortical SETD1A expression is low and
    SETD1A-regulated genes are correspondingly downregulated, which is why this
    node is curated as a mechanism of schizophrenia rather than as an
    annotation on the mutation carriers.
  molecular_functions:
  - preferred_term: SETD1A histone H3K4 methyltransferase activity
    modifier: DECREASED
    term:
      id: GO:0042800
      label: histone H3K4 methyltransferase activity
  downstream:
  - target: DNA Damage Accumulation in Postmitotic Neurons
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:41422157
      reference_title: "SETD1A regulates psychiatric gene networks involved in genomic stability and synaptic function in rare and sporadic schizophrenia."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "SETD1A haploinsufficiency causes accelerated neurogenesis, reduced neuronal complexity, and DNA damage accumulation in postmitotic neurons"
      explanation: >-
        Isogenic human iPSC-derived neurons carrying a SETD1A loss-of-function
        allele accumulate DNA damage, which is the edge from reduced
        methyltransferase activity to the genome-instability node.
  - target: Abnormality of Glutamergic Signaling
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:41422157
      reference_title: "SETD1A regulates psychiatric gene networks involved in genomic stability and synaptic function in rare and sporadic schizophrenia."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "including downregulated glutamatergic synapse genes and upregulation of early synapse and metabolic genes"
      explanation: >-
        Single-cell transcriptomes of SETD1A mutant neurons show glutamatergic
        synapse genes downregulated, joining this node to the entry's existing
        glutamatergic node. The evidence is transcriptional in an iPSC model,
        not a measurement of glutamatergic transmission in patients, so the
        edge is recorded as contributory.
  evidence:
  - reference: PMID:41422157
    reference_title: "SETD1A regulates psychiatric gene networks involved in genomic stability and synaptic function in rare and sporadic schizophrenia."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "SETD1A preferentially binds the promoters of polygenic risk loci for psychiatric disorders that regulate chromatin remodeling, DNA repair, and synaptic function"
    explanation: >-
      Establishes that SETD1A's targets are themselves psychiatric risk loci,
      which is what makes reduced SETD1A activity a disease mechanism rather
      than a generic chromatin defect.
  - reference: PMID:41422157
    reference_title: "SETD1A regulates psychiatric gene networks involved in genomic stability and synaptic function in rare and sporadic schizophrenia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In postmortem SCZ cortical tissue, individuals who lack SETD1A mutations exhibit reduced SETD1A expression, associated with downregulation of SETD1A-regulated genes, implicating SETD1A-H3K4me dysfunction in sporadic SCZ cases."
    explanation: >-
      Extends the node beyond rare mutation carriers: postmortem cortex from
      sporadic cases shows the same reduced SETD1A expression and target-gene
      downregulation.
- name: DNA Damage Accumulation in Postmitotic Neurons
  biological_scale: CELLULAR
  description: >-
    Neurons carrying SETD1A loss-of-function alleles accumulate DNA
    double-strand breaks, preferentially at long neural genes. SETD1A occupies
    DNA damage-prone sites in both neural progenitors and postmitotic neurons,
    so the instability tracks where the methyltransferase normally acts rather
    than being a nonspecific consequence of illness.
  cell_types:
  - preferred_term: cortical neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: DNA damage response
    modifier: INCREASED
    term:
      id: GO:0006974
      label: DNA damage response
  evidence:
  - reference: PMID:41422157
    reference_title: "SETD1A regulates psychiatric gene networks involved in genomic stability and synaptic function in rare and sporadic schizophrenia."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Additionally, SETD1A binds to DNA damage-prone sites in neural progenitor cells and postmitotic neurons."
    explanation: >-
      Locates the damage where SETD1A binds, in the cell types this node names.
- name: Dysregulation of Dopamine Neurotransmission
  synonyms:
  - Dopamine Hypothesis
  description: >-
    Imbalance in dopamine transmission in the brain. Meta-analytic PET localizes
    the elevation of presynaptic dopamine function to the associative and
    sensorimotor (dorsal) striatal subdivisions rather than the limbic
    subdivision, which is inconsistent with a strictly mesolimbic formulation.
    Elevation is a group-level finding rather than a universal feature: patients
    whose illness is treatment resistant do not show it.
  genes:
  - preferred_term: DRD2
    term:
      id: hgnc:3023
      label: DRD2
  - preferred_term: COMT
    term:
      id: hgnc:2228
      label: COMT
  biological_processes:
  - preferred_term: dopamine secretion
    term:
      id: GO:0014046
      label: dopamine secretion
  locations:
  - preferred_term: striatum
  downstream:
  - target: Hallucinations
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Aberrant salience attributed to internal representations is experienced directly as
      hallucination. The intermediate step is psychological rather than neurochemical, which
      is why this is not a direct link.
    evidence:
    - reference: PMID:35390609
      reference_title: "Schizophrenia: A developmental disorder with a risk of non-specific but avoidable decline."
      supports: SUPPORT
      snippet: Striatal dopamine dysregulation follows, causing abnormal salience and resultant psychotic symptoms.
      explanation: This 2022 review describes how dopamine dysregulation in the striatum creates abnormal salience attribution which directly results in the psychotic symptoms characteristic of schizophrenia.
    - reference: PMID:12505794
      reference_title: "Psychosis as a state of aberrant salience: a framework linking biology,
        phenomenology, and pharmacology in schizophrenia."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Delusions are a cognitive effort by the patient to make sense of these aberrantly
        salient experiences, whereas hallucinations reflect a direct experience of the aberrant
        salience of internal representations.
      explanation: >
        Kapur's framework is what separates this edge from the Delusions edge: the same
        hyperdopaminergic state reaches the two phenotypes by different routes, hallucination
        being the direct experience of aberrant salience. A theoretical synthesis rather than
        a study, hence evidence_source OTHER.
  - target: Delusions
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Delusions arise as the patient's explanatory response to aberrantly salient experience,
      so the dopaminergic state reaches this phenotype through an interposed cognitive step.
    evidence:
    - reference: PMID:35390609
      reference_title: "Schizophrenia: A developmental disorder with a risk of non-specific but avoidable decline."
      supports: SUPPORT
      snippet: Striatal dopamine dysregulation follows, causing abnormal salience and resultant psychotic symptoms.
      explanation: This 2022 review describes how dopamine dysregulation in the striatum creates abnormal salience attribution which directly results in the psychotic symptoms characteristic of schizophrenia.
    - reference: PMID:12505794
      reference_title: "Psychosis as a state of aberrant salience: a framework linking biology,
        phenomenology, and pharmacology in schizophrenia."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Delusions are a cognitive effort by the patient to make sense of these aberrantly
        salient experiences, whereas hallucinations reflect a direct experience of the aberrant
        salience of internal representations.
      explanation: >
        The delusion arm of the same framework: an interpretive effort layered on aberrant
        salience, which is why the link is INDIRECT_KNOWN_INTERMEDIATES rather than DIRECT.
        A theoretical synthesis rather than a study, hence evidence_source OTHER.
  evidence:
  - reference: PMID:27206569
    reference_title: "Pathway-Specific Dopamine Abnormalities in Schizophrenia."
    supports: SUPPORT
    snippet: Findings have converged to suggest early dysregulation in the striatum, especially in the rostral caudate, manifesting as excess synthesis and release. Recent data showed deficit extending to most cortical regions and even to other extrastriatal subcortical regions not previously considered to be 'hypodopaminergic' in schizophrenia.
    explanation: While the literature supports dopamine dysregulation in various brain regions, it does not specifically emphasize the mesolimbic and mesocortical pathways alone.
  - reference: PMID:24986384
    reference_title: "A neurobiological hypothesis for the classification of schizophrenia: type A (hyperdopaminergic) and type B (normodopaminergic)."
    supports: NO_EVIDENCE
    snippet: 'A neurobiological hypothesis for the classification of schizophrenia: type A (hyperdopaminergic) and type B (normodopaminergic).'
    explanation: The abstract does not provide specific information supporting the imbalance of dopamine transmission specifically in the mesolimbic and mesocortical pathways as described in the statement.
  - reference: PMID:1981107
    reference_title: "Schizophrenia: a subcortical neurotransmitter imbalance syndrome?"
    supports: NO_EVIDENCE
    snippet: This article discusses the possibility that a deficient activity within the cortico-striatal glutamatergic pathway is an important pathophysiological component in some cases of schizophrenia and that glutamatergic agonists may prove beneficial in this disorder.
    explanation: The study focuses on glutamate dysregulation rather than dopamine transmission dysregulation in mesolimbic and mesocortical pathways.
  - reference: PMID:24128684
    reference_title: "Is schizophrenia a dopamine supersensitivity psychotic reaction?"
    supports: SUPPORT
    snippet: This clinical picture is generally associated with supersensitivity to dopamine, and activates dopamine neurotransmission that is usually alleviated or blocked by drugs that block dopamine D2 receptors.
    explanation: There is an implication of dopamine dysregulation, but the specifics of mesolimbic and mesocortical pathways are not confirmed.
  - reference: PMID:29301039
    reference_title: "Defining the Locus of Dopaminergic Dysfunction in Schizophrenia: A Meta-analysis and Test of the Mesolimbic Hypothesis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These demonstrated significant increases in patients compared to controls in associative (g = 0.73, P = .002) and sensorimotor (g = 0.54, P = .005) regions, but not limbic (g = 0.29, P = .09)."
    explanation: >-
      Meta-analysis of 21 molecular imaging studies (269 patients, 313 controls)
      places the presynaptic dopamine elevation in the associative and
      sensorimotor striatum, with no significant limbic effect. This is the
      source for the node's anatomical correction away from a strictly
      mesolimbic locus, and it is a group-level PET result rather than an
      anatomical lesion demonstrated in every patient.
  - reference: PMID:21768612
    reference_title: "Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The psychotic transition group had greater dopamine synthesis capacity in the striatum (effect size=1.18) and its associative subdivision (effect size=1.24) than did the healthy comparison subjects and showed a positive correlation between dopamine synthesis capacity and symptom severity."
    explanation: >-
      Prospective [18F]-DOPA PET in 24 antipsychotic-naive ultra-high-risk
      participants, nine of whom transitioned, shows the elevation precedes
      clinical conversion and again localizes to the associative subdivision.
      This establishes temporal ordering and predictive association only: the
      endpoint was transition to psychosis rather than a schizophrenia-specific
      diagnosis, and an observational biomarker difference in nine transitions
      cannot exclude a shared upstream cause.
  - reference: PMID:23034655
    reference_title: Dopamine synthesis capacity in patients with treatment-resistant schizophrenia.
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "There were no significant differences between patients with treatment-resistant illness and healthy volunteers in the whole striatum or any of its subdivisions."
    explanation: >-
      Bounds the node rather than supporting it. In this three-group PET
      comparison, presynaptic dopamine elevation was confined to
      antipsychotic-responsive illness; the treatment-resistant group was
      indistinguishable from controls. Dopamine dysregulation is therefore not a
      universal feature of schizophrenia. Note the sample is twelve patients per
      group and selected for treatment response, so it demonstrates
      heterogeneity without estimating what fraction of an unselected
      schizophrenia population is dopamine normal.
- name: Abnormality of Glutamergic Signaling
  synonyms:
  - Glutamate Hypothesis
  description: Dysfunction in glutamate neurotransmission, impacting synaptic plasticity and brain circuit function.
  genes:
  - preferred_term: GRIN1
    term:
      id: hgnc:4584
      label: GRIN1
  - preferred_term: GRIN2A
    term:
      id: hgnc:4585
      label: GRIN2A
  cell_types:
  - preferred_term: parvalbumin-positive interneuron
    description: NMDA hypofunction on parvalbumin interneurons leads to cortical disinhibition.
    term:
      id: CL:0000099
      label: interneuron
  biological_processes:
  - preferred_term: synaptic transmission, glutamatergic
    term:
      id: GO:0035249
      label: synaptic transmission, glutamatergic
  locations:
  - preferred_term: prefrontal cortex
    term:
      id: UBERON:0000451
      label: prefrontal cortex
  - preferred_term: hippocampus
    term:
      id: UBERON:0001954
      label: Ammon's horn
  downstream:
  - target: Abnormality of GABAergic Signaling
    causal_link_type: DIRECT
    description: >-
      NMDA receptors on fast-spiking parvalbumin interneurons are the first casualty of
      receptor hypofunction; losing their excitatory drive disinhibits the pyramidal cells
      they normally restrain. This is the step that makes the glutamatergic and GABAergic
      nodes one circuit rather than two parallel abnormalities.
    evidence:
    - reference: PMID:18395805
      reference_title: Circuit-based framework for understanding neurotransmitter and risk
        gene interactions in schizophrenia.
      supports: SUPPORT
      directness: DIRECT
      evidence_source: OTHER
      snippet: One action of antagonists is to reduce the excitation of fast-spiking interneurons,
        resulting in disinhibition of pyramidal cells.
      explanation: >
        States the glutamate-to-GABA step of the Lisman circuit model directly. A review
        proposing a framework rather than reporting an experiment, hence OTHER.
  - target: Disorganized Thinking
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      NMDA antagonists reproduce formal thought disorder in humans, which dopaminergic
      psychotomimetics do not — the observation that first separated the glutamatergic model
      from the dopamine model on symptom coverage.
    evidence:
    - reference: PMID:1654746
      reference_title: Recent advances in the phencyclidine model of schizophrenia.
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: HUMAN_CLINICAL
      snippet: PCP-induced psychosis also uniquely incorporates the formal thought disorder
        and neuropsychological deficits associated with schizophrenia.
      explanation: >
        A review of human PCP pharmacology. INDIRECT because the argument runs from a drug
        that produces the phenotype in healthy people to the endogenous abnormality, not
        from a measurement in patients.
  - target: Social Withdrawal
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      NMDA receptor blockade produces the negative-symptom domain, including emotional
      withdrawal, in people with no psychiatric illness.
    evidence:
    - reference: PMID:1654746
      reference_title: Recent advances in the phencyclidine model of schizophrenia.
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: HUMAN_CLINICAL
      snippet: 'As opposed to amphetamine-induced psychosis, PCP-induced psychosis incorporates
        both positive (e.g., hallucinations, paranoia) and negative (e.g., emotional withdrawal,
        motor retardation) schizophrenic symptoms.'
      explanation: >
        Names emotional withdrawal specifically, and contrasts it with the dopaminergic
        psychotomimetic — which is why the negative-symptom edges hang off this node rather
        than off the dopamine node.
    - reference: PMID:32437573
      reference_title: "Association of Ketamine With Psychiatric Symptoms and Implications
        for Its Therapeutic Use and for Understanding Schizophrenia: A Systematic Review and
        Meta-analysis."
      supports: SUPPORT
      quote_role: PRIMARY_RESULT
      directness: INDIRECT
      evidence_source: HUMAN_CLINICAL
      snippet: This study found that acute ketamine administration was associated with schizophrenia-like
        or psychotomimetic symptoms with large effect sizes, but there was a greater increase
        in positive than negative symptoms and when a bolus was used.
      explanation: >
        Meta-analysis of 36 within-subject placebo-controlled studies in 725 healthy
        volunteers, quantifying the effect. Note the qualification it carries: the negative
        symptom effect is real but smaller than the positive one, so this edge is weaker than
        the dopamine-to-positive-symptom edges.
  - target: Flat Affect
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Blunted affect is part of the negative-symptom picture NMDA antagonism reproduces in
      healthy volunteers.
    evidence:
    - reference: PMID:32437573
      reference_title: "Association of Ketamine With Psychiatric Symptoms and Implications
        for Its Therapeutic Use and for Understanding Schizophrenia: A Systematic Review and
        Meta-analysis."
      supports: SUPPORT
      quote_role: BACKGROUND
      directness: INDIRECT
      evidence_source: HUMAN_CLINICAL
      snippet: In particular, in addition to inducing positive symptoms, such as perceptual
        changes and delusions, ketamine induces negative symptoms, such as blunted affect
        and emotional withdrawal.
      explanation: >
        Names blunted affect explicitly. Provenance note: this sentence is the paper's
        introduction summarising the prior literature it went on to meta-analyse, not a
        result of the meta-analysis itself; the pooled negative-symptom effect is quoted on
        the Social Withdrawal edge.
  evidence:
  - reference: PMID:11532718
    reference_title: "The emerging role of glutamate in the pathophysiology and treatment of schizophrenia."
    supports: SUPPORT
    snippet: Research has implicated dysfunction of glutamatergic neurotransmission in the pathophysiology of schizophrenia.
    explanation: The literature specifically states that glutamatergic neurotransmission dysfunction is associated with the pathophysiology of schizophrenia, supporting the provided statement.
  - reference: PMID:28754595
    reference_title: "Mapping the Consequences of Impaired Synaptic Plasticity in Schizophrenia through Development: An Integrative Model for Diverse Clinical Features."
    supports: SUPPORT
    snippet: Accumulating evidence suggests that synaptic plasticity is impaired in schizophrenia. Given the role of synaptic plasticity in learning, memory, and neural circuit maturation, impaired plasticity may underlie many features of the schizophrenia syndrome.
    explanation: The literature discusses the impairment of synaptic plasticity in schizophrenia and its interaction with brain maturation, aligning with the statement.
  - reference: PMID:29954475
    reference_title: "Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis: dopamine, serotonin, and glutamate."
    supports: SUPPORT
    snippet: Psychosis is now widely hypothesized to involve neural networks beyond the classical dopaminergic mesolimbic pathway, including serotonin and glutamate systems as well.
    explanation: This reference supports the involvement of glutamatergic systems in schizophrenia, reinforcing the statement.
  - reference: PMID:22351070
    reference_title: "Synaptic dysfunction in schizophrenia."
    supports: SUPPORT
    snippet: Schizophrenia is believed to result from problems during neural development that lead to improper function of synaptic transmission and plasticity, and in agreement, many of the susceptibility genes encode proteins critical for neural development.
    explanation: The literature supports the idea that schizophrenia impacts synaptic transmission and plasticity, specifically implicating glutamatergic, GABAergic, dopaminergic, and cholinergic synapses.
- name: Abnormality of GABAergic Signaling
  synonyms:
  - GABAergic Dysfunction
  description: Dysfunction in GABAergic inhibitory neurotransmission, contributing to excitatory/inhibitory (E/I) imbalance in cortical circuits.
  genes:
  - preferred_term: GAD1
    term:
      id: hgnc:4092
      label: GAD1
  - preferred_term: RELN
    term:
      id: hgnc:9957
      label: RELN
  cell_types:
  - preferred_term: parvalbumin-positive interneuron
    description: Parvalbumin-positive GABAergic interneurons show reduced function, leading to cortical disinhibition.
    term:
      id: CL:0000099
      label: interneuron
  biological_processes:
  - preferred_term: synaptic transmission, GABAergic
    term:
      id: GO:0051932
      label: synaptic transmission, GABAergic
  locations:
  - preferred_term: prefrontal cortex
    term:
      id: UBERON:0000451
      label: prefrontal cortex
  downstream:
  - target: Dysregulation of Dopamine Neurotransmission
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Loss of interneuron restraint leaves pyramidal cells overactive, and that overactivity
      — hippocampal in particular — drives the subcortical hyperdopaminergic state. This is
      the edge that makes the cortical and dopaminergic halves of the entry one graph: it is
      how a cortical lesion produces a striatal symptom.
    evidence:
    - reference: PMID:18395805
      reference_title: Circuit-based framework for understanding neurotransmitter and risk
        gene interactions in schizophrenia.
      supports: SUPPORT
      directness: DIRECT
      evidence_source: OTHER
      snippet: Overactive pyramidal cells, notably those in the hippocampus, can drive a hyperdopaminergic
        state that produces psychosis.
      explanation: >
        The disinhibition-to-dopamine step. INDIRECT_KNOWN_INTERMEDIATES because pyramidal
        overactivity is the named intermediate and is not itself a node in this entry.
        evidence_source OTHER: a framework review, and the sentence is hedged ("can drive").
  - target: Working Memory Deficits
    causal_link_type: DIRECT
    description: >-
      Parvalbumin basket-cell inhibition of pyramidal cells is what generates prefrontal
      gamma oscillations, and those oscillations are required for working memory. The deficit
      is a direct functional consequence of the inhibitory abnormality, not a downstream
      dopaminergic effect — which is why antipsychotics do not treat it.
    evidence:
    - reference: PMID:29936230
      reference_title: Alterations in cortical interneurons and cognitive function in schizophrenia.
      supports: SUPPORT
      directness: DIRECT
      evidence_source: OTHER
      snippet: 'disturbances in this signaling contribute to altered gamma oscillations and
        working memory in schizophrenia'
      explanation: >
        A review converging in-vivo neuroimaging and postmortem findings on the
        PV-interneuron/gamma/working-memory chain. evidence_source OTHER because it is a
        synthesis across both study types rather than one of them.
  evidence:
  - reference: PMID:10372507
    reference_title: "GABA-ergic neurons and the neurobiology of schizophrenia and other psychoses."
    supports: SUPPORT
    snippet: At the cellular level, gamma-aminobutyric acid (GABA)-ergic interneurons are a common feature in psychotic states... and are themselves synchronised by the ascending dopamine and serotonin innervations.
    explanation: The literature highlights that GABAergic interneurons play a significant role in the cellular characteristics found in psychotic states, including schizophrenia.
  - reference: PMID:22308256
    reference_title: "[Biological study in schizophrenia]."
    supports: SUPPORT
    snippet: Disturbances in glutamate and GABAergic neurotransmission may underlie the pathophysiology of schizophrenia.
    explanation: This reference directly states that disturbances in GABAergic neurotransmission may underlie the pathophysiology of schizophrenia.
  - reference: PMID:34584230
    reference_title: "Glutamatergic and GABAergic metabolite levels in schizophrenia-spectrum disorders: a meta-analysis of (1)H-magnetic resonance spectroscopy studies."
    supports: SUPPORT
    snippet: Reduced GABA levels indicate that the disruption of excitatory/inhibitory balance may be related to the pathophysiology of schizophrenia-spectrum disorders.
    explanation: This meta-analysis supports the idea that reduced GABA levels and thus GABAergic dysfunction are related to the pathophysiology of schizophrenia.
  - reference: PMID:25432637
    reference_title: "GABA receptor subunit distribution and FMRP-mGluR5 signaling abnormalities in the cerebellum of subjects with schizophrenia, mood disorders, and autism."
    supports: SUPPORT
    snippet: Gamma-aminobutyric acid (GABA) is the main inhibitory neurotransmitter in the brain. GABAergic receptor abnormalities have been documented in several major psychiatric disorders including schizophrenia.
    explanation: The abnormalities in GABAergic receptors in schizophrenia support the idea of GABAergic signaling abnormalities being part of the disorder’s pathophysiology.
  - reference: PMID:22351070
    reference_title: "Synaptic dysfunction in schizophrenia."
    supports: SUPPORT
    snippet: Here, we will review evidence for altered neurotransmission at ... GABAergic ... synapses in schizophrenia...
    explanation: This article reviews evidence for altered GABAergic neurotransmission in schizophrenia, supporting the stated claim.
- name: Cortical Muscarinic M1 Receptor Deficit
  biological_scale: MOLECULAR
  synonyms:
  - CHRM1 deficit
  - Muscarinic receptor-deficit schizophrenia (MRDS)
  description: >-
    Selective loss of M1 muscarinic acetylcholine receptor protein, mRNA and pirenzepine
    binding in dorsolateral prefrontal cortex (Brodmann area 9). The deficit is bimodally
    rather than uniformly distributed: kernel density estimation separates a distinct
    postmortem subgroup — muscarinic receptor-deficit schizophrenia (MRDS) — at roughly a
    quarter of cases, with a ~74% reduction in cortical binding, from a non-MRDS majority
    whose binding overlaps controls.
  mechanism_confidence: PROVISIONAL
  genes:
  - preferred_term: CHRM1
    term:
      id: hgnc:1950
      label: CHRM1
  molecular_functions:
  - preferred_term: M1 muscarinic acetylcholine receptor activity
    modifier: DECREASED
    term:
      id: GO:0016907
      label: G protein-coupled acetylcholine receptor activity
  biological_processes:
  - preferred_term: muscarinic acetylcholine receptor signalling in prefrontal cortex
    modifier: DECREASED
    term:
      id: GO:0007213
      label: G protein-coupled acetylcholine receptor signaling pathway
  locations:
  - preferred_term: dorsolateral prefrontal cortex (Brodmann area 9)
    term:
      id: UBERON:0009834
      label: dorsolateral prefrontal cortex
  notes: >-
    Whether the M1 deficit is upstream or downstream is unsettled. Transcriptomic profiling
    of MRDS cortex found 65 differentially expressed genes whose interactions the authors
    read as lying largely upstream of the M1 receptor (PMID:27801890), which would make the
    receptor loss a readout of an earlier lesion rather than the initiating one. The node is
    therefore stated as a receptor-level deficit and not as a primary cause, and its
    mechanism_confidence is PROVISIONAL.
    MRDS is a postmortem construct. No validated in-life assay assigns a living patient to
    it, so it does not currently stratify treatment and is not curated as a has_subtypes
    entry.
  downstream:
  - target: Working Memory Deficits
    description: >-
      Prefrontal M1 signalling supports working memory and verbal learning, and a
      muscarinic agonist improved exactly those measures in patients — an inference from
      therapeutic response rather than a direct demonstration that the receptor deficit
      causes the impairment.
    evidence:
    - reference: PMID:18593778
      reference_title: Selective muscarinic receptor agonist xanomeline as a novel treatment
        approach for schizophrenia.
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: HUMAN_CLINICAL
      snippet: In the cognitive test battery, subjects in the xanomeline group showed improvements
        most robustly in measures of verbal learning and short-term memory function.
      explanation: >
        M1/M4 agonism improved verbal learning and short-term memory in patients, so the
        cognitive domain is muscarinic-responsive. INDIRECT because a drug response
        establishes that the receptor system modulates the phenotype, not that the observed
        cortical receptor deficit produces it.
  evidence:
  - reference: PMID:12476323
    reference_title: Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex
      of subjects with schizophrenia.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: The level of M1R protein (0.11 +/- 0.007 vs 0.15 +/- 0.008 OD; P < 0.01), but
      not M4R protein, was decreased in BA9 from schizophrenic subjects with neither receptor
      protein being altered in BA 40.
    explanation: >
      The measured protein-level deficit, in 20 patients against 20 age/sex-matched controls,
      and the source of this node's two selectivity claims — M1 over M4, and BA9 over BA40.
  - reference: PMID:18317461
    reference_title: Decreased cortical muscarinic receptors define a subgroup of subjects
      with schizophrenia.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: We suggest that these individuals make up 'muscarinic receptor-deficit schizophrenia'
      (MRDS).
    explanation: >
      Names the subgroup that the study's kernel density estimation separated from the rest
      of the schizophrenia cohort — 26% of subjects, with a 74% reduction in cortical
      pirenzepine binding — which is what licenses stating this node as a subgroup finding
      rather than a syndrome-wide one.
  - reference: PMID:12505810
    reference_title: In vivo determination of muscarinic acetylcholine receptor availability
      in schizophrenia.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: Muscarinic receptor availability was significantly less in patients with schizophrenia
      than in normal subjects in all regions of interest except the pons.
    explanation: >
      Replicates the cortical deficit in living, medication-free patients by SPECT, ruling
      out both postmortem artefact and antipsychotic-induced receptor change.
- name: Loss of M4 Receptor Restraint of Striatal Dopamine Release
  biological_scale: CELLULAR
  synonyms:
  - Cholinergic-dopaminergic imbalance in the striatum
  description: >-
    Cholinergic input to the striatum and substantia nigra normally holds dopaminergic
    transmission in check through the M4 muscarinic receptor: M4 activation on spiny
    projection neurons produces a sustained depression of striatal dopamine release, and
    nigral M4 opposes D1 signalling in direct-pathway presynaptic terminals. Weakened M4
    restraint is proposed to permit the striatal dopamine dysregulation that generates
    positive symptoms, and supplies the mechanistic route by which a non-D2 muscarinic
    agonist reaches the canonical dopamine node.
  mechanism_confidence: HYPOTHETICAL
  genes:
  - preferred_term: CHRM4
    term:
      id: hgnc:1953
      label: CHRM4
  cell_types:
  - preferred_term: striatal spiny projection neuron
    description: Carries the M4 receptors whose activation depresses striatal dopamine release.
    term:
      id: CL:1001474
      label: medium spiny neuron
  - preferred_term: cholinergic neuron
    description: >-
      Source of the acetylcholine acting at M4, from striatal interneurons and from
      pedunculopontine projections to the substantia nigra pars reticulata.
    term:
      id: CL:0000108
      label: cholinergic neuron
  biological_processes:
  - preferred_term: muscarinic restraint of striatal dopamine release
    modifier: DECREASED
    term:
      id: GO:0033602
      label: negative regulation of dopamine secretion
  locations:
  - preferred_term: striatum
    term:
      id: UBERON:0002435
      label: striatum
  - preferred_term: substantia nigra pars reticulata
    term:
      id: UBERON:0002038
      label: substantia nigra
  notes: >-
    The M4-dopamine mechanism is established in rodent pharmacology and electrophysiology,
    not in human tissue; the human evidence for the node is the inverse correlation between
    striatal muscarinic availability and positive symptoms, which is associative. The
    CB2-receptor dependence reported for M4-mediated dopamine suppression (PMID:27618677)
    is unreplicated in humans and is not asserted here. mechanism_confidence is HYPOTHETICAL
    for that reason.
  downstream:
  - target: Dysregulation of Dopamine Neurotransmission
    description: >-
      Reduced M4-mediated cholinergic braking releases striatal dopamine release from
      restraint, feeding the dopaminergic dysregulation that drives positive symptoms.
    evidence:
    - reference: PMID:27618677
      reference_title: Antipsychotic-like Effects of M4 Positive Allosteric Modulators Are
        Mediated by CB2 Receptor-Dependent Inhibition of Dopamine Release.
      supports: SUPPORT
      directness: DIRECT
      evidence_source: MODEL_ORGANISM
      snippet: activation of M4 receptors on striatal spiny projection neurons results in
        a novel form of dopaminergic regulation resulting in a sustained depression of striatal
        dopamine release
      explanation: >
        Demonstrates the causal direction of the edge in rodent striatum — M4 tone suppresses
        dopamine release, so losing it raises dopaminergic transmission.
  evidence:
  - reference: PMID:29268098
    reference_title: Cholinergic Projections to the Substantia Nigra Pars Reticulata Inhibit
      Dopamine Modulation of Basal Ganglia through the M(4) Muscarinic Receptor.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: MODEL_ORGANISM
    snippet: extra-striatal cholinergic projections from the pedunculopontine nucleus to the
      substantia nigra pars reticulata (SNr) act on muscarinic acetylcholine receptor subtype
      4 (M4) to oppose cAMP-dependent dopamine receptor subtype 1 (D1) signaling in presynaptic
      terminals of direct pathway striatal spiny projections neurons
    explanation: >
      Locates a second, extra-striatal arm of M4 opposition to dopamine signalling, and is
      why this node's locations include the substantia nigra as well as the striatum.
  - reference: PMID:12505810
    reference_title: In vivo determination of muscarinic acetylcholine receptor availability
      in schizophrenia.
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: Positive symptoms of schizophrenia correlated negatively with muscarinic receptor
      availability in the striatum and the frontal cortex.
    explanation: >
      The only human data tying striatal muscarinic tone to the symptom domain this node is
      proposed to explain. INDIRECT because it is a cross-sectional correlation with total
      muscarinic binding, not a measurement of M4-specific control of dopamine release.
- name: Complement-Mediated Excessive Synaptic Pruning
  description: >-
    Excessive loss of cortical and hippocampal synapses associated with
    complement component C4A. The effector step is contested rather than
    settled: mouse C4 overexpression paradigms disagree on whether the synaptic
    loss requires microglial complement receptor 3, and one of them reports
    decreased rather than increased microglia-synapse interaction, so
    CR3-dependent microglial engulfment should be read as one candidate
    mechanism among several. The developmental window is likewise unsettled,
    since human postmortem complement activator expression peaks well before
    adolescence.
  genes:
  - preferred_term: C4A
    term:
      id: hgnc:1323
      label: C4A
  - preferred_term: C3
    term:
      id: hgnc:1318
      label: C3
  cell_types:
  - preferred_term: microglial cell
    description: Microglia eliminate synapses tagged by complement components during critical developmental periods.
    term:
      id: CL:0000129
      label: microglial cell
  biological_processes:
  - preferred_term: complement activation
    term:
      id: GO:0006956
      label: complement activation
  - preferred_term: synapse pruning
    term:
      id: GO:0098883
      label: synapse pruning
  locations:
  - preferred_term: prefrontal cortex
    term:
      id: UBERON:0000451
      label: prefrontal cortex
  - preferred_term: hippocampus
    term:
      id: UBERON:0001954
      label: Ammon's horn
  evidence:
  - reference: PMID:26814963
    reference_title: "Schizophrenia risk from complex variation of complement component 4."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We found that these alleles generated widely varying levels of C4A and C4B expression in the brain, with each common C4 allele associating with schizophrenia in proportion to its tendency to generate greater expression of C4A."
    explanation: >-
      Human genetic and brain-expression evidence anchors the upstream C4A-risk
      component of the complement-pruning hypothesis without relying on the
      paper's separate model-organism synapse-elimination result.
  - reference: PMID:37041418
    reference_title: "The synaptic hypothesis of schizophrenia version III: a master mechanism."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Genome-wide association studies have identified a number of schizophrenia risk variants converging on pathways regulating synaptic elimination, formation and plasticity, including complement factors and microglial-mediated synaptic pruning."
    explanation: >-
      This review integrates genetic, imaging, postmortem, iPSC, and preclinical
      data and directly places complement factors and microglial synaptic pruning
      in the synaptic hypothesis of schizophrenia.
  - reference: PMID:30718903
    reference_title: "Increased synapse elimination by microglia in schizophrenia patient-derived models of synaptic pruning."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Using a reprogrammed in vitro model of microglia-mediated synapse engulfment, we demonstrate increased synapse elimination in patient-derived neural cultures and isolated synaptosomes."
    explanation: >-
      Patient-derived neural cultures and synaptosomes provide disease-relevant
      in vitro evidence that microglia-mediated synapse elimination is increased
      in schizophrenia models.
  - reference: PMID:33353966
    reference_title: "Overexpression of schizophrenia susceptibility factor human complement C4A promotes excessive synaptic loss and behavioral changes in mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "However, overexpressing C4A in mice reduced cortical synapse density, increased microglial engulfment of synapses and altered mouse behavior."
    explanation: >-
      Human C4A overexpression in mice is mechanistically sufficient to reduce
      cortical synapse density and increase microglial synapse engulfment,
      supporting the C4A-overpruning arm of the hypothesis.
  - reference: PMID:38510107
    reference_title: "Microglia-neuron interactions in schizophrenia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Synaptic loss, one of the central pathological hallmarks of schizophrenia, is believed to be due to excess removal of synapses by activated microglia, primarily affecting glutamatergic neurons."
    explanation: >-
      This recent review supports the broader microglia-neuron interaction model
      in which activated microglia excessively remove synapses in schizophrenia.
  - reference: PMID:41903141
    reference_title: Schizophrenia-associated complement C4 impairs synaptic connectivity and decreases microglia-synapse interactions through CR3 signaling.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "We show that C4-OE alters synapse density and function and that these effects are rescued in CR3-deficient mice."
    explanation: >-
      Supports the CR3 arm of this node: the synaptic consequences of frontal
      cortex C4 overexpression are abolished when microglial CR3 is absent. The
      route, however, is not the one this node originally asserted. The same
      study reports that C4 overexpression decreases microglial surveilled
      volume, motility, and contact frequency with synaptic structures, so the
      proposed mechanism is CR3-dependent loss of microglial surveillance rather
      than CR3-dependent excess engulfment.
  - reference: PMID:39227431
    reference_title: The schizophrenia risk gene C4 induces pathological synaptic loss by impairing AMPAR trafficking.
    supports: REFUTE
    evidence_source: MODEL_ORGANISM
    snippet: "Here, we report that C4-mediated cortical hypoconnectivity is CR3-independent. Instead, C4-OE triggers impaired GluR1 trafficking through an intracellular mechanism involving the endosomal protein SNX27, resulting in pathological synaptic loss."
    explanation: >-
      Contradicts the CR3-dependent microglial effector step in a second mouse
      C4 overexpression paradigm, locating the synaptic loss in a neuron
      intrinsic endosomal trafficking defect instead. Paired with PMID:41903141
      this is a live disagreement over the effector mechanism, not a settled
      replacement: the two studies differ in construct, expression pattern,
      circuit, age, and readout, and neither identifies the operative pathway in
      human disease.
  downstream:
  - target: Dysregulation of Dopamine Neurotransmission
    description: >-
      Excessive complement- and microglia-mediated synapse elimination can
      disrupt cortical pyramidal-neuron circuits and disinhibit mesostriatal
      projections, providing an indirect route from adolescent synaptic loss to
      dopamine overactivity and psychosis.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - cortical pyramidal-neuron dysfunction
    - disinhibited projections to mesostriatal regions
    hypothesis_groups:
    - complement_synaptic_pruning_hypothesis
    evidence:
    - reference: PMID:37041418
      reference_title: "The synaptic hypothesis of schizophrenia version III: a master mechanism."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "We propose the loss of synapses disrupts pyramidal neuron function in the cortex to contribute to negative and cognitive symptoms and disinhibits projections to mesostriatal regions to contribute to dopamine overactivity and psychosis."
      explanation: >-
        The review proposes (does not demonstrate) that synapse loss disrupts
        cortical pyramidal-neuron function and mesostriatal disinhibition; this
        is the hypothesized indirect route from complement-mediated pruning to
        dopamine dysregulation, consistent with this edge being modeled as a
        hypothesis rather than an established causal link.
  - target: Abnormality of Glutamergic Signaling
    causal_link_type: DIRECT
    description: >-
      The synapses removed are overwhelmingly cortical excitatory ones, so over-pruning is
      a route into the glutamatergic node as well as the dopaminergic one. The same sentence
      of the synaptic-hypothesis review carries both arms: pyramidal-neuron dysfunction here,
      mesostriatal disinhibition on the dopamine edge above.
    hypothesis_groups:
    - complement_synaptic_pruning_hypothesis
    evidence:
    - reference: PMID:37041418
      reference_title: "The synaptic hypothesis of schizophrenia version III: a master mechanism."
      supports: SUPPORT
      directness: DIRECT
      evidence_source: OTHER
      snippet: "We propose the loss of synapses disrupts pyramidal neuron function in the cortex to contribute to negative and cognitive symptoms and disinhibits projections to mesostriatal regions to contribute to dopamine overactivity and psychosis."
      explanation: >-
        The cortical arm of the proposal. As on the dopamine edge, the review proposes rather
        than demonstrates this, which is why the edge carries the hypothesis group.
    - reference: PMID:33353966
      reference_title: Overexpression of schizophrenia susceptibility factor human complement
        C4A promotes excessive synaptic loss and behavioral changes in mice.
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: MODEL_ORGANISM
      snippet: overexpressing C4A in mice reduced cortical synapse density, increased microglial
        engulfment of synapses and altered mouse behavior
      explanation: >
        Shows the pruning step is sufficient to reduce cortical synapse density in vivo.
        INDIRECT for this edge specifically: the study measured total cortical synapse
        density and did not resolve it by transmitter type, so the inference that the lost
        synapses are predominantly glutamatergic comes from cortical synapse composition
        generally, not from this measurement.
- name: Oligodendrocyte and Myelin Dysfunction
  description: Abnormalities in oligodendrocytes and myelin sheaths leading to white matter changes and network dysconnectivity across brain regions.
  cell_types:
  - preferred_term: oligodendrocyte
    description: Oligodendrocyte dysfunction contributes to impaired myelination and dysconnectivity.
    term:
      id: CL:0000128
      label: oligodendrocyte
  biological_processes:
  - preferred_term: myelination
    term:
      id: GO:0042552
      label: myelination
  locations:
  - preferred_term: prefrontal cortex
    term:
      id: UBERON:0000451
      label: prefrontal cortex
  - preferred_term: hippocampus
    term:
      id: UBERON:0001954
      label: Ammon's horn
  notes: >-
    Deliberately left with no downstream edge. The obvious one to draw is
    myelin/dysconnectivity to formal thought disorder, and the study that tested it does not
    support it: white matter integrity was reduced in patients versus controls across every
    language-related tract, but the correlations with thought-disorder severity did not
    survive multiple-comparison correction, and patients with severe and mild thought
    disorder did not differ (PMID:29861197). So the node is real and the phenotype link is
    not established. An edge here would be graph tidiness bought with a citation that does
    not carry it.
  evidence:
  - reference: PMID:31653579
    reference_title: Reduced density of oligodendrocytes and oligodendrocyte clusters in the
      caudate nucleus in major psychiatric illnesses.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: A significant reduction in the Nv of oligodendrocytes was found in schizophrenia
      and BPD as compared to the control group
    explanation: >
      Postmortem stereological cell counts establishing the cellular deficit this node
      asserts. Not specific to schizophrenia — the same reduction appears in bipolar
      disorder, which the node's description should not be read as denying.
  - reference: PMID:29861197
    reference_title: Formal thought disorder is related to aberrations in language-related
      white matter tracts in patients with schizophrenia.
    supports: REFUTE
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: No difference in FA was found between patients with severe and patients with
      mild FTD.
    explanation: >
      Cited against the tempting downstream link rather than for it: if white matter
      integrity does not separate severe from mild formal thought disorder, it does not
      support an edge from this node to Disorganized Thinking. Recorded so the absent edge
      reads as a finding rather than an omission.
- name: Mitochondrial Dysfunction and Oxidative Stress
  description: Bioenergetic deficits including complex I inhibition, decreased glutathione, increased lactate, and oxidative/nitrosative stress creating a feed-forward cycle with neuroinflammation.
  biological_processes:
  - preferred_term: oxidative phosphorylation
    term:
      id: GO:0006119
      label: oxidative phosphorylation
  - preferred_term: cellular response to oxidative stress
    term:
      id: GO:0034599
      label: cellular response to oxidative stress
  locations:
  - preferred_term: prefrontal cortex
    term:
      id: UBERON:0000451
      label: prefrontal cortex
  downstream:
  - target: Abnormality of GABAergic Signaling
    causal_link_type: DIRECT
    description: >-
      Parvalbumin interneurons are the cortical cell type most exposed to redox stress —
      their high firing rate and metabolic load make them the first to fail when glutathione
      synthesis is impaired. This is the node's route into the cortical circuit, and it is
      why an antioxidant is a candidate treatment for a GABAergic lesion.
    evidence:
    - reference: PMID:34080015
      reference_title: "Timely N-Acetyl-Cysteine and Environmental Enrichment Rescue Oxidative
        Stress-Induced Parvalbumin Interneuron Impairments via MMP9/RAGE Pathway: A Translational
        Approach for Early Intervention in Psychosis."
      supports: SUPPORT
      directness: DIRECT
      evidence_source: MODEL_ORGANISM
      snippet: We show that a sequential combination of NAC+EE applied after an early-life
        oxidative insult recovers integrity and function of PVI network in adult Gclm KO,
        via the inhibition of MMP9/RAGE.
      explanation: >
        A rescue experiment in a glutathione-deficient mouse: relieving the oxidative insult
        restores the parvalbumin interneuron network, which establishes the direction of this
        edge rather than mere co-occurrence.
    - reference: PMID:34080015
      reference_title: "Timely N-Acetyl-Cysteine and Environmental Enrichment Rescue Oxidative
        Stress-Induced Parvalbumin Interneuron Impairments via MMP9/RAGE Pathway: A Translational
        Approach for Early Intervention in Psychosis."
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: HUMAN_CLINICAL
      snippet: Six-month NAC treatment in EP patients reduces plasma sRAGE in association with
        increased prefrontal GABA, improvement of cognition and clinical symptoms, suggesting
        similar neuroprotective mechanisms.
      explanation: >
        The human arm of the same paper, from a randomised placebo-controlled trial in
        early-psychosis patients. INDIRECT: prefrontal GABA rose under antioxidant treatment,
        which argues the edge runs this way in people, but it is a therapeutic response and
        not a measurement of interneuron integrity.
  evidence:
  - reference: PMID:33221354
    reference_title: "Mitochondrial dysfunction in schizophrenia: With a focus on postmortem
      studies."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: Decreased activity of complexes I and IV are prominent as well as abnormal levels
      of individual subunits that comprise the complexes of the electron transport chain.
    explanation: >
      Postmortem review supporting the complex I deficit this node's description asserts,
      which until now carried no citation at all.
  - reference: PMID:40162239
    reference_title: Transcriptomic and genetic analysis suggests a role for mitochondrial dysregulation in schizophrenia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A gene program largely shared between neuronal subtypes, astrocytes, and oligodendrocytes was significantly enriched for schizophrenia risk, supporting an aetiological role for perturbed protein modification, ion transport, and mitochondrial function."
    explanation: >-
      Single-nucleus RNA-seq of 536,618 nuclei from dorsal prefrontal cortex of
      43 cases and 42 controls ties a mitochondrial gene program to schizophrenia
      genetic risk. This is a different claim from the postmortem enzyme-activity
      citation above: it connects the bioenergetic lesion to inherited risk rather
      than measuring respiratory-chain function. Two limits on how far it reaches:
      the finding is postmortem differential expression and co-expression
      enrichment, so it cannot order bioenergetic failure relative to synaptic or
      interneuron changes, and the deposited record is a medRxiv preprint.
- name: Blood-Brain Barrier Dysfunction
  description: Increased BBB permeability with elevated CSF albumin and immunoglobulins, involving dysfunction of endothelial cells, pericytes, and astrocytes in the neurovascular unit.
  cell_types:
  - preferred_term: endothelial cell
    term:
      id: CL:0000115
      label: endothelial cell
  - preferred_term: astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  locations:
  - preferred_term: blood-brain barrier
  notes: >-
    Deliberately left with no downstream edge. The intuitive one — barrier leak admitting
    peripheral immune activity that feeds the complement-pruning node — is not something the
    available evidence establishes; the human data show the leak (raised CSF/serum albumin
    and IgG ratios) without connecting it to synapse elimination. Note also how small the
    effect is: the same study found CSF white cell count, total protein and IgG index NOT
    significantly elevated, so this is a subtle group-level shift rather than a barrier
    breach, and the node should not be read as asserting neuroinflammation.
  evidence:
  - reference: PMID:35939296
    reference_title: Cerebrospinal Fluid and Blood Biomarkers of Neuroinflammation and Blood-Brain
      Barrier in Psychotic Disorders and Individually Matched Healthy Controls.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "CSF/serum albumin ratio (Relative Mean Difference (MD): 1.11; 95%CI: 1.00-1.23;
      P = .044) and CSF/serum IgG ratio (MD: 1.17; 95%CI: 1.01-1.36; P = .036) was increased
      in patients compared to controls."
    explanation: >
      104 recent-onset psychosis patients against 104 individually matched controls — the
      largest matched CSF series for this claim, and the source for the raised albumin and
      IgG ratios in this node's description, which previously carried no citation.
phenotypes:
- category: Psychiatric
  name: Hallucinations
  frequency: FREQUENT
  diagnostic: true
  notes: Often auditory in nature, such as hearing voices. Can also be visual, tactile, or olfactory.
  evidence:
  - reference: PMID:28437056
    reference_title: "Psychotic and Bipolar Disorders: Schizophrenia."
    supports: SUPPORT
    snippet: 'Schizophrenia symptoms fall into six common symptom clusters: delusions and hallucinations, disorganization of speech, cognitive dysfunction, negative symptoms, affective symptoms, and motor system abnormalities.'
    explanation: Delusions and hallucinations are recognized as common symptom clusters in schizophrenia, supporting the statement that hallucinations are frequent and a part of the psychiatric diagnostic category.
  - reference: PMID:25773224
    reference_title: "Ophthalmology issues in schizophrenia."
    supports: SUPPORT
    snippet: Schizophrenia is a complex mental disorder associated with not only cognitive dysfunctions, such as memory and attention deficits, but also changes in basic sensory processing.
    explanation: This supports the note that hallucinations in schizophrenia can be auditory, visual, tactile, or olfactory in nature, indicating changes in sensory processing.
  - reference: PMID:21545448
    reference_title: "Clinical correlates of olfactory hallucinations in schizophrenia."
    supports: SUPPORT
    snippet: Prevalence of OHs and hallucinations in other modalities differed according to the WHO-10 international centre. Across centres, OHs were present in 13% of the WHO-10 dataset, similar to the 17% prevalence rate in the SAPS/SANS dataset.
    explanation: This supports the claim that olfactory hallucinations are among the types of hallucinations experienced by schizophrenic patients, although less frequent than auditory hallucinations.
  - reference: PMID:35383683
    reference_title: "Auditory Verbal Hallucinations in Schizophrenia, Part II: Phenomenological Qualities and Evolution."
    supports: SUPPORT
    snippet: We found that a substantial proportion of patients could not clearly distinguish between thinking and hallucinating. The emotional tone of the voices increased in negativity.
    explanation: This supports the auditory nature of hallucinations (hearing voices) but does not provide comprehensive support for visual, tactile, or olfactory hallucinations.
  phenotype_term:
    preferred_term: Hallucinations
    term:
      id: HP:0000738
      label: Hallucinations
- category: Psychiatric
  name: Delusions
  frequency: FREQUENT
  diagnostic: true
  notes: False beliefs, often paranoid or grandiose in nature. Resistant to contradictory evidence.
  evidence:
  - reference: PMID:33485408
    reference_title: "Delusions beyond beliefs: a critical overview of diagnostic, aetiological, and therapeutic schizophrenia research from a clinical-phenomenological perspective."
    supports: SUPPORT
    snippet: Delusions are commonly conceived as false beliefs that are held with certainty and which cannot be corrected. This conception of delusion has been influential throughout the history of psychiatry and continues to inform how delusions are approached in clinical practice and in contemporary schizophrenia research.
    explanation: The literature describes delusions as false beliefs that are resistant to contradictory evidence, which aligns with the statement's note that delusions in schizophrenia are often paranoid or grandiose in nature.
  - reference: PMID:949230
    reference_title: "The Capgras phenomenon."
    supports: SUPPORT
    snippet: The underlying diagnosis of Capgras delusion is not found to be exclusively paranoid schizophrenia, nor is the sex exclusively female, as once was believed.
    explanation: While Capgras delusion may involve delusions, the reference suggests that these delusions are not exclusively found in paranoid schizophrenia. This partially supports the statement but adds another layer of complexity.
  - reference: PMID:29151090
    reference_title: "De Clérambault Syndrome, Othello Syndrome, Folie à Deux and Variants."
    supports: NO_EVIDENCE
    snippet: Non-bizarre delusion, defined as a false belief possible although highly unlikely, is the main manifestation of delusional disorders, previously known as paranoia.
    explanation: The description of non-bizarre delusions aligns with the statement that delusions, which are false beliefs, are a frequent psychiatric diagnostic category in schizophrenia.
  - reference: PMID:24677735
    reference_title: "Unravelling offending in schizophrenia: factors characterising subgroups of offenders."
    supports: SUPPORT
    snippet: Persecutory and/or grandiose delusions were more strongly associated with each offender group compared with non-offenders, most so with late first offenders.
    explanation: This reference supports the statement as it mentions paranoid and grandiose delusions being prevalent in patients with schizophrenia.
  phenotype_term:
    preferred_term: Delusions
    term:
      id: HP:0000746
      label: Delusion
- category: Cognitive
  name: Disorganized Thinking
  frequency: FREQUENT
  diagnostic: true
  notes: Impaired logical thought process and communication. May manifest as loose associations or incoherent speech.
  evidence:
  - reference: PMID:30488088
    reference_title: "[Impairments of language and communication in schizophrenia]."
    supports: SUPPORT
    snippet: Disorganized speech is one of the key symptoms of schizophrenia. This article provides an overview of those areas of speech and communication impaired in patients with schizophrenia.
    explanation: Disorganized thinking is closely related to disorganized speech, which is highlighted as a frequent impairment in schizophrenia.
  - reference: PMID:2084786
    reference_title: "Studies of the course of schizophasia."
    supports: SUPPORT
    snippet: The course of psychoses of schizophrenic type follows rules which are still not adequately understood. It is, however, clear that certain symptoms appear mostly early, others only late... we studied 44 final phase patients whose main symptom was disordered thinking of the schizophasic type.
    explanation: The study highlights disordered thinking (a form of cognitive impairment) as a main symptom in later stages of schizophrenia.
  - reference: PMID:37040138
    reference_title: "Deficits in Analytic and Common-Sense Reasoning in Schizophrenia."
    supports: SUPPORT
    snippet: Patients with schizophrenia were impaired in both analytic and common-sense thinking.
    explanation: Impaired logical thought processes and communication, which might manifest as loose associations or incoherent speech, align with the cognitive phenotype of disorganized thinking.
  - reference: PMID:35752547
    reference_title: "Syntactic complexity of spoken language in the diagnosis of schizophrenia: A probabilistic Bayes network model."
    supports: SUPPORT
    snippet: We conclude that an early drift towards linguistic disorganization/impoverishment of clause complexity-at the granular level of nominal subject per clause-is a distinctive feature of schizophrenia that decreases longitudinally, thus differentiating schizophrenia from other psychotic illnesses with shared phenomenology.
    explanation: Linguistic disorganization and impoverishment of clause complexity are reflective of impaired logical thought process and communication, supporting the cognitive phenotype of disorganized thinking.
  - reference: PMID:17477206
    reference_title: "Delusional thinking and cognitive disorder."
    supports: SUPPORT
    snippet: The data of interest are (a) the failure to find evidence of cognitive impairment in diagnosed paranoid patients...
    explanation: While the study discusses delusional thinking with little evidence of cognitive impairment in paranoid patients, it does suggest that cognitive mechanisms in schizophrenia may differ, providing partial support to the cognitive phenotype.
- category: Occupational
  name: Social Withdrawal
  frequency: FREQUENT
  notes: Reduction in social interactions and engagement. Can lead to isolation and difficulty maintaining relationships.
  evidence:
  - reference: PMID:31390645
    reference_title: "Social Life in the Schizophrenia Spectrum: A Phenomenological Study of Five Patients."
    supports: SUPPORT
    snippet: A 'positively withdrawn' position characterizes a wider group of patients than originally reported. Further, we identified a preference for partaking in social activities in particular circumstances with clearly circumscribed goals or social roles and rules.
    explanation: The study indicates that social withdrawal is a significant aspect of schizophrenia and is frequently observed among patients.
  - reference: PMID:35102081
    reference_title: "Social withdrawal and neurocognitive correlates in schizophrenia."
    supports: SUPPORT
    snippet: Social withdrawal was measured by a specific item of the Heinrichs-Carpenter Quality of Life Scale. Social withdrawal was associated with a lower score in the neurocognitive composite score and in 'Verbal memory,' 'Processing speed' and 'Working memory' scores.
    explanation: The study confirms the association between social withdrawal and various neurocognitive deficits in schizophrenia, supporting its frequent occurrence.
  - reference: PMID:11103877
    reference_title: "Animal models for the negative symptoms of schizophrenia."
    supports: SUPPORT
    snippet: Negative symptoms encompass, among others, anhedonia, flat affect, avolition and social withdrawal.
    explanation: The review details social withdrawal as a prominent negative symptom in schizophrenia, further corroborating its frequent occurrence.
  - reference: PMID:28637195
    reference_title: "Social Disconnection in Schizophrenia and the General Community."
    supports: SUPPORT
    snippet: Social disability is a defining characteristic of schizophrenia... One component, social disconnection, occurs extensively... Social disconnection is an objective, long-standing lack of social/family relationships and minimal participation in social activities.
    explanation: The paper discusses social withdrawal as a central component of social disability in schizophrenia.
- category: Mood
  name: Flat Affect
  phenotype_term:
    preferred_term: Flat Affect
    term:
      id: HP:0030213
      label: Emotional dearth
  frequency: FREQUENT
  notes: Reduced expression of emotions. May appear unresponsive or lacking emotional depth.
  evidence:
  - reference: PMID:16452608
    reference_title: "Flat affect in schizophrenia: relation to emotion processing and neurocognitive measures."
    supports: SUPPORT
    snippet: Impaired emotional functioning in schizophrenia is a prominent clinical feature that manifests primarily as flat affect... Flat affect was more common in men and was associated with poorer premorbid adjustment, worse current quality of life, and worse outcome at 1-year follow-up.
    explanation: The study provides evidence that flat affect is a frequent and prominent clinical feature of schizophrenia, which aligns with the statement.
  - reference: PMID:23846857
    reference_title: "Clinical phenotypes of psychosis in the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP)."
    supports: SUPPORT
    snippet: Schizophrenia probands showed more symptoms and lower psychosocial functioning than probands with psychotic bipolar disorder, but there was considerable overlap in clinical manifestations.
    explanation: The reference suggests that flat affect, which is an emotional deficit, is part of the clinical phenotype of schizophrenia.
  - reference: PMID:31839552
    reference_title: "Voice patterns in schizophrenia: A systematic review and Bayesian meta-analysis."
    supports: SUPPORT
    snippet: Voice atypicalities have been a characteristic feature of schizophrenia ... They are often associated with core negative symptoms such as flat affect and alogia ... This suggests that voice atypicalities may represent a marker of clinical features and social functioning in schizophrenia.
    explanation: The study mentions flat affect as one of the core negative symptoms of schizophrenia, supporting its frequent occurrence within the schizophrenia phenotype.
  - reference: PMID:11103877
    reference_title: "Animal models for the negative symptoms of schizophrenia."
    supports: SUPPORT
    snippet: In schizophrenia, negative symptoms encompass, among others, anhedonia, flat affect, avolition, and social withdrawal.
    explanation: This review states that flat affect is one of the negative symptoms associated with schizophrenia, supporting the frequent occurrence.
  - reference: PMID:28242515
    reference_title: "Emotional word usage in groups at risk for schizophrenia-spectrum disorders: An objective investigation of attention to emotion."
    supports: SUPPORT
    snippet: Both extreme levels of social anhedonia (SocAnh) and extreme levels of perceptual aberration/magical ideation (PerMag) indicate increased risk for schizophrenia-spectrum disorders and are associated with emotional deficits.
    explanation: The study discusses emotional deficits in groups at risk for schizophrenia, implying the presence of flat affect as a frequent feature.
  - reference: PMID:11122987
    reference_title: "Defining the schizophrenia phenotype."
    supports: SUPPORT
    snippet: The schizophrenia phenotype has been traditionally defined by chronic psychosis and functional deterioration ... Subtle clinical signs and symptoms, cognitive impairment particularly in attention and memory, and neurophysiologic deficits such as in sensory gating and smooth-pursuit eye movements all define aspects of the schizophrenia phenotype.
    explanation: Even though flat affect is not explicitly mentioned, the reference discusses emotional and cognitive impairments, supporting the statement indirectly.
- category: Cognitive
  name: Working Memory Deficits
  frequency: FREQUENT
  notes: Difficulties in short-term information storage and manipulation.
  evidence:
  - reference: PMID:36252418
    reference_title: "Evidence that a working memory cognitive phenotype within schizophrenia has a unique underlying biology."
    supports: SUPPORT
    snippet: Our data gives preliminary support to the hypotheses that there is a working memory deficit phenotype within the syndrome of schizophrenia with has a biological underpinning.
    explanation: Evidence suggests there is a working memory deficit phenotype within schizophrenia.
  - reference: PMID:30104335
    reference_title: "Posterior Parietal Cortex Dysfunction Is Central to Working Memory Storage and Broad Cognitive Deficits in Schizophrenia."
    supports: SUPPORT
    snippet: PFC dysfunction is widely believed to underlie working memory (WM) deficits in people with schizophrenia (PSZ)...These results indicate that PPC dysfunction is central to WM storage deficits in PSZ and may play a key role in the broad cognitive deficits associated with schizophrenia.
    explanation: The literature highlights WM deficits as a central part of cognitive impairment in schizophrenia.
  - reference: PMID:20053864
    reference_title: "Iconic decay in schizophrenia."
    supports: SUPPORT
    snippet: Working memory impairment is considered a core deficit in schizophrenia.
    explanation: The study directly supports the existence of working memory deficits as a core phenotype in schizophrenia.
  - reference: PMID:19328655
    reference_title: "Schizophrenia, \"just the facts\" 4. Clinical features and conceptualization."
    supports: SUPPORT
    snippet: It is characterized by an admixture of positive, negative, cognitive, mood, and motor symptoms whose severity varies across patients and through the course of the illness.
    explanation: Although the snippet is general, cognitive deficits typically encompass working memory as part of the broader impairment in schizophrenia.
- category: Behavioral
  name: Catatonia
  frequency: OCCASIONAL
  notes: Abnormal motor behavior, ranging from excessive movement to immobility.
  evidence:
  - reference: PMID:11478416
    reference_title: "Catatonia: syndrome or schizophrenia subtype? Recognition and treatment."
    supports: SUPPORT
    snippet: Catatonia is a parallel behavior phenomenon to delusions (in thought) and delirium (in cognition).
    explanation: The reference suggests catatonia is associated with schizophrenia but does not specify the frequency of this phenotype.
  - reference: PMID:34785041
    reference_title: "Low physical activity is associated with two hypokinetic motor abnormalities in psychosis."
    supports: SUPPORT
    snippet: Lower activity levels correlated with increased age and severity of catatonia and parkinsonism. The 22 patients with catatonia had lower activity as well as higher scores on parkinsonism, involuntary movements, and negative symptoms compared to the 30 patients without catatonia.
    explanation: The study indicates catatonia is present in some patients with schizophrenia but does not specify its frequency.
  - reference: PMID:22814247
    reference_title: "Motor symptoms and schizophrenia."
    supports: SUPPORT
    snippet: Classical schizophrenia literature reports motor symptoms as characteristic of the disorder... This review of the literature supports the idea that motor symptoms are closely related to the neurodevelopmental disturbances of schizophrenia and a distinct syndromal dimension with its own pathophysiology.
    explanation: The literature suggests catatonia, as a motor symptom, is a recognized aspect of schizophrenia.
  - reference: PMID:30177576
    reference_title: "[Symptoms Specific to Schizophrenia]."
    supports: NO_EVIDENCE
    snippet: Symptoms specific to schizophrenia include self-disturbances, delusional perception and loosening of associations.
    explanation: Though this reference focus on other symptoms, it indirectly supports catatonia as one of the reported motor symptoms in schizophrenia spectrum conditions.
  - reference: PMID:37655417
    reference_title: "[Periodic catatonia in schizophrenia spectrum disorders]."
    supports: SUPPORT
    snippet: 'Three forms of periodic catatonia have been identified: hypokinetic, parakinetic, multikinetic.'
    explanation: The study supports the presence of catatonia in schizophrenia but does not clarify the frequency.
  - reference: PMID:20587767
    reference_title: "Clozapine-withdrawal catatonia."
    supports: NO_EVIDENCE
    snippet: Case reports in which abrupt clozapine discontinuation led to a return of psychosis, autonomic instability, or catatonia.
    explanation: This case study does not provide evidence about the general frequency of catatonia in schizophrenia.
biochemical:
- name: Dopamine Metabolites
  presence: Elevated
  context: Observed in cerebrospinal fluid and postmortem brain analysis.
  evidence:
  - reference: PMID:37271040
    reference_title: "CSF dopamine is elevated in first-episode psychosis and associates to symptom severity and cognitive performance."
    supports: SUPPORT
    snippet: CSF dopamine was reliably detected in 50% of healthy controls and in 65% of first-episode psychosis subjects and significantly higher in first-episode psychosis subjects compared to age-matched healthy controls.
    explanation: This study shows increased cerebrospinal fluid dopamine levels, which are related to dopamine metabolism, in first-episode psychosis subjects, supporting elevated dopamine metabolites in CSF in schizophrenia.
  - reference: PMID:9278185
    reference_title: "Cortical dopamine in schizophrenia: strategies for postmortem studies."
    supports: NO_EVIDENCE
    snippet: The application of this strategy, and its value in overcoming some of the potential pitfalls of postmortem studies, is demonstrated in a series of investigations designed to test the hypothesis that dopamine neurotransmission is impaired in the entorhinal cortex in schizophrenia.
    explanation: While it discusses postmortem brain analysis and dopamine dysfunction in schizophrenia, it does not specifically state elevated dopamine metabolites.
  - reference: PMID:18366307
    reference_title: "Cerebrospinal fluid: identification of diagnostic markers for schizophrenia."
    supports: NO_EVIDENCE
    snippet: Although numerous studies have aimed to identify potential diagnostic markers in the CSF of schizophrenia patients, as yet not one has found its way to clinical application.
    explanation: The study discusses the difficulty in identifying reliable diagnostic markers in the cerebrospinal fluid of schizophrenia patients without specifically mentioning elevated dopamine metabolites.
- name: Glutamate Levels
  presence: Elevated
  context: Observed in cerebrospinal fluid and postmortem brain analysis.
  evidence:
  - reference: PMID:18366307
    reference_title: "Cerebrospinal fluid: identification of diagnostic markers for schizophrenia."
    supports: NO_EVIDENCE
    snippet: Although numerous studies have aimed to identify potential diagnostic markers in the CSF of schizophrenia patients, as yet not one has found its way to clinical application.
    explanation: The study discusses the search for diagnostic markers in CSF but does not provide specific evidence for elevated glutamate levels.
  - reference: PMID:11684348
    reference_title: "Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia."
    supports: NO_EVIDENCE
    snippet: Kynurenic acid is an endogenous glutamate antagonist with a preferential action at the glycine-site of the N-methyl D-aspartate-receptor.
    explanation: This study focuses on the elevated levels of kynurenic acid, not directly on glutamate levels.
  - reference: PMID:20846490
    reference_title: "Alterations in dopamine and glutamate neurotransmission in tetrahydrobiopterin deficient spr-/- mice: relevance to schizophrenia."
    supports: SUPPORT
    snippet: Accordingly, it is possible that abnormalities in the biochemical cascades regulated by BH(4) may alter DA, 5-HT and Glu neurotransmission, and consequently contribute to the pathophysiology of different neuropsychiatric diseases including schizophrenia.
    explanation: The study mentions alterations in glutamate (Glu) neurotransmission in schizophrenia, aligning with the statement.
  - reference: PMID:37752221
    reference_title: "Glutamatergic basis of antipsychotic response in first-episode psychosis: a dual voxel study of the anterior cingulate cortex."
    supports: SUPPORT
    snippet: A subgroup of patients with schizophrenia is believed to have aberrant excess of glutamate in the frontal cortex.
    explanation: The study provides evidence of elevated glutamate levels in the frontal cortex in schizophrenia patients.
  - reference: PMID:17156977
    reference_title: "A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia."
    supports: NO_EVIDENCE
    snippet: Levels of L-serine, L-glutamine and L-glutamate were unaffected.
    explanation: The study reported no significant change in glutamate levels in the brain of schizophrenia patients, contrasting with the statement.
genetic:
- name: SETD1A
  gene_term:
    preferred_term: SETD1A
    term:
      id: hgnc:29010
      label: SETD1A
  association: Risk Factor
  relationship_type: RISK_FACTOR
  notes: >-
    Rare loss-of-function variants confer large-effect schizophrenia risk;
    encodes a histone H3K4 methyltransferase critical for chromatin regulation
    in cortical excitatory neurons. SETD1A was the first and, for several years,
    the only single gene robustly associated with schizophrenia by rare coding
    variation, and it remains one of the ten exome-wide-significant SCHEMA
    genes. A separate founder-population missense allele (p.Pro596Leu) has been
    associated with bipolar disorder rather than schizophrenia; that association
    is nominal and unreplicated and is curated on the Bipolar Disorder entry,
    not here.
  evidence:
  - reference: PMID:26974950
    reference_title: "Rare loss-of-function variants in SETD1A are associated with schizophrenia and developmental disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "we identified a genome-wide significant association between rare loss-of-function (LoF) variants in SETD1A and risk for schizophrenia (P = 3.3 × 10(-9))"
    explanation: >-
      The primary genome-wide-significant association establishing SETD1A rare
      loss-of-function variants as a large-effect schizophrenia risk factor.
  - reference: PMID:26974950
    reference_title: "Rare loss-of-function variants in SETD1A are associated with schizophrenia and developmental disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We found only two heterozygous LoF variants in 45,376 exomes from individuals without a neuropsychiatric diagnosis, indicating that SETD1A is substantially depleted of LoF variants in the general population."
    explanation: >-
      Quantifies the constraint that underlies the large effect size - SETD1A
      LoF is close to absent in unaffected individuals.
  - reference: PMID:26974950
    reference_title: "Rare loss-of-function variants in SETD1A are associated with schizophrenia and developmental disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Combining these data with previous common variant evidence, we suggest that epigenetic dysregulation, specifically in the histone H3K4 methylation pathway, is an important mechanism in the pathogenesis of schizophrenia."
    explanation: >-
      Sources the mechanistic claim in the notes - that the relevant lesion is
      H3K4-methylation-pathway epigenetic dysregulation, not a synaptic protein
      defect.
  - reference: PMID:35396579
    reference_title: "Rare coding variants in ten genes confer substantial risk for schizophrenia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the analysis of URVs has had limited success in delivering individual gene discovery in schizophrenia because of power limitations, with only a single gene, SETD1A, identified as robustly associated"
    explanation: >-
      SCHEMA, the largest schizophrenia exome meta-analysis (24,248 cases),
      confirms SETD1A as the one gene robustly implicated by rare coding
      variation before that study. The quoted sentence describes that prior
      state of the field; SETD1A's place among SCHEMA's ten
      exome-wide-significant genes is stated in the entry notes rather than
      claimed from this snippet.
- name: NRXN1
  gene_term:
    preferred_term: NRXN1
    term:
      id: hgnc:8008
      label: NRXN1
  association: Risk Factor
  notes: Rare heterozygous deletions and loss-of-function variants confer large-effect schizophrenia risk; encodes a presynaptic neurexin essential for synaptic adhesion and neurotransmitter release.
- name: 22q11.2 deletion (DiGeorge / Velocardiofacial Syndrome locus)
  association: Risk Factor
  notes: Recurrent 22q11.2 microdeletion is one of the strongest known schizophrenia risk factors (~25-30% of carriers develop psychotic disorders by adulthood); encompasses multiple genes including COMT, TBX1, and DGCR8.
- name: DRD2
  gene_term:
    preferred_term: DRD2
    term:
      id: hgnc:3023
      label: DRD2
  association: Risk Factor
  notes: Dopamine D2 receptor; primary antipsychotic target; GWAS-implicated gene explaining >20% liability in aggregate with other common variants.
- name: GRIN1
  gene_term:
    preferred_term: GRIN1
    term:
      id: hgnc:4584
      label: GRIN1
  association: Risk Factor
  notes: NMDA receptor subunit; implicated in glutamatergic dysfunction and cortical disinhibition.
- name: GRIN2A
  gene_term:
    preferred_term: GRIN2A
    term:
      id: hgnc:4585
      label: GRIN2A
  association: Risk Factor
  notes: NMDA receptor subunit; involved in NMDA hypofunction on parvalbumin interneurons.
- name: GAD1
  gene_term:
    preferred_term: GAD1
    term:
      id: hgnc:4092
      label: GAD1
  association: Risk Factor
  notes: GAD67 enzyme; epigenetically regulated; contributes to GABAergic dysfunction.
- name: RELN
  gene_term:
    preferred_term: RELN
    term:
      id: hgnc:9957
      label: RELN
  association: Risk Factor
  notes: Reelin protein; epigenetically regulated; involved in cortical development and interneuron maturation.
- name: C4A
  gene_term:
    preferred_term: C4A
    term:
      id: hgnc:1323
      label: C4A
  association: Risk Factor
  notes: Complement component 4A; drives excessive microglial synaptic pruning during adolescence.
- name: C3
  gene_term:
    preferred_term: C3
    term:
      id: hgnc:1318
      label: C3
  association: Risk Factor
  notes: Complement component 3; works with C4A in complement-mediated synaptic elimination.
- name: DISC1
  gene_term:
    preferred_term: DISC1
    term:
      id: hgnc:2888
      label: DISC1
  association: Risk Factor
  evidence:
  - reference: PMID:30286368
    reference_title: "Association on DISC1 SNPs with schizophrenia risk: A meta-analysis."
    supports: SUPPORT
    snippet: DISC1 gene has been shown as a risk factor for schizophrenia in some reports.
    explanation: The meta-analysis confirms associations between specific SNPs in the DISC1 gene and schizophrenia risk.
  - reference: PMID:24056909
    reference_title: "Questions about DISC1 as a genetic risk factor for schizophrenia."
    supports: NO_EVIDENCE
    snippet: Questions about DISC1 as a genetic risk factor for schizophrenia.
    explanation: This reference raises questions about the role of DISC1 as a risk factor, implying a lack of consensus.
  - reference: PMID:30285728
    reference_title: "The TRAX, DISC1, and GSK3 complex in mental disorders and therapeutic interventions."
    supports: SUPPORT
    snippet: The human DISC1 gene is located on chromosome 1 and is highly associated with schizophrenia and other mental disorders.
    explanation: This study associates the DISC1 gene with schizophrenia among other mental disorders, supporting its role as a risk factor.
  - reference: PMID:20302823
    reference_title: "Modeling schizophrenia in flies."
    supports: NO_EVIDENCE
    snippet: Modeling the disease in genetically tractable animals is thus a challenging but increasingly important task. In this review, I discuss the potential problems and perspectives associated with modeling schizophrenia in fruit flies, and briefly review the recent studies analyzing the molecular and cellular functions of Disrupted-In-Schizophrenia-1 (DISC1) in transgenic flies.
    explanation: This review highlights the relevance of studying DISC1 functions in the context of schizophrenia.
- name: COMT
  gene_term:
    preferred_term: COMT
    term:
      id: hgnc:2228
      label: COMT
  association: Risk Factor
  evidence:
  - reference: PMID:23573605
    reference_title: "Schizophrenia, the prefrontal cortex, and a mechanism of genetic susceptibility."
    supports: SUPPORT
    snippet: 'COMT is an enzyme that is distributed widely throughout the brain, but seems to be uniquely relevant to how dopamine affects information-processing in the prefrontal cortex. There is a common variation in the genetic sequence of the COMT gene, which causes a dramatic change in its enzyme activity. In people with schizophrenia, in their healthy siblings, and also in normal controls, the COMT genotype predicts 4% of the variation in human executive cognition and working memory. We have thus identified a genetic mechanism in the human species that affects the efficiency and efficacy of information-processing in the prefrontal cortex. It is, also, a weak genetic risk factor for schizophrenia: in family studies, it increases the risk of schizophrenia by 50-80%.'
    explanation: The COMT gene is identified as a weak genetic risk factor for schizophrenia, increasing the risk by 50-80% in family studies.
- name: NRG1
  gene_term:
    preferred_term: NRG1
    term:
      id: hgnc:7997
      label: NRG1
  association: Risk Factor
  evidence:
  - reference: PMID:16520822
    reference_title: "Association of the NRG1 gene and schizophrenia: a meta-analysis."
    supports: SUPPORT
    snippet: Our meta-analysis provides support for the association of NRG1 with schizophrenia, but indicates that firmly establishing the role of NRG1 gene in schizophrenia by genetic association requires much larger sample sizes than have hitherto been reported.
    explanation: The meta-analysis found some evidence supporting the association of NRG1 with schizophrenia, but also highlighted the need for larger sample sizes to firmly establish this role.
  - reference: PMID:15162166
    reference_title: "Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophrenia."
    supports: SUPPORT
    snippet: Recently, the gene that encodes neuregulin-1 (NRG1) has been identified as a potential susceptibility gene for schizophrenia, and defects in the expression of erbB3, one of the NRG1 receptors, have been shown to occur in the prefrontal cortex of schizophrenic patients...
    explanation: This reference identifies NRG1 as a potential susceptibility gene for schizophrenia, indicating a genetic association.
  - reference: PMID:20600464
    reference_title: "Genetic findings in schizophrenia patients related to alterations in the intracellular Ca-homeostasis."
    supports: SUPPORT
    snippet: We mainly focus on genes including:...NRG1 (Neuregulin 1)... Taken together there is converging evidence for the contribution of genes potentially related to alterations in intracellular Ca-homeostasis to the risk of schizophrenia.
    explanation: This review points to NRG1 as a gene potentially related to the risk of schizophrenia.
  - reference: PMID:24968777
    reference_title: "Dopaminergic function in relation to genes associated with risk for schizophrenia: translational mutant mouse models."
    supports: SUPPORT
    snippet: '...It considers models for understanding the role(s) of risk genes, with a particular focus on DTNBP1 and NRG1...'
    explanation: This paper focuses on NRG1 as one of the risk genes associated with schizophrenia.
- name: DTNBP1
  gene_term:
    preferred_term: DTNBP1
    term:
      id: hgnc:17328
      label: DTNBP1
  association: Risk Factor
  evidence:
  - reference: PMID:19862852
    reference_title: "Association study of DTNBP1 with schizophrenia in a US sample."
    supports: SUPPORT
    snippet: This study shows that DTNBP1 is a risk gene for schizophrenia in EAs. Variation at DTNBP1 may modify risk for schizophrenia in this population.
    explanation: This reference provides evidence that DTNBP1 is associated with an increased risk of schizophrenia, particularly in European-Americans.
  - reference: PMID:18474210
    reference_title: "Genetics of clinical features and subtypes of schizophrenia: a review of the recent literature."
    supports: SUPPORT
    snippet: To date, DTNBP1 has provided the greatest evidence of illness modification, as associations with negative and cognitive symptoms and worse outcome have been published in independent samples.
    explanation: This reference elaborates on the association of DTNBP1 with specific clinical features of schizophrenia, further supporting its role as a risk factor.
  - reference: PMID:24968777
    reference_title: "Dopaminergic function in relation to genes associated with risk for schizophrenia: translational mutant mouse models."
    supports: SUPPORT
    snippet: It considers models for understanding the role(s) of risk genes, with a particular focus on DTNBP1 and NRG1, their interactions with environmental factors, and with each other (epistasis).
    explanation: This reference discusses the role of DTNBP1 as a risk gene for schizophrenia within the context of genetic and environmental interactions.
environmental:
- name: Prenatal Stress
  description: Exposure to stress during fetal development may increase risk.
  evidence:
  - reference: PMID:33544627
    reference_title: "Early Environmental Upheaval and the Risk for Schizophrenia."
    supports: SUPPORT
    snippet: we appraise the evidence linking schizophrenia spectrum disorder to prenatal maternal stress.
    explanation: The review provides evidence linking prenatal stress to the risk of schizophrenia spectrum disorder.
  - reference: PMID:26968981
    reference_title: "Schizophrenia and reelin: a model based on prenatal stress to study epigenetics, brain development and behavior."
    supports: SUPPORT
    snippet: prenatal stress induces neurodevelopmental alterations in the prefrontal cortex that are expressed as cognitive impairment observed in schizophrenia.
    explanation: The article discusses the association between prenatal stress and neurodevelopmental changes leading to schizophrenia.
  - reference: PMID:26753951
    reference_title: "Fetal exposure to maternal stress and risk for schizophrenia spectrum disorders among offspring: Differential influences of fetal sex."
    supports: SUPPORT
    snippet: Findings suggest sex-specific fetal sensitivity to maternal reported daily life stress during pregnancy on risk for SSD, with males appearing to be more vulnerable to the influences of maternal stress during pregnancy.
    explanation: The study found that maternal stress during pregnancy is associated with increased risk of schizophrenia spectrum disorders in offspring, particularly males.
  - reference: PMID:37116354
    reference_title: "A consideration of the increased risk of schizophrenia due to prenatal maternal stress, and the possible role of microglia."
    supports: SUPPORT
    snippet: Epidemiological findings are rather consistent in supporting the association, albeit they are mitigated by effects of sex and gestational timing.
    explanation: The article evaluates evidence linking prenatal maternal stress with an elevated risk of schizophrenia and discusses the role of microglial activation.
  - reference: PMID:37783300
    reference_title: "Prenatal risk factors and postnatal cannabis exposure: Assessing dual models of schizophrenia-like rodents."
    supports: SUPPORT
    snippet: Schizophrenia (SCZ) is a multifactorial neurodevelopmental disorder caused by genetic and environmental alterations, especially during prenatal stages.
    explanation: The review states that prenatal environmental alterations, including stress, are associated with an increased risk of schizophrenia.
  exposure_term:
    preferred_term: Prenatal stress exposure
    term:
      id: XCO:0001265
      label: stress
- name: Cannabis Use
  description: Associated with increased risk and earlier onset in genetically predisposed individuals.
  evidence:
  - reference: PMID:24957864
    reference_title: "Genetic predisposition to schizophrenia associated with increased use of cannabis."
    supports: SUPPORT
    snippet: Although considerable evidence implicates cannabis use as a component cause of schizophrenia, it remains unclear whether this is entirely due to cannabis directly raising risk of psychosis, or whether the same genes that increases psychosis risk may also increase risk of cannabis use.
    explanation: The study suggests that there is an association between cannabis use and schizophrenia, but it indicates that the genetic components might play a significant role, making it partially supportive.
  - reference: PMID:26232243
    reference_title: "Environmental factors and the age at onset in first episode psychosis."
    supports: SUPPORT
    snippet: Individuals with a history of cannabis abuse had an earlier age at onset by nearly six years.
    explanation: The study provides direct evidence that cannabis use is associated with an earlier age at onset of psychosis.
  - reference: PMID:21068828
    reference_title: "The environment and schizophrenia."
    supports: SUPPORT
    snippet: onset is associated with environmental factors such as early life adversity, growing up in an urban environment, minority group position and cannabis use.
    explanation: The association of environmental factors, including cannabis use, supports the idea of increased risk of schizophrenia.
  - reference: PMID:28142064
    reference_title: "Cannabis use, COMT, BDNF and age at first-episode psychosis."
    supports: SUPPORT
    snippet: The relationship between age at psychosis onset and COMT Val158Met and BDNF Val66Met polymorphisms with early cannabis use as well as those factors associated with early cannabis use were investigated.
    explanation: The study highlights the important role of early cannabis use and genetic polymorphisms in influencing the age at psychosis onset, thereby supporting the statement.
  - reference: PMID:37185055
    reference_title: "Tobacco use in first-episode psychosis, a multinational EU-GEI study."
    supports: SUPPORT
    snippet: Tobacco use was associated with an earlier age at psychosis onset...; however, these results were no longer significant after controlling for cannabis use.
    explanation: The study indicates that cannabis use correlates with an earlier age at onset of psychosis, supporting the statement.
  exposure_term:
    preferred_term: Cannabis exposure
    term:
      id: ECTO:0100005
      label: exposure to cannabis
treatments:
- name: Xanomeline-Trospium (KarXT)
  description: >-
    First-in-class M1/M4 muscarinic receptor agonist (xanomeline) combined
    with the peripherally-restricted pan-muscarinic antagonist trospium
    chloride to mitigate peripheral cholinergic side effects. FDA-approved
    September 2024 for schizophrenia in adults, marketed as Cobenfy. Acts
    without direct D2 dopamine-receptor blockade, which shows that direct D2
    antagonism is not required for antipsychotic efficacy. That is a weaker
    statement than a dopamine independent mechanism: M4 receptor activation
    produces a sustained depression of striatal dopamine release, so muscarinic
    agonism may still converge on the dopamine system downstream.
  therapeutic_modality: SMALL_MOLECULE
  dosing_interval: twice per day
  dosing_interval_days: 0.5
  mechanism:
  - name: M1/M4 muscarinic receptor agonism
    description: >-
      Xanomeline is a dual M1/M4-preferring muscarinic agonist with no direct D2
      receptor blocking activity; trospium contributes no central action and is
      present only to antagonise peripheral muscarinic receptors.
  target_mechanisms:
  - target: Loss of M4 Receptor Restraint of Striatal Dopamine Release
    treatment_effect: RESTORES
    description: >-
      Xanomeline agonism at M4 restores cholinergic restraint on striatal dopamine
      release, which is the proposed route by which the drug reaches the dopamine
      node without binding D2 receptors.
    evidence:
    - reference: PMID:38104575
      reference_title: "Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium)
        in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind,
        placebo-controlled, flexible-dose phase 3 trial."
      supports: SUPPORT
      quote_role: BACKGROUND
      directness: INDIRECT
      evidence_source: HUMAN_CLINICAL
      snippet: Xanomeline is a dual M1 and M4-preferring muscarinic receptor agonist that
        does not block D2 dopamine receptors, unlike all currently approved treatments for
        schizophrenia.
      explanation: >
        Establishes the pharmacology of the link — M4 agonism with no D2 activity. INDIRECT
        because the trial measures symptom change, not the striatal dopamine release this
        edge asserts is restored; that step rests on the rodent work cited at the target
        node.
  - target: Cortical Muscarinic M1 Receptor Deficit
    treatment_effect: MODULATES
    description: >-
      Agonist occupancy raises signalling through the M1 receptors that remain rather than
      replacing lost receptor protein, so the drug compensates for the deficit without
      correcting it. `MODULATES` rather than `BYPASSES`: the drug acts on the very receptor
      the node describes, so it is not routing around the lesion by another pathway. Not
      `RESTORES` either — receptor protein stays low. Whether patients with the marked
      cortical deficit (MRDS) respond
      better than others has never been tested, because trial entry has never been
      stratified by muscarinic status.
    evidence:
    - reference: PMID:18593778
      reference_title: Selective muscarinic receptor agonist xanomeline as a novel treatment
        approach for schizophrenia.
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: HUMAN_CLINICAL
      snippet: In the cognitive test battery, subjects in the xanomeline group showed improvements
        most robustly in measures of verbal learning and short-term memory function.
      explanation: >
        The cognitive domain attributed to prefrontal M1 signalling improved under M1/M4
        agonism in an unstratified cohort. INDIRECT — it shows the pathway is drug-tractable,
        not that the cortical receptor deficit itself was engaged.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: xanomeline
      term:
        id: CHEBI:10056
        label: xanomeline
    - preferred_term: trospium
      term:
        id: CHEBI:145791
        label: trospium
  evidence:
  - reference: PMID:41506001
    reference_title: "Long-term efficacy, safety, and tolerability of xanomeline and trospium chloride in schizophrenia: A 52-week, open-label trial (EMERGENT-5)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The M1/M4 muscarinic receptor agonist xanomeline combined with the peripherally restricted pan-muscarinic receptor antagonist trospium chloride is the first approved treatment for adults with schizophrenia with no direct D2 dopamine receptor blockade."
    explanation: >-
      EMERGENT-5 confirms KarXT's first-in-class non-D2 antipsychotic
      mechanism, supporting the model's qualification that D2 antagonism
      is not exclusively required for antipsychotic efficacy.
  - reference: PMID:38104575
    reference_title: "Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium)
      in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind,
      placebo-controlled, flexible-dose phase 3 trial."
    supports: SUPPORT
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: The trial met the primary endpoint with a mean change from baseline to week
      5 in PANSS total score that favoured KarXT (-21·2 points, SE 1·7) versus placebo (-11·6
      points, 1·6; least squares mean difference -9·6; 95% CI -13·9 to -5·2; p<0·0001, Cohen's
      d effect size=0·61).
    explanation: >
      EMERGENT-2, the pivotal placebo-controlled phase 3 trial (n=252, 5 weeks), quantifying
      the efficacy of the treatment on total symptom burden.
  - reference: PMID:38691387
    reference_title: "Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia:
      A Randomized Clinical Trial."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: These findings, together with the previously reported and consistent results
      from the EMERGENT-1 and EMERGENT-2 trials, support the potential of xanomeline-trospium
      to be the first in a putative new class of antipsychotic medications without D2 dopamine
      receptor blocking activity.
    explanation: >
      EMERGENT-3 independently replicates the result in a second phase 3 cohort, which is
      what raises the finding above a single-trial effect.
- name: Antipsychotic Medications
  description: Medications such as risperidone, olanzapine, and clozapine to manage symptoms.
  therapeutic_modality: SMALL_MOLECULE
  mechanism:
  - name: dopamine D2 receptor antagonism
    description: Primary action through dopamine D2 receptor antagonism
  target_mechanisms:
  - target: Dysregulation of Dopamine Neurotransmission
    treatment_effect: INHIBITS
    description: >-
      Antipsychotics block striatal dopamine D2 receptors, dampening the
      mesolimbic dopaminergic hyperactivity that drives positive psychotic
      symptoms.
  evidence:
  - reference: PMID:12769630
    reference_title: "Current status of antipsychotic treatment."
    supports: SUPPORT
    snippet: With the use of chlorpromazine and other traditional antipsychotics for psychosis, it was soon discovered that the antipsychotic efficacy of this class of medications was closely associated with their ability to block dopamine D(2) receptors in the brain.
    explanation: This reference supports the statement that antipsychotic medications act through dopamine D2 receptor antagonism. It also mentions medications like clozapine, risperidone, and others, but does not specifically mention olanzapine in this context.
  - reference: PMID:8626371
    reference_title: "Management of schizophrenia."
    supports: SUPPORT
    snippet: The introduction of novel antipsychotic agents, such as clozapine and risperidone, has enhanced the clinicians' ability to manage schizophrenic patients.
    explanation: This supports the usage of clozapine and risperidone but does not detail the mechanism focused on dopamine D2 receptor antagonism.
  - reference: PMID:8823348
    reference_title: "Treatment-resistant schizophrenic patients."
    supports: SUPPORT
    snippet: Clozapine has shown to be effective in some poor or partially responsive patients in three prospective, random assignment, double-blind trials.
    explanation: Supports effectiveness of clozapine in treatment-resistant patients but does not address dopamine D2 receptor antagonism directly.
  - reference: PMID:32464195
    reference_title: "Blood plasma proteomic modulation induced by olanzapine and risperidone in schizophrenia patients."
    supports: SUPPORT
    snippet: To improve treatment efficacy during the critical early stages of schizophrenia, we aimed to identify molecular signatures at baseline (T0) for prediction of a positive response to the atypical antipsychotics olanzapine and risperidone after 6 weeks (T6) treatment.
    explanation: This supports the use of olanzapine and risperidone but does not detail the mechanism involving dopamine D2 receptor antagonism.
  - reference: PMID:17845145
    reference_title: "Schizophrenia endophenotypes as treatment targets."
    supports: SUPPORT
    snippet: The drug discovery process has focused mostly on targeting D2 dopamine receptors.
    explanation: This reference supports the focus on D2 dopamine receptors in drug discovery, which aligns with the mechanism described.
  - reference: PMID:41694052
    reference_title: "Clinical practice guidelines for management of schizophrenia in India: A comprehensive overview."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Pharmacological strategies emphasize rational antipsychotic use, including early intervention principles, maintenance treatment, long-acting injectable antipsychotics, therapeutic drug monitoring-particularly for clozapine"
    explanation: The Indian schizophrenia clinical practice guidelines center rational antipsychotic use, including maintenance treatment, long-acting injectables, and clozapine drug monitoring.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: risperidone
      term:
        id: CHEBI:8871
        label: risperidone
    - preferred_term: olanzapine
      term:
        id: CHEBI:7735
        label: olanzapine
    - preferred_term: clozapine
      term:
        id: CHEBI:3766
        label: clozapine
- name: Cognitive Behavioral Therapy (CBT)
  description: Therapy aimed at changing maladaptive thought patterns and behaviors.
  evidence:
  - reference: PMID:20880828
    reference_title: "Cognitive behavior therapy for schizophrenia and psychosis: current status and future directions."
    supports: SUPPORT
    snippet: There is good evidence from a considerable number of clinical trials that CBTp has a consistent clinical benefit when used in addition to standard care.
    explanation: This indicates that Cognitive Behavioral Therapy (CBT) is a recognized treatment for schizophrenia that aims at changing maladaptive thought patterns and behaviors.
  - reference: PMID:27335156
    reference_title: "From Clozapine to Cognitive Remediation."
    supports: SUPPORT
    snippet: Cognitive behavioural therapy for psychosis and cognitive remediation are 2 psychosocial interventions that have demonstrated positive outcomes for violence in SCZ.
    explanation: This highlights that CBT, which focuses on changing maladaptive thought patterns and behaviors, is effective in treating certain symptoms of schizophrenia.
  - reference: PMID:17716100
    reference_title: "Cognitive approaches to schizophrenia: theory and therapy."
    supports: SUPPORT
    snippet: A theoretical analysis of schizophrenia based on a cognitive model integrates the complex interaction of predisposing neurobiological, environmental, cognitive, and behavioral factors with the diverse symptomatology.
    explanation: The statement aligns with the cognitive approach to schizophrenia, which underpins CBT.
  - reference: PMID:31699627
    reference_title: "Cognitive remediation for schizophrenia: An expert working group white paper on core techniques."
    supports: NO_EVIDENCE
    snippet: Cognitive remediation is now widely recognized as an effective treatment for cognitive deficits in schizophrenia.
    explanation: Although this reference focuses on cognitive remediation, it aligns with the efficacy of cognitive therapies like CBT.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: behavioral counseling
    term:
      id: NCIT:C181743
      label: Behavioral Counseling
- name: Social Skills Training
  description: Programs to enhance social interactions and functioning.
  evidence:
  - reference: PMID:16885207
    reference_title: "Recent advances in social skills training for schizophrenia."
    supports: SUPPORT
    snippet: Social skills training consists of learning activities utilizing behavioral techniques that enable persons with schizophrenia and other disabling mental disorders to acquire interpersonal disease management and independent living skills for improved functioning in their communities.
    explanation: The study states that social skills training helps individuals with schizophrenia to improve functioning in their communities by acquiring interpersonal and independent living skills.
  - reference: PMID:31708048
    reference_title: "Evidence-Based Psychosocial Treatment for Individuals with Early Psychosis."
    supports: SUPPORT
    snippet: Common elements to these interventions include building a therapeutic alliance, recovery orientation, education, and skills training, which can be directed to a range of targets, including problem-solving, communication, social skills, and social cognition.
    explanation: Clinical therapies for first-episode psychosis as part of coordinated specialty care (CSC) include skills training directed at social skills.
  - reference: PMID:23773889
    reference_title: "Psychosocial Treatments for Schizophrenia: An Evaluation of Theoretically Divergent Treatment Paradigms, and Their Efficacy."
    supports: SUPPORT
    snippet: 'METHODOLOGY: Social skills training, cognitive behavioral therapy, cognitive remediation, and social cognitive training therapy paradigms were searched and the extant literature is summarized for each, with particular focus on: 1) the rationale for treatment methodology; 2) particular methods of treatment; and, 3) meta-analytic data regarding their efficacy and/or effectiveness.'
    explanation: This reference indicates that social skills training is a recognized psychosocial method used to treat schizophrenia and discusses its efficacy.
  - reference: PMID:36050663
    reference_title: "Cognitive Enhancement Therapy vs social skills training in schizophrenia: a cluster randomized comparative effectiveness evaluation."
    supports: SUPPORT
    snippet: Although pharmacological treatments can often lessen the psychotic symptoms that are a hallmark of schizophrenia, they do not lessen the social and cognitive deficits that create the greatest impediments to community engagement and functional recovery.
    explanation: The study compares Cognitive Enhancement Therapy and Social Skills Training (HOPES/SST), highlighting their role in improving social and community functioning.
  - reference: PMID:32614046
    reference_title: "Online Social Cognition Training in Schizophrenia: A Double-Blind, Randomized, Controlled Multi-Site Clinical Trial."
    supports: SUPPORT
    snippet: To address this need, we have developed SocialVille-an online, plasticity-based training program that targets SC deficits in schizophrenia...These results provide support for the efficacy of a remote, plasticity-based social cognitive training program in improving SC and social functioning in schizophrenia.
    explanation: The study shows that social cognitive training programs, which could include elements similar to Social Skills Training, improve social functioning in schizophrenia patients.
  - reference: PMID:21860049
    reference_title: "Social-cognitive remediation in schizophrenia: generalization of effects of the Training of Affect Recognition (TAR)."
    supports: SUPPORT
    snippet: Intention-to-treat analyses found significantly larger pre-post improvements with TAR than with CRT in prosodic affect recognition, ToM, and social competence and a trend effect in global social functioning.
    explanation: The study indicates that training aimed at social cognition, such as TAR, may improve social skills and functions, relevant to social skills training programs.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: behavioral counseling
    term:
      id: NCIT:C181743
      label: Behavioral Counseling
- name: Supportive Therapy
  description: Ongoing support to help manage daily life and stress.
  evidence:
  - reference: PMID:15176765
    reference_title: "Supportive therapy for schizophrenia: possible mechanisms and implications for adjunctive psychosocial treatments."
    supports: SUPPORT
    snippet: This article posits that the positive findings for supportive therapy (ST) in recent trials may indicate an important but undervalued aspect of psychosocial interventions for schizophrenia.
    explanation: The article discusses the benefits of supportive therapy in schizophrenia treatment and emphasizes mechanisms such as the therapeutic alliance and social support, indicating that ongoing support helps manage daily life and stress.
  - reference: PMID:23244011
    reference_title: "Supportive psychodynamic psychotherapy versus treatment as usual for first-episode psychosis: two-year outcome."
    supports: SUPPORT
    snippet: The intervention group improved significantly on measures of both PANSS and GAF scores, with large effect sizes at two years follow-up after inclusion. Further, improvement on GAF(function) (p = 0.000) and GAF(symptom) (p = 0.010) significantly favored SPP in combination with TaU over TaU alone.
    explanation: Supportive psychodynamic psychotherapy, a variant of supportive therapy, was found to significantly improve symptoms and functional outcomes, underscoring its role in ongoing support for managing stress and daily life in schizophrenia.
  - reference: PMID:31708048
    reference_title: "Evidence-Based Psychosocial Treatment for Individuals with Early Psychosis."
    supports: SUPPORT
    snippet: Group, individual, and family therapies in CSC aim to help the client and family understand and cope with the experience of psychosis, promote symptomatic and functional recovery and improve quality of life, and support the pursuit of personally meaningful goals of the client.
    explanation: Coordinated specialty care, including supportive interventions, focuses on coping, recovery, and quality of life, indicating the importance of ongoing support.
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
- name: Vocational Rehabilitation
  description: Help with gaining and maintaining employment.
  evidence:
  - reference: PMID:8749891
    reference_title: "Vocational rehabilitation in schizophrenia."
    supports: SUPPORT
    snippet: Most vocational rehabilitation programs have a positive influence on work-related activities, but most have failed to show substantial and enduring impacts on independent, competitive employment.
    explanation: While vocational rehabilitation programs have positive influences on work-related activities, they have not generally shown substantial and enduring impacts on competitive employment.
  - reference: PMID:31327504
    reference_title: "First-episode psychosis and vocational outcomes: A predictive model."
    supports: SUPPORT
    snippet: At the end of two years in the service, 829 (70.4%) patients were meaningfully employed and 348 (29.6%) patients were unemployed.
    explanation: Vocational programs have shown promise with a significant portion of patients being gainfully employed, but it does not necessarily indicate maintaining stable employment over long periods.
  - reference: PMID:18715755
    reference_title: "Neurocognitive enhancement therapy with vocational services: work outcomes at two-year follow-up."
    supports: SUPPORT
    snippet: NET training improved vocational outcomes, suggesting the value of combining cognitive remediation with other rehabilitation methods to enhance functional outcomes.
    explanation: Neurocognitive enhancement therapy combined with vocational services showed improved employment outcomes, supporting the positive impact on gaining and maintaining employment.
  - reference: PMID:32393158
    reference_title: "Blending Traditional Vocational Services and Individualized Placement and Support for Formerly Incarcerated Veterans."
    supports: SUPPORT
    snippet: Veterans in the hybrid condition, compared with the AFVP alone, were more likely to find employment, had higher rates of full-time employment, and earned significantly more money over the course of the study.
    explanation: Blended vocational services significantly improved employment outcomes, supporting the effectiveness of vocational rehabilitation in gaining and maintaining employment.
  - reference: PMID:29135426
    reference_title: "Integrated Supported Employment for People With Schizophrenia in Mainland China: A Randomized Controlled Trial."
    supports: SUPPORT
    snippet: Significantly higher employment rate and longer job tenure were found in the ISE group (63.0%, 29.56 wk) compared with the IPS group (50.0%, 25.47 wk) and TVR group (33.3%, 9.91 wk).
    explanation: Integrated supported employment led to higher employment rates and longer job tenure, indicating that such vocational rehabilitation can help with gaining and maintaining employment.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: occupational therapy
    term:
      id: NCIT:C121351
      label: Occupational Therapy
- name: Virtual Reality-Assisted Therapy (VRT)
  description: >-
    Immersive virtual reality-based intervention that uses simulated environments to help patients with auditory verbal hallucinations (AVH) confront, understand, and manage their voices. VRT creates a presence-based experience where patients can practice coping strategies in a safe, controlled setting with voice avatars representing hallucinations.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: behavioral counseling
    term:
      id: NCIT:C181743
      label: Behavioral Counseling
  target_mechanisms:
  - target: Hallucinations
    treatment_effect: INHIBITS
    description: >-
      Nine sessions of virtual reality-assisted therapy reduced auditory verbal
      hallucination severity relative to a 9-session targeted short course of
      cognitive behavioral therapy in a randomized, assessor-blind trial of
      adults with treatment-resistant schizophrenia. VRT achieved moderate
      effect sizes at 3 months (d=0.614) and showed sustained benefits compared
      to that CBT comparator.
    evidence:
    - reference: PMID:42671824
      reference_title: "Virtual Reality-Assisted Therapy Compared to Cognitive Behavioral Therapy for Patients with Treatment-Resistant Schizophrenia: A Randomized, Assessor-Blind Controlled Trial."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "VRT outperformed a targeted short course of CBT in reducing persistent AVH for up to three months after the intervention"
      explanation: >-
        Randomized, assessor-blind, parallel-group trial comparing 9-session VRT
        to 9-session CBT in 136 participants with treatment-resistant
        schizophrenia. Intention-to-treat analyses showed significant
        time-by-treatment interaction favoring VRT (p=0.013) with moderate effect
        size at 3 months (d=0.614).
  evidence:
  - reference: PMID:42671824
    reference_title: "Virtual Reality-Assisted Therapy Compared to Cognitive Behavioral Therapy for Patients with Treatment-Resistant Schizophrenia: A Randomized, Assessor-Blind Controlled Trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "VRT outperformed a targeted short course of CBT in reducing persistent AVH for up to three months after the intervention in a North American population with treatment-resistant schizophrenia."
    explanation: >-
      Randomized, assessor-blind, parallel-group trial (NCT04054778) comparing 9-session VRT to 9-session CBT in 136 adults with treatment-resistant schizophrenia or schizoaffective disorder and persistent AVH. Intention-to-treat analyses showed significant time-by-treatment interaction favoring VRT (p=0.013) with moderate effect size at 3 months (d=0.614). Both therapies demonstrated within-group improvements, with VRT showing large effect sizes (d=0.81 post-therapy, d=1.17 at 3-month follow-up) versus CBT's moderate effects (d=0.58 post-therapy, d=0.39 at 3 months). There were no between-group differences for secondary outcomes; within-group improvements in general psychotic symptoms, emotional regulation, and voice acceptance were observed for both therapies.
diagnosis:
- name: Positive and Negative Syndrome Scale (PANSS)
  presence: >-
    Clinician-rated scale for the typological and dimensional assessment of
    schizophrenia symptoms, used to grade symptom severity; a systematic review
    of its measurement properties calls it the most widely used tool for
    assessing the symptoms of schizophrenia. It is a severity measure, not a
    diagnostic test.
  notes: >-
    No LOINC code is bound because LOINC carries no PANSS code. The Monarch KG
    LOINC search returned nothing for "PANSS", "positive and negative syndrome
    scale", "BPRS" or "Brief psychiatric rating scale"; "schizophrenia" returned
    only a PhenX schizophrenia protocol panel, Minimum Data Set items and
    family-history items. No LOINC 2.83 Long Common Name (the Tuva Project
    release pinned in data/loinc/MANIFEST.yaml) contains PANSS, Positive and
    Negative Syndrome, BPRS or Brief Psychiatric Rating. With no LOINC score
    code there is nothing to key a severity band on, so no reference range is
    recorded. The diagnosis_term is the NCIT term for the PANSS, which is
    reachable from Clinical Intervention or Procedure. The instrument's items
    are not reproduced in this entry.
  diagnosis_term:
    preferred_term: PANSS
    term:
      id: NCIT:C124712
      label: Positive and Negative Syndrome Scale Clinical Classification
  evidence:
  - reference: PMID:3616518
    reference_title: The positive and negative syndrome scale (PANSS) for schizophrenia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: >-
      We report on the development and initial standardization of the Positive
      and Negative Syndrome Scale (PANSS) for typological and dimensional
      assessment.
    explanation: >-
      The development paper establishes the PANSS as a standardized instrument
      for assessing schizophrenia symptoms.
  - reference: PMID:40255437
    reference_title: COSMIN systematic review and meta-analysis of the measurement properties of the Positive and Negative Syndrome Scale (PANSS).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: >-
      Although the PANSS is the standard scale for schizophrenia symptom
      severity, its shortcomings regarding fundamental psychometric domains and
      practical applicability warrant the development of new scales for which
      appropriate methods should be applied from the start.
    explanation: >-
      A systematic review identifies the PANSS as the standard severity scale
      while recording its psychometric limitations.
clinical_trials:
- name: NCT04054778
  phase: NOT_APPLICABLE
  status: COMPLETED
  description: >-
    Assessor-blind randomized controlled trial comparing 9-session virtual
    reality-assisted therapy with 9-session cognitive behavioral therapy for
    persistent auditory verbal hallucinations in adults with treatment-resistant
    schizophrenia. The trial enrolled 136 participants with treatment-resistant
    schizophrenia or schizoaffective disorder with chronic auditory verbal
    hallucinations.
  target_phenotypes:
  - preferred_term: Auditory hallucination
    term:
      id: HP:0008765
      label: Auditory hallucination
  evidence:
  - reference: clinicaltrials:NCT04054778
    reference_title: A Randomized Controlled Trial Comparing Avatar Therapy to Cognitive Behavioral Therapy in Schizophrenia With Treatment Refractory Hallucinations
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The main goal of the currently proposed RCT study will be to examine if AT is superior to CBT for the treatment of chronic auditory hallucinations in schizophrenia."
    explanation: >-
      ClinicalTrials.gov registration record documenting the trial objective to
      compare avatar therapy versus cognitive behavioral therapy for treatment of
      auditory hallucinations in schizophrenia.
discussions:
- discussion_id: gap_schizophrenia_complement_pruning_human_causal_chain
  prompt: >-
    How do schizophrenia-associated complement C4A activity, microglial
    synapse engulfment, adolescent cortical synapse loss, dopamine
    dysregulation, and positive, negative, or cognitive symptom domains connect
    causally in living human patients?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Complement-Mediated Excessive Synaptic Pruning
  - pathophysiology#Dysregulation of Dopamine Neurotransmission
  rationale: >-
    The complement-pruning mechanism is supported by convergent review evidence,
    patient-derived in vitro models, and mouse C4A-overexpression experiments.
    The remaining gap is the human-specific causal ordering: whether C4A dosage
    or activity is sufficient to drive excessive synapse elimination during the
    relevant developmental window, whether this produces measurable synaptic
    density loss in the same cortical circuits in patients, and how that loss
    maps onto dopamine overactivity and specific symptom domains. Resolving this
    gap would require longitudinal human data that align complement genotype or
    expression, microglial activation or complement tagging, synaptic-density
    imaging, dopamine-system readouts, and symptom trajectories in the same
    individuals.
  proposed_experiments:
  - experiment_id: exp_schizophrenia_c4a_pruning_longitudinal_cohort
    name: Longitudinal C4A-pruning-dopamine cohort
    description: >-
      Follow adolescents and young adults stratified by complement C4 structural
      alleles or C4A expression with serial synaptic-density PET, microglial or
      complement-activation biomarkers, dopamine-system imaging, cognitive and
      negative-symptom measures, and positive-symptom conversion outcomes.
    experiment_type:
      preferred_term: longitudinal multimodal cohort study
    decision_criterion: >-
      The complement-pruning model would be strengthened if higher C4A risk or
      activity preceded increased microglial/complement activation, accelerated
      cortical synaptic-density loss, subsequent dopamine dysregulation, and
      worsening symptom trajectories in the same participants.
- discussion_id: mismatch_schizophrenia_setd1a_h3k4_demethylase_target
  prompt: >-
    Which H3K4 demethylase is the correct therapeutic target for restoring the
    SETD1A-H3K4 methylation imbalance in human neurons - KDM5, which rescues
    SETD1A-deficiency phenotypes in human iPSC-derived neural models, or LSD1
    (KDM1A), which rescues them in mouse Setd1a models where KDM5 inhibition
    does not?
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - pathophysiology#Reduced SETD1A H3K4 Methyltransferase Activity at Psychiatric Risk Gene Promoters
  - genetic#SETD1A
  rationale: >-
    The therapeutic logic of SETD1A haploinsufficiency is unusually direct:
    SETD1A writes H3K4 methylation, so inhibiting the demethylase that erases it
    should restore the balance. Which demethylase to inhibit, however, comes out
    differently in mouse and in human cells, and the two results are not
    reconcilable by dose or timing alone. In mouse Setd1a models the
    neuronal-morphology and synaptic phenotypes are rescued by LSD1 (KDM1A)
    inhibition and explicitly NOT by KDM5 inhibition. In human iPSC-derived
    isogenic SETD1A loss-of-function neurons, KDM5 inhibition rescues the DNA
    damage accumulation, and in independent patient-derived cells carrying the
    Old Order Amish p.Pro596Leu hypomorph, KDM5 inhibition partially rescues
    replication stress and neurite deficits. So the human evidence converges on
    KDM5 across two different SETD1A perturbations and two laboratories, while
    the mouse evidence specifically excludes it. This matters beyond the rare
    LoF carriers: postmortem cortex from schizophrenia cases WITHOUT SETD1A
    mutations shows reduced SETD1A expression and downregulation of
    SETD1A-regulated genes, so the target population for H3K4-restoring therapy
    would be far broader than the mutation carriers, and picking the wrong
    demethylase on the strength of the mouse data would misdirect it. Note also
    that the human rescue is explicitly partial - 10-20% of neural progenitors
    still became senescent under KDM5 inhibition - so even the human-supported
    target does not fully normalise the cellular phenotype.
  proposed_experiments:
  - experiment_id: exp_schizophrenia_setd1a_kdm5_vs_lsd1_head_to_head
    name: Head-to-head KDM5 versus LSD1 inhibition in matched human and mouse SETD1A models
    description: >-
      Apply KDM5 and LSD1 (KDM1A) inhibitors side by side, at matched target
      engagement, to isogenic human iPSC-derived SETD1A loss-of-function neurons
      and to primary neurons from Setd1a haploinsufficient mice, reading out the
      same endpoints in both (H3K4me3 at SETD1A-bound promoters, DNA damage
      markers, neurite complexity, progenitor senescence, network activity).
    experiment_type:
      preferred_term: comparative pharmacologic rescue study
    decision_criterion: >-
      A genuine species difference would be supported if the KDM5-versus-LSD1
      ordering reverses between human and mouse cells under identical endpoints
      and matched target engagement; a shared mechanism obscured by assay
      differences would instead show both inhibitors rescuing in both species
      once the endpoints are harmonised, in which case the original discrepancy
      is methodological rather than biological.
  evidence:
  - reference: PMID:41422157
    reference_title: "SETD1A regulates psychiatric gene networks involved in genomic stability and synaptic function in rare and sporadic schizophrenia."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "SETD1A haploinsufficiency causes accelerated neurogenesis, reduced neuronal complexity, and DNA damage accumulation in postmitotic neurons that is rescued by inhibiting the H3K4me2/3 demethylase KDM5."
    explanation: >-
      The human-model arm of the mismatch - KDM5 inhibition rescues SETD1A
      loss-of-function phenotypes in isogenic human iPSC-derived neurons.
  - reference: PMID:41422157
    reference_title: "SETD1A regulates psychiatric gene networks involved in genomic stability and synaptic function in rare and sporadic schizophrenia."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "These phenotypes are rescued by LSD1 (KDM1A) inhibition but not by KDM5 inhibition"
    explanation: >-
      The animal-model arm of the mismatch. Note the provenance: this sentence
      is PMID:41422157's introduction summarizing prior mouse work by a
      different group (Mukai et al., their reference 16), not a result of the
      citing study. The same paper elsewhere contrasts "our CUT&Tag findings
      and ChIP-seq findings in Mukai et al." as mouse-versus-human differences.
      In those mouse Setd1a models the rescuing demethylase is LSD1 and KDM5
      inhibition specifically fails, which is the claim the mismatch turns on.
  - reference: PMID:41422157
    reference_title: "SETD1A regulates psychiatric gene networks involved in genomic stability and synaptic function in rare and sporadic schizophrenia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In postmortem SCZ cortical tissue, individuals who lack SETD1A mutations exhibit reduced SETD1A expression, associated with downregulation of SETD1A-regulated genes, implicating SETD1A-H3K4me dysfunction in sporadic SCZ cases."
    explanation: >-
      Establishes why resolving the target question matters beyond rare
      mutation carriers - SETD1A-H3K4 dysfunction is also present in sporadic
      schizophrenia cortex.
  - reference: PPR:PPR1277941
    reference_title: "Clinical, cellular, and genomic consequences of a population-enriched SETD1A missense variant"
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Pharmacologic inhibition of the H3K4 demethylase KDM5 partially rescued
      replication stress and neurite deficits, supporting an epigenetic
      mechanism and suggesting therapeutic tractability.
    explanation: >-
      Independent convergence on KDM5 in a different human system - patient-derived
      cells carrying a founder-population SETD1A hypomorph rather than an
      engineered loss-of-function allele. This is a non-peer-reviewed preprint
      and the rescue is explicitly partial, so it corroborates PMID:41422157
      rather than standing alone.
- discussion_id: gap_schizophrenia_mrds_stratification_of_muscarinic_response
  prompt: >-
    Does the cortical muscarinic M1 receptor deficit that defines MRDS predict who responds
    to a muscarinic agonist, and can that deficit be measured in a living patient before
    treatment?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Cortical Muscarinic M1 Receptor Deficit
  - treatments#Xanomeline-Trospium (KarXT)
  rationale: >-
    The muscarinic hypothesis and the drug built on it have never been joined at the level
    of the individual patient. MRDS was defined on postmortem tissue by pirenzepine binding
    in Brodmann area 9, and separates roughly a quarter of cases with a ~74% reduction from
    a majority overlapping controls — so the receptor deficit the mechanism turns on is
    present in a minority. Every KarXT trial, from the 20-patient pilot through the
    EMERGENT phase 3 programme, enrolled without regard to muscarinic status, and the drug
    is prescribed the same way. Two readings of the phase 3 results are therefore still open
    and have different consequences. If response tracks the deficit, the unstratified trials
    understate the effect in MRDS patients and a pre-treatment assay would be worth having.
    If response is independent of it, then M1/M4 agonism is a general pharmacological lever
    on the dopamine and prefrontal circuitry rather than replacement of a specific missing
    signal — which would weaken the aetiological hypothesis while leaving the treatment
    untouched. Closing this needs an in-life measure: the postmortem assay does not
    transfer, and existing muscarinic PET/SPECT ligands such as IQNB bind muscarinic
    receptors non-selectively rather than reporting M1 specifically. Current antipsychotic
    treatment lowers muscarinic availability on its own — dose-dependently and substantially
    for clozapine (PMID:12799613) — so any such measure has to handle medication status as a
    confound rather than a covariate.
  proposed_experiments:
  - experiment_id: exp_schizophrenia_m1_biomarker_stratified_muscarinic_trial
    name: M1-stratified trial of muscarinic agonism
    description: >-
      Develop or qualify an M1-selective in-life measure of cortical muscarinic status
      (subtype-selective PET ligand, or a validated peripheral or transcriptomic proxy
      benchmarked against postmortem pirenzepine binding), then stratify patients by that
      measure at entry to a placebo-controlled trial of xanomeline-trospium and compare
      symptom and cognitive response between the deficit and non-deficit strata, with
      washout or medication status handled as a prespecified confounder.
    experiment_type:
      preferred_term: biomarker-stratified randomized controlled trial
    would_support:
    - pathophysiology#Cortical Muscarinic M1 Receptor Deficit
    supporting_outcome:
    - >-
      A larger reduction in PANSS total score, or a larger cognitive gain, in the
      receptor-deficit stratum than in the non-deficit stratum, under identical dosing.
    refuting_outcome:
    - >-
      Equivalent response across strata, showing that M1/M4 agonism works independently of
      baseline receptor status — the treatment effect intact, its support for the cortical
      deficit as a driving lesion removed.
    decision_criterion: >-
      The aetiological arm of the muscarinic hypothesis would be strengthened if
      receptor-deficit patients respond better than non-deficit patients under identical
      dosing, and weakened if the strata respond equivalently.
  evidence:
  - reference: PMID:18317461
    reference_title: Decreased cortical muscarinic receptors define a subgroup of subjects
      with schizophrenia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Being able to define a subgroup within schizophrenia using a central biological
      parameter is a pivotal step towards understanding the biochemistry underlying at least
      one form of the disorder and may represent a biomarker that can be used in neuroimaging.
    explanation: >
      The authors themselves propose the deficit as a candidate neuroimaging biomarker,
      which is the step this gap records as still not taken almost two decades later.
- discussion_id: gap_schizophrenia_catatonia_has_no_mechanism_node
  prompt: >-
    Which pathophysiological node in this entry produces catatonia, and is catatonic
    schizophrenia mechanistically continuous with the rest of the disorder or a distinct
    process that co-occurs with it?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - phenotypes#Catatonia
  - pathophysiology#Abnormality of GABAergic Signaling
  rationale: >-
    Catatonia is the one phenotype in this entry with no incoming causal edge, and that is
    a recorded finding rather than an unfinished section. The candidate parent is the
    GABAergic node — catatonia responds to lorazepam, which argues for a GABA-A mechanism —
    but the argument does not survive inspection. The benzodiazepine response is a treatment
    observation, not a localisation; the reviews that discuss mechanism list aberrant
    motor-pathway activity, neurotransmitter dysregulation and oligodendrocyte dysfunction
    side by side as proposals without deciding between them; and catatonia is transdiagnostic,
    occurring in mania, depression, anti-NMDA-receptor encephalitis, and several general
    medical conditions, which cuts against its arising from the cortical circuit lesion this
    entry models. Drawing an edge from the GABAergic node on the strength of lorazepam would
    assert a localisation nobody has established, in the graph position where readers expect
    a mechanism.
    What would close it is a study relating a measured GABAergic parameter — motor-cortex
    GABA-A binding, or prefrontal GABA concentration — to catatonic sign severity within
    schizophrenia, rather than to diagnosis or to treatment response.
  evidence:
  - reference: PMID:34842777
    reference_title: "Catatonia: Clinical Overview of the Diagnosis, Treatment, and Clinical
      Challenges."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Aberrant neuronal activity in different motor pathways, defective neurotransmitter
      regulation, and impaired oligodendrocyte function have all been proposed as the pathophysiology
      behind catatonia.
    explanation: >
      Three unreconciled proposals listed together in a clinical review is the state of the
      field, and is the reason this phenotype is left unattached rather than wired to the
      GABAergic node.
- discussion_id: gap_schizophrenia_glutamate_pharmacology_translation
  prompt: >-
    Do the failed phase 3 trials of glutamate-modulating drugs mean that the
    glutamatergic target is wrong in schizophrenia, or that the trials enrolled
    patients unselected for a glutamatergic abnormality?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Abnormality of Glutamergic Signaling
  - mechanistic_hypotheses#canonical_dopamine_glutamate_neurodevelopmental_model
  rationale: >-
    This entry curates glutamatergic dysfunction as an established
    pathophysiological component while the therapeutic prediction that follows
    from it has repeatedly failed: an mGluR2/3 agonist and a GlyT1 inhibitor
    both missed their primary endpoints in large placebo-controlled trials.
    The gap is that neither programme tested the mechanistic prediction
    directly. Enrolment was by clinical diagnosis, not by a glutamatergic
    biomarker, and target engagement was not uniformly demonstrated, so a null
    result in an unselected population cannot separate a wrong target from the
    wrong patients. Nothing here licenses the stronger reading that trial
    failure refutes glutamate pathophysiology as a class; it bounds the
    therapeutic prediction for the specific agents, doses, endpoints, and
    populations that were studied.
  proposed_experiments:
  - experiment_id: exp_schizophrenia_biomarker_stratified_glutamate_trial
    name: Biomarker-stratified glutamate-modulator trial
    description: >-
      Randomize first-episode psychosis patients to a glutamate-modulating agent
      or placebo after stratifying on baseline hippocampal glutamate and
      glutamine by magnetic resonance spectroscopy, with SV2A PET as a secondary
      synaptic-density measure, and test the treatment-by-stratum interaction
      rather than the unstratified main effect.
    experiment_type:
      preferred_term: biomarker-stratified randomized controlled trial
    would_support:
    - pathophysiology#Abnormality of Glutamergic Signaling
    supporting_outcome:
    - >-
      Patients in the elevated-glutamate stratum improve relative to placebo
      while patients with normal baseline glutamate do not, indicating that the
      earlier null results reflect an unselected population rather than an
      invalid target.
    refuting_outcome:
    - >-
      No benefit in either stratum despite demonstrated target engagement,
      indicating that the glutamatergic abnormality is not a tractable
      therapeutic target in established illness.
    decision_criterion: >-
      A significant treatment-by-stratum interaction on the primary symptom or
      cognition endpoint, with target engagement independently confirmed.
  evidence:
  - reference: PMID:25539791
    reference_title: "A Double-Blind, Placebo-Controlled Comparator Study of LY2140023 monohydrate in patients with schizophrenia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Neither LY2140023 dose showed significant improvement compared to placebo on PANSS total in either population"
    explanation: >-
      Documents one half of the gap. Pomaglumetad, a selective mGluR2/3 agonist,
      failed on PANSS total in 1013 patients while risperidone separated from
      placebo in the same trial, so the null result is not attributable to an
      insensitive study. Patients were enrolled on clinical criteria, not on a
      glutamatergic biomarker.
  - reference: PMID:41233083
    reference_title: "Efficacy and safety of iclepertin for cognitive impairment associated with schizophrenia (CONNEX programme): results from three phase 3 randomised controlled trials."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Iclepertin was not associated with significant improvements in cognition in adults with schizophrenia, but it was well tolerated by patients."
    explanation: >-
      Documents the other half. Three phase 3 trials of the GlyT1 inhibitor
      iclepertin in 1835 patients found no cognitive benefit, extending the
      failure to a second glutamatergic target and to the cognitive endpoint the
      NMDA-hypofunction account most directly predicts. Enrolment was again
      unselected for glutamatergic abnormality.
- discussion_id: controversy_schizophrenia_c4_synaptic_loss_effector_mechanism
  prompt: >-
    By what effector mechanism does elevated C4 reduce cortical synapse
    density: CR3-dependent alteration of microglia-synapse interaction, or a
    neuron-intrinsic endosomal trafficking defect that does not require CR3?
  kind: CONTROVERSY
  status: OPEN
  attaches_to:
  - pathophysiology#Complement-Mediated Excessive Synaptic Pruning
  - mechanistic_hypotheses#complement_synaptic_pruning_hypothesis
  rationale: >-
    Two mouse C4-overexpression studies reach opposite conclusions about
    whether microglial complement receptor 3 is required. One finds the
    synaptic phenotype rescued in CR3-deficient mice and attributes it to
    decreased microglial surveillance and contact, which is itself the opposite
    of the excess-engulfment model this node was built on. The other finds the
    hypoconnectivity CR3-independent and locates it in impaired GluR1
    trafficking via the endosomal protein SNX27. The disagreement is real but
    should not be read as two mutually exclusive universal mechanisms: the
    studies differ in construct, expression pattern, circuit, age, and readout,
    so parallel or context-dependent extracellular and intracellular routes
    remain possible. Neither identifies the operative pathway in human disease,
    which is why the effector step in this entry is now recorded as contested
    rather than as CR3-mediated engulfment.
  notes: >-
    Raised by the 2026 openscientist assessment of the complement synaptic
    pruning hypothesis, which retained the disagreement as real while
    qualifying the report's stronger claim of universal contradiction. The
    supporting citations sit on the pathophysiology node itself.
disease_term:
  preferred_term: schizophrenia
  term:
    id: MONDO:0005090
    label: schizophrenia
classifications:
  harrisons_chapter:
  - classification_value: NEUROLOGIC
datasets:
- accession: geo:GSE278808
  title: Mutations of schizophrenia risk gene SETD1A dysregulate synaptic function in human neurons
  description: Schizophrenia (SCZ) is a complex neuropsychiatric disorder associated with both common risk variants of small effect sizes and rare risk variants of high penetrance. Rare protein truncating variants (PTVs) in SETD1A (SET Domain Containing 1A) show a strong association with SCZ; however, it remains largely unclear how rare PTVs in SETD1A contribute to the pathophysiology of SCZ. To understand the impact of SETD1A rare PTVs in human neurons, we CRISPR/Cas9-engineered five isogenic pairs of human induced pluripotent stem cells (iPSCs), with a recurrent heterozygous patient-specific PTV mutation c.4582-2delAG in two donor lines and a heterozygous frameshift mutation c.4596_4597insG (p.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_count: 26
  publication: PMID:40962831
  notes: Identified by GEO DataSets index search for Schizophrenia (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
- accession: geo:GSE293154
  title: SETD1A Regulates Psychiatric Gene Networks Involved in Genomic Stability and Synaptic Function in Rare and Sporadic Schizophrenia [CUT&Tag]
  description: Rare loss-of-function (LoF) mutations in SETD1A are associated with schizophrenia (SCZ). However, how SETD1A haploinsufficiency leads to SCZ-associated phenotypes and its relevance to patients without these rare mutations is unknown. Here, we identify SETD1A bound loci and regulated genes in human prenatal cortex and isogenic pluripotent stem cell-derived neuronal models engineered with SETD1A LoF variants, including the most common patient mutation. SETD1A preferentially binds the promoters of SCZ and Bipolar risk loci that regulate chromatin remodeling, DNA repair, and synaptic function.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: ATAC_SEQ
  sample_count: 48
  publication: PMID:41422157
  notes: Identified by GEO DataSets index search for Schizophrenia (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
- accession: ega:EGAS00000000118
  title: WTCCC2 Schizophrenia study
  description: A WTCCC2 project genome-wide case-control association study for schizophrenia (SP) in individuals from Ireland.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Schizophrenia"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: ega:EGAS00001000152
  title: Full genome sequencing of a monozygotic twin discordant for schizophrenia
  description: We sequenced the genomes from a monozygotic twin discordant for schizophrenia and a tumor-normal pair of an ovarian cancer patient. Using whole-genome twin data to discriminate between correctly identified single nucleotide variants (SNVs) and errors a strategy for the accurate detection of SNVs was developed. By applying stringent sequencing quality measures, excluding error-prone regions and selecting SNVs identified by different mapping and variation calling algorithms, error rates were ~37-fold reduced. This enabled us to identify the first discordant SNVs in monozygotic twins using whole-genome sequencing.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: WGS
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Schizophrenia"); description-level mentions were not accepted. EGA study_type: Whole Genome Sequencing. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: ega:EGAS00001001960
  title: Novel CNV contribution to schizophrenia from a genome wide study of 41,321 subjects
  description: Genomic copy number variants (CNVs) have been strongly implicated in the etiology schizophrenia (SCZ). However, apart from a small number of risk variants, elucidation of the CNV contribution to risk has been difficult due to the very low frequencies of risk alleles, all occurring in less than 1% of patients. We sought to address this obstacle through a collaborative effort unprecedented in psychiatry in which we applied a centralized analysis pipeline to a large SCZ cohort of 21,094 cases and 20,227 controls. A global enrichment of CNV burden is observed in SCZ patients (OR=1.11, P=5.7e-15), and persists after excluding loci implicated in previous studies (OR=1.07, P=1.7e-6).
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  publication: PMID:9820031
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Schizophrenia"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: massive:MSV000086977
  title: Schizophrenia Proteome Data High Resolution Method
  description: PTM-tolerant quantitative proteome analysis of plasma collected from schizophrenia patients and nonspychiatric healthy controls.
  notes: Located via OmicsDI, which aggregates across omics repositories; this record comes from massive. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Schizophrenia"). Retrieved 2026-08-02.
- accession: massive:MSV000086975
  title: Schizophrenia Plasma Metabolome Analysis
  description: Metabolomics analysis of plasma collected from patients with schizophrenia and non-psychiatric control subjects.
  notes: Located via OmicsDI, which aggregates across omics repositories; this record comes from massive. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Schizophrenia"). Retrieved 2026-08-02.
- accession: metabolomics_workbench:ST000568
  title: Metabolomic study on a schizophrenia and type 2 diabetes susceptibility gene
  notes: Located via OmicsDI, which aggregates across omics repositories; this record comes from metabolomics_workbench. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Schizophrenia"). Retrieved 2026-08-02.

📚

References & Deep Research

Deep Research

2

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Disorder ▸

Disorder

Name: Schizophrenia
Category: Psychiatric
Existing deep-research providers: falcon
Existing evidence reference count in YAML: 120

Key Pathophysiology Nodes

Dysregulation of Dopamine Neurotransmission
Abnormality of Glutamergic Signaling
Abnormality of GABAergic Signaling
Complement-Mediated Excessive Synaptic Pruning
Oligodendrocyte and Myelin Dysfunction
Mitochondrial Dysfunction and Oxidative Stress
Blood-Brain Barrier Dysfunction
Deep research literature mapping

Citation Inventory (for evidence mapping)

DOI:10.1038/s41380-023-02005-2
DOI:10.3389/fncel.2024.1345349
DOI:10.3390/antiox13060709
DOI:10.3390/biom14080906
DOI:10.3390/ijms25021250
DOI:10.3390/ijms251910668

Falcon ▸

Disease Pathophysiology Research Report

Edison Scientific Literature 20 citations 2025-12-15T09:48:11.356081

Disease Pathophysiology Research Report

Target Disease - Disease Name: Schizophrenia - MONDO ID: MONDO:0005090 - Category: Psychiatric

1) Core Pathophysiology (current understanding) - Polygenic liability and synaptic biology: Schizophrenia is highly polygenic; common variation now explains “more than 20% of the liability” in aggregate, with risk genes enriched in synaptic pathways and including DRD2, consistent with antipsychotic mechanisms (direct quote: “now we can explain more than 20% of the liability to schizophrenia by considering all analyzable common genetic variants,” Molecular Psychiatry, Mar 2023; URL: https://doi.org/10.1038/s41380-023-02005-2) (nakamura2023themolecularpathology pages 16-16). - Dopamine and glutamate interplay with cortical E/I imbalance: Contemporary models integrate mesolimbic hyperdopaminergia (positive symptoms) with cortical NMDA receptor hypofunction on GABAergic/parvalbumin (PV) interneurons, producing disinhibition, excitatory/inhibitory (E/I) imbalance, and downstream dopaminergic dysregulation; ketamine/PCP reproduce psychosis-like states; D-serine (an NMDA co-agonist) and kynurenine/kynurenic acid metabolism abnormalities contribute to NMDA hypofunction (Int J Mol Sci, Oct 2024; URL: https://doi.org/10.3390/ijms251910668) (zhang2024advancesinthe pages 13-14, rawani2024theunderlyingneurobiological pages 4-5). - Immune–microglial complement signaling and synaptic pruning: Genetic and experimental evidence implicate complement component C4A and microglial CR3 pathways in excessive synaptic elimination, with human and model-system data converging on complement-mediated pruning as a driver of synapse loss (Frontiers in Cellular Neuroscience, Mar 2024; URL: https://doi.org/10.3389/fncel.2024.1345349) (hartmann2024microglianeuroninteractionsin pages 16-16). - Oligodendrocyte/myelin and network dysconnectivity: Myelin/oligodendrocyte abnormalities and white-matter changes are repeatedly observed and conceptually linked to dysconnectivity across brain regions (Antioxidants, Jun 2024; URL: https://doi.org/10.3390/antiox13060709) (rawani2024theunderlyingneurobiological pages 15-16, stanca2024thecellulardysfunction pages 1-2). - Mitochondrial–oxidative stress axis: Bioenergetic deficits (e.g., complex I inhibition), decreased glutathione, increased lactate, and inflammatory cytokines support a feed-forward cycle linking mitochondrial dysfunction, oxidative/nitrosative stress, and neuroinflammation; excessive Ca2+ influx via NMDARs can overload mitochondria and trigger cell-death signaling (Antioxidants, Jun 2024; URL: https://doi.org/10.3390/antiox13060709) (rawani2024theunderlyingneurobiological pages 15-16, rawani2024theunderlyingneurobiological pages 4-5). - Neurovascular/BBB dysfunction: Increased BBB permeability (elevated CSF albumin/immunoglobulins) and neurovascular unit abnormalities (endothelial cells, pericytes, astrocytes) are reported and positioned upstream of neurotransmitter dyshomeostasis (Int J Mol Sci, Jan 2024; URL: https://doi.org/10.3390/ijms25021250) (stanca2024thecellulardysfunction pages 1-2).

2) Key Molecular Players - Genes/proteins (HGNC): - DRD2 (dopamine D2 receptor; antipsychotic target; GWAS-implicated) (Molecular Psychiatry, 2023; URL above) (nakamura2023themolecularpathology pages 16-16). - GRIN1/GRIN2A (NMDAR subunits), GAD1 (GAD67), RELN (Reelin) (NMDA/PV interneuron dysfunction and epigenetic regulation discussed) (Int J Mol Sci, 2024; URL above; Antioxidants, 2024; URL above) (zhang2024advancesinthe pages 13-14, rawani2024theunderlyingneurobiological pages 4-5, rawani2024theunderlyingneurobiological pages 25-26). - C4A (complement component 4A), C3, ITGAM/CD11b (CR3) (microglial complement-mediated synaptic pruning) (Frontiers in Cellular Neuroscience, 2024; URL above) (hartmann2024microglianeuroninteractionsin pages 16-16). - Myelin/oligodendrocyte-associated proteins (conceptual involvement; oligodendroglial/myelination deficits) (Antioxidants, 2024; URL above) (rawani2024theunderlyingneurobiological pages 15-16). - Chemical entities (CHEBI): - Dopamine (CHEBI:18243), glutamate (CHEBI:29985), GABA (CHEBI:16865) (core neurotransmitters) (rawani2024theunderlyingneurobiological pages 4-5, correll2024whatremainsto pages 1-2). - D-serine (CHEBI:17115), kynurenic acid (CHEBI:17368), kynurenine (CHEBI:30785) (NMDAR co-agonist and KP metabolites) (Int J Mol Sci, 2024; URL above) (zhang2024advancesinthe pages 13-14). - Cell types (CL): - PV interneurons (CL:0000099, parvalbumin-positive GABAergic interneurons; NMDA hypofunction/disinhibition) (Int J Mol Sci, 2024; URL above) (zhang2024advancesinthe pages 13-14). - Microglia (CL:0000129; complement-dependent synaptic pruning) (Frontiers in Cellular Neuroscience, 2024) (hartmann2024microglianeuroninteractionsin pages 16-16). - Astrocytes (CL:0000127), endothelial cells (CL:0000115), pericytes (CL:0000669) (neurovascular/BBB) (Int J Mol Sci, 2024; URL above) (stanca2024thecellulardysfunction pages 1-2). - Oligodendrocytes (CL:0000128) (myelin deficits) (Antioxidants, 2024; URL above) (rawani2024theunderlyingneurobiological pages 15-16). - Anatomical locations (UBERON): - Prefrontal cortex (UBERON:0003126), hippocampus (UBERON:0001954), thalamus (UBERON:0001897) (regions linked to cognition and network communication; E/I imbalance, inflammation, and myelin changes) (rawani2024theunderlyingneurobiological pages 4-5, rawani2024theunderlyingneurobiological pages 15-16, stanca2024thecellulardysfunction pages 1-2).

3) Biological Processes (GO terms) disrupted - Glutamatergic synaptic transmission and plasticity (GO:0098978; GO:0060291 LTP): NMDA hypofunction, co-agonist deficiency, and KP metabolite modulation (zhang2024advancesinthe pages 13-14). - GABAergic synaptic transmission and interneuron-mediated inhibition (GO:0098982): PV interneuron dysfunction and cortical disinhibition/E/I imbalance (zhang2024advancesinthe pages 13-14, rawani2024theunderlyingneurobiological pages 4-5). - Dopamine signaling (GO:0007212) and presynaptic modulation by cortical inputs (hyperdopaminergia in mesolimbic circuits) (correll2024whatremainsto pages 1-2, rawani2024theunderlyingneurobiological pages 4-5). - Complement activation and synaptic pruning (GO:0006956; GO:0098883): microglia–CR3–C4/C3 pathways (hartmann2024microglianeuroninteractionsin pages 16-16). - Myelination and axon ensheathment (GO:0042552; GO:0008366): oligodendrocyte disruption and dysconnectivity (rawani2024theunderlyingneurobiological pages 15-16). - Mitochondrial electron transport/oxidative phosphorylation (GO:0006119) and cellular response to oxidative stress (GO:0034599) (rawani2024theunderlyingneurobiological pages 15-16). - Regulation of blood–brain barrier permeability and endothelial junction organization (e.g., GO:0071605, GO:0005911 related components): BBB leakage and neurovascular unit dysfunction (stanca2024thecellulardysfunction pages 1-2).

4) Cellular Components (where key processes occur) - Postsynaptic density (GO:0014069) and glutamatergic synapse (GO:0098978) for NMDA-dependent signaling (zhang2024advancesinthe pages 13-14). - Presynaptic active zone (GO:0048786) and dopaminergic terminals (mesostriatal/mesolimbic) (correll2024whatremainsto pages 1-2). - Microglial phagocytic machinery in perisynaptic microdomains; complement opsonins at synapses (hartmann2024microglianeuroninteractionsin pages 16-16). - Myelin sheath (GO:0043209) and nodes of Ranvier (GO:0033268) for conduction/dysconnectivity (rawani2024theunderlyingneurobiological pages 15-16). - Mitochondrion (GO:0005739) as a hub for redox-bioenergetics and Ca2+-induced injury (rawani2024theunderlyingneurobiological pages 15-16). - Endothelial cell–cell junctions and astrocytic endfeet at BBB (stanca2024thecellulardysfunction pages 1-2).

5) Disease Progression (staged model) - Neurodevelopmental priming: Genetic liability (common and rare) plus early-life immune/inflammatory exposures perturb cortical development, interneuron maturation, and synaptic/myelin programs; polygenic architecture “explains more than 20% of liability” (Molecular Psychiatry, 2023; URL above) (nakamura2023themolecularpathology pages 16-16). Epigenetic alterations impacting NMDARs, GABAergic markers (GAD67), and reelin are noted (Antioxidants, 2024; URL: https://doi.org/10.3390/antiox13060709) (rawani2024theunderlyingneurobiological pages 25-26). - Adolescent critical period: Excessive complement-tagged synaptic pruning by microglia (C4A/C3–CR3) and NMDA hypofunction on PV interneurons drive cortical E/I imbalance; concurrent oligodendrocyte/myelin vulnerability and BBB changes may exacerbate dysconnectivity and neuroinflammation (Frontiers in Cellular Neuroscience, 2024; Int J Mol Sci, 2024; URLs above) (hartmann2024microglianeuroninteractionsin pages 16-16, stanca2024thecellulardysfunction pages 1-2, zhang2024advancesinthe pages 13-14). - Prodrome to first-episode psychosis: Emergence of cognitive/negative symptoms with cortical disinhibition and glutamatergic dysregulation; mesolimbic hyperdopaminergia manifests as positive symptoms (Biomolecules, Jul 2024; URL: https://doi.org/10.3390/biom14080906) (correll2024whatremainsto pages 1-2, rawani2024theunderlyingneurobiological pages 4-5). - Chronic course: Persistent synaptic loss, redox–mitochondrial stress, and myelin/white-matter alterations contribute to refractory negative and cognitive symptoms; ongoing low-grade inflammation and BBB dysfunction may maintain pathophysiology (Antioxidants, 2024; Int J Mol Sci, 2024; URLs above) (rawani2024theunderlyingneurobiological pages 15-16, stanca2024thecellulardysfunction pages 1-2).

6) Phenotypic Manifestations (linkage to mechanisms) - Positive symptoms (hallucinations/delusions): Most directly related to striatal/mesolimbic dopamine excess; antipsychotics work as “postsynaptic dopamine antagonists” (Biomolecules, Jul 2024; URL above) (correll2024whatremainsto pages 1-2). - Negative and cognitive symptoms: Associated with cortical NMDA hypofunction and PV interneuron-mediated disinhibition (E/I imbalance) leading to impairments in working memory/executive function; D-serine reduction and KP metabolite elevations (kynurenic acid) are implicated (Int J Mol Sci, Oct 2024; URL above) (zhang2024advancesinthe pages 13-14). “Ketamine/PCP” models reproduce cognitive and negative symptom domains via NMDAR blockade (rawani2024theunderlyingneurobiological pages 4-5). - Functional dysconnectivity: Oligodendrocyte/myelin deficits and inflammation contribute to large-scale network dysconnectivity underlying broad symptom burden (Antioxidants, Jun 2024; URL above) (rawani2024theunderlyingneurobiological pages 15-16).

Applications and Real-World Implementations (biomarkers and therapeutics) - Biomarkers: - CSF/metabolic redox markers: Increased lactate and decreased glutathione have been reported in brain/CSF in schizophrenia, consistent with bioenergetic–oxidative stress (Antioxidants, Jun 2024; URL above) (rawani2024theunderlyingneurobiological pages 15-16). - Neuroinflammatory cytokines (e.g., IL‑6, IL‑8, TNF‑α) are elevated in first-episode and chronic cases (Antioxidants, Jun 2024; URL above) (rawani2024theunderlyingneurobiological pages 4-5). - BBB leakage indices: Elevated CSF albumin/immunoglobulins indicating increased BBB permeability (Int J Mol Sci, Jan 2024; URL above) (stanca2024thecellulardysfunction pages 1-2). - Therapeutic developments: - Dopaminergic antagonism remains the cornerstone for positive symptoms but leaves cognitive/negative symptoms insufficiently treated (Biomolecules, Jul 2024; URL above) (correll2024whatremainsto pages 1-2). - Glutamatergic strategies (e.g., NMDAR co-agonists, glycine transporter or D‑amino acid oxidase inhibitors, mGluR modulators) are being advanced to target cognition and negative symptoms (Int J Mol Sci, Oct 2024; URL above) (zhang2024advancesinthe pages 13-14). - Novel modalities: “Molecular polypharmacy” and biased signaling; KarXT (xanomeline + trospium) exemplifies circuit-/network-minded approaches beyond D2 antagonism (Biomolecules, Jul 2024; URL above) (correll2024whatremainsto pages 1-2).

Relevant Statistics and Data - Prevalence: “approximately 1% of the global population,” emphasizing disability and unmet needs (Biomolecules, Jul 2024; URL above) (correll2024whatremainsto pages 1-2). - Genetics: “now we can explain more than 20% of the liability” from common variants in aggregate; DRD2 is a validated GWAS target reflecting monoaminergic involvement (Molecular Psychiatry, Mar 2023; URL above) (nakamura2023themolecularpathology pages 16-16).

Expert Opinions and Analysis - Therapeutic perspective: Correll et al. emphasize that “schizophrenia’s pathophysiology is not solely reliant on neurotransmitter–receptor interactions,” and promote circuit-level targets, biased agonism, and multi-target strategies to address cognitive/negative symptoms and treatment resistance (Biomolecules, Jul 2024; URL above) (correll2024whatremainsto pages 1-2). - Mechanistic synthesis: Reviews converge that neurotransmission dysregulation (dopamine–glutamate–GABA), neuroinflammation (microglia/complement), redox–mitochondrial stress, and myelin/BBB pathology are interdependent domains that jointly drive clinical heterogeneity (Antioxidants, Jun 2024; URL above; Int J Mol Sci, Jan/Oct 2024; URLs above) (rawani2024theunderlyingneurobiological pages 15-16, stanca2024thecellulardysfunction pages 1-2, zhang2024advancesinthe pages 13-14).

Structured Annotations for Knowledge Base - Gene/protein (HGNC): DRD2; GRIN1/GRIN2A; GAD1 (GAD67); RELN; C4A; C3; ITGAM (CR3/CD11b). Evidence: GWAS (DRD2) and mechanistic reviews (complement, NMDA, PV interneuron) (nakamura2023themolecularpathology pages 16-16, zhang2024advancesinthe pages 13-14, hartmann2024microglianeuroninteractionsin pages 16-16). - Biological process (GO): glutamatergic synaptic transmission (GO:0098978); GABAergic synaptic transmission (GO:0098982); complement activation (GO:0006956); synaptic pruning (GO:0098883); myelination (GO:0042552); oxidative phosphorylation (GO:0006119); cellular response to oxidative stress (GO:0034599); regulation of BBB permeability (GO:0071605) (zhang2024advancesinthe pages 13-14, hartmann2024microglianeuroninteractionsin pages 16-16, rawani2024theunderlyingneurobiological pages 15-16, stanca2024thecellulardysfunction pages 1-2). - Cellular component (GO): postsynaptic density (GO:0014069); glutamatergic synapse (GO:0098978); myelin sheath (GO:0043209); mitochondrion (GO:0005739); endothelial cell–cell junction (GO:0005911-related) (zhang2024advancesinthe pages 13-14, rawani2024theunderlyingneurobiological pages 15-16, stanca2024thecellulardysfunction pages 1-2). - Cell types (CL): PV interneurons (CL:0000099); microglia (CL:0000129); astrocytes (CL:0000127); endothelial cells (CL:0000115); oligodendrocytes (CL:0000128) (zhang2024advancesinthe pages 13-14, hartmann2024microglianeuroninteractionsin pages 16-16, stanca2024thecellulardysfunction pages 1-2, rawani2024theunderlyingneurobiological pages 15-16). - Anatomical locations (UBERON): prefrontal cortex (UBERON:0003126); hippocampus (UBERON:0001954); thalamus (UBERON:0001897) (rawani2024theunderlyingneurobiological pages 4-5, rawani2024theunderlyingneurobiological pages 15-16, stanca2024thecellulardysfunction pages 1-2). - Phenotype associations (HP): Positive psychotic symptoms (HP:0031464); Negative symptoms (HP:0031466); Cognitive impairment (HP:0100543). Mechanistic links summarized above (zhang2024advancesinthe pages 13-14, correll2024whatremainsto pages 1-2, rawani2024theunderlyingneurobiological pages 4-5). - Chemical entities (CHEBI): dopamine (CHEBI:18243); glutamate (CHEBI:29985); GABA (CHEBI:16865); D-serine (CHEBI:17115); kynurenic acid (CHEBI:17368); kynurenine (CHEBI:30785) (zhang2024advancesinthe pages 13-14, rawani2024theunderlyingneurobiological pages 4-5).

Directly quoted supporting statements - “now we can explain more than 20% of the liability to schizophrenia by considering all analyzable common genetic variants” (Molecular Psychiatry, Mar 2023; URL: https://doi.org/10.1038/s41380-023-02005-2) (nakamura2023themolecularpathology pages 16-16). - Postsynaptic dopamine antagonists have been “the cornerstone” of treatment, yet “significant challenges remain,” motivating network- and biased-signaling–based approaches (Biomolecules, Jul 2024; URL: https://doi.org/10.3390/biom14080906) (correll2024whatremainsto pages 1-2).

Limitations and gaps - Many biomarker findings (e.g., cytokine panels, redox markers) require replication in large, medication-naïve cohorts. Complement-pruning mechanisms, while strongly supported, still need human in vivo biomarkers to stratify subtypes. Nonetheless, convergent 2023–2024 evidence corroborates multi-domain pathophysiology spanning neurotransmission, immune pruning, myelin/BBB, and redox–mitochondria.

References (URLs and dates) - Nakamura T, Takata A. The molecular pathology of schizophrenia… Molecular Psychiatry, Mar 2023. URL: https://doi.org/10.1038/s41380-023-02005-2 (nakamura2023themolecularpathology pages 16-16). - Zhang T et al. Advances in the treatment of cognitive impairment in schizophrenia: targeting NMDA receptor pathways. Int J Mol Sci, Oct 2024. URL: https://doi.org/10.3390/ijms251910668 (zhang2024advancesinthe pages 13-14). - Correll CU et al. What remains to be discovered in schizophrenia therapeutics… Biomolecules, Jul 2024. URL: https://doi.org/10.3390/biom14080906 (correll2024whatremainsto pages 1-2). - Rawani NS et al. The underlying neurobiological mechanisms of psychosis… Antioxidants, Jun 2024. URL: https://doi.org/10.3390/antiox13060709 (rawani2024theunderlyingneurobiological pages 15-16, rawani2024theunderlyingneurobiological pages 4-5, rawani2024theunderlyingneurobiological pages 25-26). - Stanca S et al. The cellular dysfunction of the brain–blood barrier… Int J Mol Sci, Jan 2024. URL: https://doi.org/10.3390/ijms25021250 (stanca2024thecellulardysfunction pages 1-2). - Hartmann S-M et al. Microglia–neuron interactions in schizophrenia. Frontiers in Cellular Neuroscience, Mar 2024. URL: https://doi.org/10.3389/fncel.2024.1345349 (hartmann2024microglianeuroninteractionsin pages 16-16).

References

(nakamura2023themolecularpathology pages 16-16): Takumi Nakamura and Atsushi Takata. The molecular pathology of schizophrenia: an overview of existing knowledge and new directions for future research. Molecular Psychiatry, 28:1868-1889, Mar 2023. URL: https://doi.org/10.1038/s41380-023-02005-2, doi:10.1038/s41380-023-02005-2. This article has 51 citations and is from a highest quality peer-reviewed journal.
(zhang2024advancesinthe pages 13-14): Ting Zhang, Chang Liu, Ning Zhong, Yichen Wang, Yiyun Huang, and Xiaoqin Zhang. Advances in the treatment of cognitive impairment in schizophrenia: targeting nmda receptor pathways. International Journal of Molecular Sciences, 25:10668, Oct 2024. URL: https://doi.org/10.3390/ijms251910668, doi:10.3390/ijms251910668. This article has 14 citations and is from a poor quality or predatory journal.
(rawani2024theunderlyingneurobiological pages 4-5): Neha S. Rawani, Allen W. Chan, Serdar M. Dursun, and Glen B. Baker. The underlying neurobiological mechanisms of psychosis: focus on neurotransmission dysregulation, neuroinflammation, oxidative stress, and mitochondrial dysfunction. Antioxidants, 13:709, Jun 2024. URL: https://doi.org/10.3390/antiox13060709, doi:10.3390/antiox13060709. This article has 55 citations and is from a poor quality or predatory journal.
(hartmann2024microglianeuroninteractionsin pages 16-16): Sophia-Marie Hartmann, Johanna Heider, Richard Wüst, Andreas J. Fallgatter, and Hansjürgen Volkmer. Microglia-neuron interactions in schizophrenia. Frontiers in Cellular Neuroscience, Mar 2024. URL: https://doi.org/10.3389/fncel.2024.1345349, doi:10.3389/fncel.2024.1345349. This article has 34 citations and is from a poor quality or predatory journal.
(rawani2024theunderlyingneurobiological pages 15-16): Neha S. Rawani, Allen W. Chan, Serdar M. Dursun, and Glen B. Baker. The underlying neurobiological mechanisms of psychosis: focus on neurotransmission dysregulation, neuroinflammation, oxidative stress, and mitochondrial dysfunction. Antioxidants, 13:709, Jun 2024. URL: https://doi.org/10.3390/antiox13060709, doi:10.3390/antiox13060709. This article has 55 citations and is from a poor quality or predatory journal.
(stanca2024thecellulardysfunction pages 1-2): Stefano Stanca, Martina Rossetti, Leona Bokulic Panichi, and Paolo Bongioanni. The cellular dysfunction of the brain–blood barrier from endothelial cells to astrocytes: the pathway towards neurotransmitter impairment in schizophrenia. International Journal of Molecular Sciences, 25:1250, Jan 2024. URL: https://doi.org/10.3390/ijms25021250, doi:10.3390/ijms25021250. This article has 17 citations and is from a poor quality or predatory journal.
(rawani2024theunderlyingneurobiological pages 25-26): Neha S. Rawani, Allen W. Chan, Serdar M. Dursun, and Glen B. Baker. The underlying neurobiological mechanisms of psychosis: focus on neurotransmission dysregulation, neuroinflammation, oxidative stress, and mitochondrial dysfunction. Antioxidants, 13:709, Jun 2024. URL: https://doi.org/10.3390/antiox13060709, doi:10.3390/antiox13060709. This article has 55 citations and is from a poor quality or predatory journal.
(correll2024whatremainsto pages 1-2): Christoph U. Correll, Massimo Tusconi, Mauro Giovanni Carta, and Serdar M. Dursun. What remains to be discovered in schizophrenia therapeutics: contributions by advancing the molecular mechanisms of drugs for psychosis and schizophrenia. Biomolecules, 14:906, Jul 2024. URL: https://doi.org/10.3390/biom14080906, doi:10.3390/biom14080906. This article has 9 citations and is from a poor quality or predatory journal.

Ask OpenScientist

OpenScientist Report

Classifications

Mechanistic Hypotheses

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Environmental Factors

Biochemical Markers

Diagnosis

Progression

Prevalence

Related Datasets

Clinical Trials

Source YAML

References & Deep Research

Deep Research

Disorder

Key Pathophysiology Nodes

Citation Inventory (for evidence mapping)